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Eukaryotic cells employ multiple posttranscriptional mechanisms to fine tune gene
expression programs in response to external signals. Regulation of messenger RNA and
microRNA by RNA-binding proteins is critical to the control of this process. Hence,
disruptions of RNA regulatory processes result in neurologic diseases, cancer, and
immunologic disorders among other complications. Posttranscriptional control of RNA
is particularly important for precise cytokine expression in T cells during adaptive
immune responses.

We have studied human lymphocyte activation as a model for correlating changes in
RNA regulation with dynamic cellular state changes and stress responses. We
hypothesize that RNA-binding proteins such as Argonaute (Ago) and HuR play critical
roles in shaping the dynamic immune response in T cells.

We have previously

demonstrated the ability to map Ago-microRNA binding sites using high-throughput
sequencing of RNA isolated by cross-linking immunoprecipitation (HITS-CLIP)
{Chi:2009ht}. Here we used HITS-CLIP to define genome-wide maps of both Ago and
HuR RNA binding sites in freshly isolated primary human T cells in the resting state and
after one hour of stimulation with anti-CD3 and anti-CD28 antibodies. We also applied
RNA sequencing and ribosomal profiling to these lymphocytes to establish their
transcriptional and translational status.

We observed different patterns of both Ago and HuR binding from HITS-CLIP in resting
and activated T cells. Comparing the Ago and HuR HITS-CLIP genome-wide maps
suggests agonistic and antagonistic actions of these two proteins to confer microRNAmediated regulation of mRNA translation. Furthermore, we overlaid these dynamic RNA
binding-protein maps with ribosomal profiles of the target transcripts to investigate
translational output as it relates to Ago and HuR regulation. By comparing the changes
in both RNA-binding maps with ribosomal profiling results from lymphocytes before and
after one hour of T cell activation, we developed a combinatorial dynamic map for these
two RNA-binding proteins. Additionally, examining the function of Ago in T cells
deficient in HuR helped us understand the relationship between these regulatory proteins
in determining the resting and activated lymphocyte states. Our results suggest that
differences in protein-RNA interactions for Ago and HuR occur quickly after T cell
activation and provide important insight into the specificity of how microRNA
translational regulation mediates the immune response.
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CHAPTER 1. Introduction

The adaptation to environmental signals is an essential component of cellular life. In
multicellular organisms, these pathways have evolved to include responses to both
external stimuli and internal signals. For example, in the immune system, lymphocytes
need to modify their states quickly to respond to the presence of potentially harmful
antigen, such as during the recognition of virally infected or malignant cells, and then
back to quiescence so as not to damage normal tissue.

The Inflammatory and Adaptive Immune Response

The spread of a pathogen is first combatted by the inflammatory response of the innate
immune system. Macrophages and dendritic cells survey the host for antigen, such as in
sites of infection and inflammation, and are triggered to ingest bacteria and infected cells
due to their recognition of molecules shared by pathogens and distinguishable from the
host. These molecules also trigger the cells to become activated and secrete cytokines,
including tumor necrosis factor (TNF), and chemokines to initiate inflammation
(Janeway and Medzhitov 2002).

Clinically, inflammation is characterized by heat,

redness, and swelling, which are caused by the cytokine induced increase in blood flow
and leakage of fluid from the bloodstream into the site, and pain, due to the infiltration of
white blood cells. The inflammatory neutrophil and macrophage populations help to
increase the flow of lymph to bring together antigen-presenting cells (APCs) with
lymphocytes to activate the adaptive immune response (Barton 2008; Nathan 2002).
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Among other inflammatory signals, local cells such as fibroblasts are stimulated by TNF
to produce a wide array of cytokines and chemokines that help to propagate the
inflammatory response and recruit white blood cells into the injured tissue. While only
short exposure to TNF is necessary for the initiation of the NF-κB transcriptional
program, which can account for much of the early response, a sustained stimulus can lead
to the induction of three temporal classes of responses: transcripts that initiate expression
within a half-hour and are quickly diminished, transcripts that accumulate over the first
two hours and then are sustained, and transcripts that increase more gradually. These
responses are highly regulated temporally to ensure the proper initiation of the
inflammatory cascade. While the induction of these signals is transcriptionally controlled,
the fate and regulation of the transcripts is defined largely post-transcriptionally (Bradley
2008; Hao and Baltimore 2009; Hoffmann 2002; Tian 2005).

When a dendritic cell ingests a pathogen, it becomes activated to mature into an APC that
is able to stimulate pathogen-specific lymphocytes in the lymph node. These activated
APCs secrete cytokines that help to shape both the innate and adaptive immune responses.
Lymphocytes circulate in the host’s bloodstream in a fairly quiescent state until they
encounter antigen and co-stimulatory molecules in the context of an APC. Such an
encounter triggers proliferation and differentiation of lymphocytes into primed effector
cells that can reject the infectious agent. These initiating interactions of the adaptive
immune response occur in the peripheral lymphoid organs such as the lymph nodes,
spleen and mucosal lymphoid tissues (Banchereau and Steinman 1998).
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While antibodies can recognize pathogens circulating in the blood and in extracellular
spaces, the cytotoxic T lymphocytes of the adaptive immune system are needed to
identify intracellular bacterial pathogens, parasites, viruses, and tumor antigens. Foreign
proteins and tumor antigens are processed and presented as peptide fragments on major
histocompatibility complex (MHC) molecules to T cells, which can kill the offensive
cells. MHC I molecules generally capture and present peptides from the cytosol of the
cell. MHC II molecules present exogenous peptide to cluster of differentiation four
(CD4) T cells that can function as “helper” cells to orchestrate T cell responses, antibody
responses, or to down regulate adaptive immune responses as suppressor cells. During
lymphocyte maturation each T cell develops a unique antigen receptor, or T cell Receptor
(TCR), which recognizes a specific antigenic peptide held by an MHC molecule. Thus
the genotype of the MHC restricts the antigen specificity of the T cell. Lymphocytes are
selected during differentiation for deletion or tolerance of lymphocytes expressing TCRs
specific for self-antigen (Rock and Goldberg 1999).

Cytotoxic T cells typically express the cluster of differentiation eight (CD8) co-receptor
on their surfaces which binds MHC class I. The TCR and CD8 molecules can bind to the
same MHC complex simultaneously, which greatly enhances the resulting activation
signal (J.-H. Wang and Reinherz 2002). Other co-stimulatory interactions may also be
necessary to stimulate a productive immune response such as with the B7 proteins, which
stimulate T cells via the cluster of differentiation twenty-eight (CD28) molecule (Jenkins
et al. 1991). Upon engagement of cognate peptide-MHC complexes, the Src family
kinases LCK and FYN are recruited to the TCR and phosphorylate tyrosine substrates in
the cytoplasmic tails of the receptor’s subunits in immunoreceptor tyrosine-based
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activation motifs (ITAMs). These phosphorylated receptor molecules recruit and then
activate a second tyrosine kinase, ZAP-70. The FYN adaptor protein also associates with
FYB, also called SLAP or ADAP, which aids in the proliferative response and cytokine
production by helping to stabilize the interaction of the TCR with APCs through integrin
clustering and adhesion (Griffiths et al. 2001; Peterson et al. 2001).

Activation of ZAP-70 in turn leads to the phosphorylation of adaptor proteins LAT and
SLP-76 that recruit other proteins that stimulate the Ras pathway, the mobilization of
calcium, and the reorganization of the cytoskeleton of the T cell. One protein that is
recruited to the membrane is phospholipase Cγ1 (PLCG1) which hydrolyzes
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG). IP3 interrogates receptors on the endoplasmic reticulum to release
Ca2+ into the cytoplasm, triggering a cascade of calcium dependent signaling leading to
the activation of NFAT and its regulated transcriptional control of interleukin-2 (IL-2)
and other cytokines (Weiss and Littman 1994). DAG in turn activates numerous protein
targets including protein kinase C (PKC) family members and Ras guanyl-nucleotidereleasing protein (RasGRP). These help to activate Ras signaling which eventually leads
to the activation of mitogen-activated protein (MAP) kinases.

This results in the

phosphorylation and activation the transcription factor AP-1, which induces both FOS
and JUN transcription among others changes. PKCs also are involved in activating the
NFκB transcription factor which contributes to the induction of pro-inflammatory
cytokines (Cantrell 2002; Jordan, Singer, and Koretzky 2003; Weiss and Littman 1994).

4

The addition of co-stimulatory CD28 signaling to CD3 stimulation leads to higher
expression and stabilization key inflammatory molecules such as IL-2, interferon gamma
(IFNG), TNF, and granulocyte-macrophage colony stimulating factor (GM-CSF)
(Lindstein et al. 1989; Thompson et al. 1989). Although it has also been reported that the
primary differential effect of CD28 engagement may be related to an increase in NFAT
signaling in the lymphocyte (Diehn et al. 2002). CD28 binding, in addition to TCR
binding, stimulates transcription of the EGR family, Nuclear Receptor Subfamily, and
CD69 (Kaye 2000; Shao et al. 1997). The interaction between a T cell and peptide-MHC
complex can be mimicked in culture by interrogation of the TCR complex via anti-CD3
antibodies and co-stimulation with anti-CD28 antibodies. By using beads coated with
both of these antibodies (CD3/CD28 beads), the signals are distributed on a surface
comparable to the size of an APC and the lymphocyte can encounter both signals
simultaneously.

Interferon gamma (IFNG) production after T cell stimulation can directly inhibit viral
replication and also help kill intracellular pathogens by initiating starvation programs in
their host cells. Additionally, IFNG signals for the increased production and expression
of major histocompatibility complex I (MHC I) and other components of antigen
processing machinery to increase the presentation of viral components to the immune
system for potential recognition and attack. IFNG synergizes with TNF to activate and
recruit macrophages to the site of infection or injury to aid in the clearance and killing of
infected material, and in antigen presentation (Boehm et al. 1997; Rock and Goldberg
1999).

IFNG mediates its antiviral and immune modulatory effects through Janus

Tyrosine Kinase (JAK) signaling. Homodimers of IFNG bind to two interferon gamma
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receptor (IFNGR) 1 molecules that have intracellular domains associated with JAK1.
Binding of IFNG leads to the joining of each IFNGR1 subunit with one of IFNGR2 that
is associated with JAK2. This brings together the active IFNG receptor complex made
up of two of each receptor and two of each JAK. The JAK1 and JAK2 molecules are
auto- and trans-phosphorylated creating a docking site for signal transducers and
activators of transcription (STAT) 1.

A homodimer of STAT1 forms after

phosphotyrosine activation by the JAKs. This STAT1 homodimer translocates to the
nuclease and binds to gamma-activated sequence (GAS) elements to induce transcription
(Horvath 2000; Levy and Darnell 2002; Shuai and Liu 2003; Stark and Darnell 2012;
Stark et al. 1998).

With the initiation of an inflammatory and adaptive immune response, it is clear that a
variety of signaling pathways lead to a vast induction of transcription. While these
transcriptional changes help to characterize the inflammatory response, they do not
complete the regulatory picture. When lymphocytes encounter antigen, they are required
to respond very quickly. Thus, it is logical that T cells not rely solely on transcriptional
changes to alter protein expression.

RNA-binding proteins can help to regulate

translation by affecting mRNA stability, localization, inclusion in stress granules, and
access to ribosomes, among other processes. RNA-binding proteins in T cells regulate
rapid changes in the production of cytokines, among other proteins. The induction of
cytokine production needs immediate control to ensure the production of an effective
immune response to antigen, but also a transient response to protect surrounding healthy
cells from destruction. RNA-binding proteins can ensure this by helping to induce
translation, or targeting transcripts for degradation or translational repression (Anderson
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2008).

To better understand lymphocyte responses, and as a surrogate system for

examining the dynamic control of mRNA, we have undertaken to study the posttranscriptional regulation of T cell activation.

Lymphocytes as a Model System for Studying Basic Cellular Function, Immune
Responses, and Disease

The elaborate transcriptional and translational regulation of T cell activation, and the
connection of these processes with the general mechanisms of the integrated stress
response make T cells a perfect system for the study of the dynamic control of RNA
regulation. Working with T cells, we can study a purified cell population rather than a
tissue made up of many cellular components without significant manipulation, as
compared to the dissociation of a tissue. Furthermore, we can work with normal human
cells without the requirement for invasive procedures or post-mortem collection of tissue.
Although CD8 T cells can have varied responses such as cytotoxic responses, immune
tolerance, and anergy, they are more uniform than CD4 lymphocytes phenotypes that
have various transcriptional profiles and cytokine secretion depending on their committed
lineage.

In this work, we studied the regulation of CD8 lymphocytes directly ex vivo from normal
human donors. Therefore, they represent true biologic samples and do not have the
biases of cells that have been transformed or otherwise propagated in culture systems.
Also, each donor sample represents a true replicate. While the donors were all normal
adults, they represent different genetic background and ages which gives much more
biologic complexity than multiple plates of cell lines or even genetically identical mice.
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Thus, processes and events that we find consistent between donor samples are more
likely to represent general mechanisms of control. Also, by pairing these studies with the
mouse system we can take advantage of genetic models and utilize the power of
conservation to rapidly dissect findings from the human system.

The in vitro activation and manipulation of lymphocytes can mimic in vivo biologic
interactions of T cells with APCs. Here we focused on broad T cell activation by
CD3/CD28 stimulation to maximize our response and best recapitulate a general stress
response, but this could also be done in an antigen-specific manner to study even more
specific cell populations and responses. Because lymphocyte activation is important for
the control of many disease states including inflammation, infection, tumor biology, and
autoimmunity, we think that studying lymphocyte stimulation is generally applicable and
biologically meaningful. Much of the signaling and regulatory mechanisms studied in
lymphocytes should be pertinent to other cellular systems, especially regarding general
regulation of the stress response. Nevertheless, because of the connection between the
translational regulation of cytokine production and the balance between stimulatory and
anergic responses, we hypothesize that understanding the basic regulatory control of T
cell activation could be especially informative in the understanding of tumor immunity
and autoimmunity.

Paraneoplastic Neurologic Degeneration

Paraneoplastic disorders refer to symptoms resulting from the presence of a tumor at a
site remote from the neoplasm and can be caused by hormone and cytokine secretion by
the tumor cells or by an immune response to the tumor. In some cases, tumor cells
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express proteins that are normally restricted to the brain, termed onconeural antigens.
Because the antigens are normally restricted to the nervous system, the ectopic
expression in the tumor makes them vulnerable to immune system surveillance, much
like foreign antigens, and can help to elicit a strong tumor immune response that correlate
with positive outcomes in subsequent cancer treatment. Unfortunately, the anti-tumor
immune reaction can lead to severe autoimmune disease mediated by these onconeural
proteins, leading to neurologic degeneration. Paraneoplastic neurologic degeneration
(PND) disorders represent some of the best-known clinical cases of spontaneous tumor
immunity, especially with identified antigenic targets of the immune system.
Interestingly, the onconeural antigens in multiple PNDs are RNA-binding proteins (R. B.
Darnell 1996; R. B. Darnell and Posner 2003a; 2003b; 2006).

While patients are often diagnosed with a PND based on the presence of onconeuralspecific antibodies, their role in disease progression is unclear as disease models utilizing
onconeural autoantibodies have failed to initiate disease (Sakai et al. 1995). Antibodies
often mediate responses to extracellular antigens, while PND antigens are often expressed
intracellularly (Okano and Darnell 1997). CD8 T cells are often key effectors of tumor
immunity due to their ability to recognize the unusual protein repertoires often expressed
in malignant cells. PND patients often have activated T cells in their cerebral spinal fluid
and previous lab members have identified onconeural antigen-specific CD8 lymphocytes
in PND patients, including the discovery of CD8 T cells that display unusual cytokine
expression phenotypes (Albert et al. 1998; Albert, Austin, and Darnell 2000; Roberts et al.
2009). Studies in mice have suggested that in normal animals there is immune tolerance
to onconeural antigens (DeLuca et al. 2009) and Blachère et al., unpublished. The
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mechanisms mediating tolerance to these neuronal proteins are unknown and the critical
method by which this tolerance is broken in PND patients leading to both tumor
immunity and neuronal autoimmunity is not yet understood. By studying the basic
regulatory processes mediating T cell activation, we hope to uncover insight into the
control of the powerful tumor immunity and devastating autoimmunity displayed by
these patients.

RNA Regulation in the Immune Response

T cell Activation and Rapid Cellular Stress Responses

When cells encounter various biologic stresses such as heat shock, amino acid starvation,
oxidative stress, or viral infection, a common integrated stress response (ISR) pathway is
induced to protect the cell from damage and adapt to the environmental changes. One
main functional outcome of this pathway is the control of the translational status of
mRNA in the cells to modulate the priority of which transcripts are made into protein
during the period of new cellular demands. While different cellular cascades help to
initiate these different responses, many converge upon the phosphorylation of serine 51
of the alpha subunit of the eukaryotic initiation factor two (EIF2A).

Serine 51

phosphorylation blocks EIF2A from helping establish active initiation complexes at the
ribosome, which decreases translation. Changes in translational control with the induction
of the ISR are also accompanied by alterations in gene expression to help the cells adapt,
including the induction of regulators of EIF2A phosphorylation such as GADD34
(PPP1R15A) (Harding et al. 2002; 2003; Murphy 2006). Unlike GADD34, constitutive
repressor of EIF2A phosphorylation (CReP or PPP1R15B) is constitutively expressed,
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but both can help dephosphorylate EIF2A blocking it from activating the ISR (Jousse et
al. 2003). In addition to changes in transcription and translation, an activated ISR can
also affect the localization of mRNA. mRNA present in the cell can be sequestered in
stress granules and p-bodies, although the presence of the latter is not depended on
EIF2A phosphorylation, to harbor latent transcripts or target them for degradation
(Anderson 2008; Brengues, Teixeira, and Parker 2005; Harding et al. 2002; Kedersha and
Anderson 2002; Murphy 2006; Scheu et al. 2006; Sheth and Parker 2006). RNA-binding
proteins, such as Argonaute (Ago) and HuR to be discussed later, can rapidly shuttle in
and out of stress granules, presumably in conjunction with bound mRNAs, to mediate
translational silencing and potentially degradation (Bhattacharyya, Habermacher, Martine,
Closs, and Filipowicz 2006a; 2006b; Leung and Sharp 2007; 2010).

The dissociation between the transcription of cytokine mRNA and synthesis of the
protein during CD4 T cell differentiation has been linked to a pathway resembling ISR
(Scheu et al. 2006). Also, in a mouse model of immune tolerance, the production of
cytokine mRNA was disconnected from the generation of effector proteins in T cells
specific for self but not foreign antigens (Villarino et al. 2011). T cell activation in
hypoxic conditions has also been shown to increase the secretion of IFNG without
increased levels of the IFNG transcript (Roman et al. 2010). Although these may not be
direct representations of the classical ISR pathway, the translational control of cytokine
expression and their localization to stress granules makes T cell activation an intriguing
system to study the regulation of these pathways and applicable to many general cellular
dynamic responses.
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RNA-Binding Proteins in Immune Cells

These observations raise the general issue of how gene regulation is manifest in the
dynamics of the immune response.

Hao and Baltimore analyzed the inflammatory

response by determining the transcriptional profiles of macrophages at various time
points after the stimulation with TNF. They described that the response could be grouped
into three sets of genes: ones that peaked in expression at half an hour after activation,
after two hours of activation, or increased steadily with stimulation and peaked at 12
hours after activation.

They concluded that transcription and mRNA turnover are

important to the control of inflammation (Hao and Baltimore 2009). Another level of
regulation, not excluded by these observations, is translational regulation.

One

predominant advantage of this point of regulatory control is in the potential for even more
rapid responses of immune cells in response to stimuli.

As immune cells survey the host for antigen, they are required to adapt quickly to
changes within their host. For example, when a lymphocyte encounters antigen, it needs
to quickly initiate an inflammatory response including the production of cytokines. This
response needs to be carefully controlled and transient so that it does not damage the
surrounding tissue. Thus, it is logical that much of lymphocyte protein expression be
regulated at the translational level. For instance, by harboring latent cytokine transcripts
in cytoplasmic granules, RNA-binding proteins can compete for interactions with their
targets. These proteins work in combination to modulate a cytokine mRNA’s stability
and access to ribosomes, which can be quickly accomplished without the need for new
transcription to initiate a response (Anderson 2008; 2010).
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AU-rich elements (ARE) are usually found in the 3’UTR of transcripts and are found in
many mRNAs encoding immediate-early and early response genes, including cytokines,
proliferative factors, and other functional groups that drive inflammation (Gruber et al.
2011). These cis-regulatory elements were first identified as binding sites for RNAbinding proteins nearly twenty-five years ago (Malter 1989). Since then it has been
elucidated that many RNA-binding proteins act at these sites to both positively and
negatively regulate mRNA turnover, changes in subcellular localization, and access to
translational machinery in response to cellular stresses. ARE-binding proteins such as
HuR (ELAVL1), TIA1/TIAR, and tristetraprolin (TTP), have been shown to have critical
inflammatory functions, such as in the regulation of cytokine mRNA (Meisner and
Filipowicz 2010).

For example, all of these factors have been shown to interact with ARE in the TNF
3’UTR in mediating the immune response. HuR deficient T cells in mice displayed
increased levels of Tnf mRNA and analyses of myeloid-restricted HuR over-expression
showed translational suppression of inflammatory mRNAs, including Tnf (Katsanou et al.
2005; Papadaki et al. 2009). TIA-1 and TIAR recruit target mRNAs to stress granules in
response to different stimuli to block their translation (Kedersha et al. 1999).
Macrophages from mice lacking either Tia-1 or Tiar and stimulated with LPS produced
increased levels of TNF protein without altering its transcript abundance or half-life
(Kedersha et al. 1999; Piecyk et al. 2000). Mice deficient in Ttp spontaneously develop
severe autoimmune disorders due to the over expression of TNF protein and other
inflammatory factors which are normally targets of deadenylation and mRNA decay due
to TTP destabilization (Blackshear 2002; Lai et al. 1999; Taylor et al. 1996).
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HuR Regulation of RNA

HuR, also known as HuA or ELAVl1, is a ubiquitously expressed RNA-binding protein
that is closely related to the neuronal proteins HuB, HuC, and HuD (Ma et al. 1996;
Okano and Darnell 1997). The neuronal isoforms are targets of the immune system in
both lung cancer cells and the nervous system in a PND known as the Hu Syndrome.
This is an interesting connection between RNA regulation and the pathology of PND and
we speculate that HuR could be critical to controlling the immune response of T cell
phenotypes that are altered in the targeting of its neuronal homologues. Hu proteins
contain three RNA recognition motifs. These proteins were identified as binding to Urich sequences and many U-rich and ARE binding motifs have been identified (Ma et al.
1996; Myer, Fan, and Steitz 1997).

HuR was shown to actively shuttle between the nucleus and cytoplasm in response to
different stress conditions including the activation of immune cells (Meisner and
Filipowicz 2010). This export of HuR into the cytoplasm is critical for its regulatory
control of certain target transcripts (X. C. Fan and Steitz 1998b; Peng et al. 1998). The
shuttling is mediated by two different pathways, one which utilizes the HuR nuclear
localization signal and is dependent on CRM1, and the second uses transportin molecules
(X. C. Fan and Steitz 1998a; Gallouzi, Brennan, and Steitz 2001; Rebane, Aab, and Steitz
2004). HuR also associates with stress granules in response to cellular stress (Gallouzi et
al. 2000). In response to cellular stimuli, signaling cascades can lead to posttranslational
modifications of HuR which may mediate its subcellular localization or influence its
RNA binding (Abdelmohsen et al. 2007; Doller, Pfeilschifter, and Eberhardt 2008). The
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levels of HuR protein have also been shown to be regulated in response to T cell
stimulation and other stress responses by multiple pathways including auto-regulation
and control by microRNAs (Abdelmohsen et al. 2008; Akool et al. 2003; Atasoy et al.
1998; X. Guo, Wu, and Hartley 2009; Jeyaraj et al. 2010; Papadaki et al. 2009; Sakai et al.
2003).

HuR has been demonstrated to regulate targeted transcripts by cooperative and
competitive interactions with other RNA-binding proteins often by interfering with AREmediated decay of mRNA by other RNA-binding proteins (Anderson 2008; Brennan and
Steitz 2001; Casolaro et al. 2008; X. C. Fan and Steitz 1998b; Myer, Fan, and Steitz
1997). Although much work studying HuR has focused on transcript stability, HuR has
also been linked to dynamic control of translation (Katsanou, Dimitriou, and
Kontoyiannis 2006; Kawai et al. 2006; Lal et al. 2004; Mazan-Mamczarz et al. 2003;
Sureban et al. 2007). Still, much of the research investigating the targets and effects of
HuR binding has been studied in vitro with reporter constructs or by over expressing HuR,
in potentially biased screens for regulation and non-physiologic conditions.

HuR Regulation in T cells

As introduced in the previous section, HuR has been shown to help regulate many
cellular processes including the stress response and immune pathways. The effects of
HuR binding vary by mRNA target, most often involving regulation of stability and
translation. HuR has been implicated in both inducing and suppressing inflammatory
responses.
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In T cells, HuR has been shown to regulate CD3ζ, CD40L, Fas, IFNG, IL-4, IL-13, and
TNF (Brennan and Steitz 2001; Izquierdo 2008; Katsanou et al. 2005; Moulton et al.
2008; Myer, Fan, and Steitz 1997; J. G. Wang et al. 2006; Yarovinsky et al. 2006).
During lymphocyte activation, HuR promotes the stabilization of cytokine transcripts by
binding to AU-rich elements (ARE) in the 3’ untranslated region (3’UTR).

By

interacting both cooperatively and competitively with other RNA-binding proteins, these
associations can promote or inhibit translation of cytokines to determine the fate of the
transcript (Anderson 2008; Casolaro et al. 2008; X. C. Fan and Steitz 1998b; Myer, Fan,
and Steitz 1997). HuR levels have also shown to be up-regulated following T cell
activation (Atasoy et al. 1998; Papadaki et al. 2009; Sakai et al. 2003).

Mice deficient in HuR are not viable, while post-natal conditional ablation of HuR causes
gastroentological inflammation, along with depletion of hematopoietic lineages and death
within the first two weeks of life (Ghosh et al. 2009; Katsanou et al. 2009). Animals
lacking HuR only in their T cells proceed throughout development. Still, these mice have
altered lymphocyte phenotypes. HuR deficient T cells show altered maturation and do
not exit the thymus at normal rates due to diminished chemotactic responses to cytokines
that have been shown to alter HuR subcellular localization. Upon CD3/CD28 stimulation,
T cells lacking HuR showed a reduced proliferative response and a decreased apoptotic
response. HuR deficient cells displayed increased levels of Tnf mRNA (Papadaki et al.
2009).

While the role of HuR in regulating cytokines has been pervasive, the majority of the
work has been done in cell culture systems that do not necessarily represent physiologic
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conditions. Furthermore, much of work studying the association of HuR with targets,
including during T cell activation, has been studied without crosslinking, which may lead
to the identification of false targets of regulation due to the potential association of RNAbinding proteins with transcripts after cell lysis for immunoprecipitation (Mili and Steitz
2004; Mukherjee et al. 2009). Genome-wide HuR binding sites have been mapped using
photoactivatable ribonucleoside crosslinking and immunoprecipitation (PAR-CLIP)
approach, but its requirement for incorporating a photo-activatable nucleotide analog into
RNA limits its use to in vitro systems that may not represent biologically meaningful
binding sites or dynamic changes in response to stress (Lebedeva et al. 2011; Mukherjee
et al. 2011). Thus, more stringent analysis of genome-wide targets is necessary in
biologically relevant samples and in dynamic cellular responses.

Ago Regulation and microRNAs

MicroRNAs are small ~22-nucleotide RNAs that help direct Ago binding to mRNA to
regulate target deadenylation, decay and translational status in diverse biologic processes
such as proliferation, differentiation, and stress responses. The majority of microRNA
genes in mammals are found in regions of the genome that were previously thought to be
intergenic, although a number of microRNA are transcribed within the introns of coding
genes. MicroRNAs are also found in genomic clusters that suggest joint transcriptional
regulation. In all cases, the microRNAs are thought to begin as longer RNA molecules
than their characteristic evolutionarily conserved stem loops. Generally, after the initial
message known as the primary microRNA is transcribed, the first step in processing is
the cleavage of the ~60-70 nucleotide stem loop from the rest of the message, by the
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RNase III enzyme Drosha, to form the precursor microRNA. This cleavage event
resolves one end of the mature microRNA duplex. The precursor microRNA is then
actively exported from the nucleus by Ran-GTP and Exportin-5. The second cleavage is
completed by another RNase III endonuclease Dicer at a fixed distance from the Drosha
cleavage site. These cleavage products become incorporated into Ago proteins as singlestranded RNA molecules in ribonucleoprotein complexes, known as the RNA-induced
silencing complex (RISC) (Ambros 2004; Bartel 2004).

MicroRNAs can mediate post-transcriptional regulation by targeting transcripts for
mRNA cleavage and degradation or by modulating translation of their targets. These
endpoints are decided by the complementarity of the microRNA sequence to the target
and by the interaction of the Ago-microRNA complex with other RNA-binding proteins
in response to cellular signaling and multiple stress responses (Bartel 2004; 2009; Leung
and Sharp 2007; 2010). Thus, Ago regulation can be dynamically controlled. For
example, the localization of Ago to stress granules is microRNA dependent and can be
transient, with evidence that Ago can shuttle in and out of a stress granule in less than a
minute (Leung, Calabrese, and Sharp 2006). Another example of rapid regulatory control
involving microRNAs is in the light adaptation response of the retina where levels of
microRNA were shown to change rapidly by decay and increased transcription to impact
mRNA control (Krol et al. 2010). These and other regulatory systems, such as in
interactions with other RNA-binding proteins, allow for rapid responses to external
stimuli to influence the final stages of gene expression within a cell.
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Some studies have indicated that microRNAs mediate repression of protein expression
predominantly by decreasing target transcript levels (Baek et al. 2008; H. Guo et al.
2010; Hendrickson et al. 2009). Others have reported that translational control precedes
corresponding changes in mRNA expression (Bazzini, Lee, and Giraldez 2012; Selbach
et al. 2008). The mechanisms mediating Ago-mediated mRNA control are also varied
including microRNA dependent deadenylation of transcripts leading to the degradation of
target transcripts unrelated to translational control, or the inhibition of protein synthesis
before or after the initiation of translation (Mathonnet et al. 2007; Olsen and Ambros
1999; Pillai et al. 2005; L. Wu, Fan, and Belasco 2006).

While most studies of

microRNA mediated translational control have focused on repression of translation, it has
also been reported that Ago binding helps to mediate translational activation of some
target mRNAs in certain biologic conditions (Henke et al. 2008; Jopling et al. 2005;
Vasudevan and Steitz 2007; Vasudevan, Tong, and Steitz 2007; 2008; Ørom, Nielsen,
and Lund 2008). In summary, Ago-microRNA regulation of targets has been linked to
repression and enhancement of translation with and without changes in target abundance
by influencing many mechanisms of translational control.

Ago Regulation in T cells

Ago regulation and microRNAs have been shown to be critical to the development of a
healthy immune system and normal inflammatory responses. The differential abundance
of microRNAs in distinct T cell lineages has been examined, but these studies have not
considered the activation state of the lymphocytes or the mRNA regulation of Ago in
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parallel (Landgraf et al. 2007; Monticelli et al. 2005; Salaun et al. 2011; H. Wu et al.
2007).

The Dicer enzyme is critical for generation of microRNAs by cleaving double stranded
precursors. Mice lacking Dicer in the T cell lineage showed greatly impaired T cell
differentiation, particularly for the development of CD8 T cells (Cobb 2005; Muljo et al.
2005). Furthermore, CD8 T cells conditionally deficient in Dicer after maturation were
shown to have a heightened response to T cell activation. Lymphocytes stimulated in
vitro showed quicker surface expression of CD69 and this activation marker persisted
longer than in wild type T cells after the termination of the TCR stimulus. The T cells
also showed quicker initiation of proliferation as seen by progression into the cell cycle.
After in vitro stimulation of wild type T cells, microRNA-130/301, thought to be
regulating CD69 expression, were increased as compared to resting cells (Zhang and
Bevan 2010). Conditional deletion of Dicer in response to T cell activation with viral
challenge led to a faulty expansion of antigen-specific T cells and poor viral clearance (T.
Wu et al. 2012). Deletion of Ago2 in the bone marrow resulted in aberrant generation of
B cells and cells of the erythroid lineage (O'Carroll et al. 2007).

T cell Differentiation and Responses Impacted by the Overexpression or Deletion of
microRNAs in Mice

Regulatory T cells deficient in mir-146a showed a deficiency in their ability to control
IFNG production themselves or in CD4 and CD8 cells due to loss of suppression of
STAT1. This selective cytokine deregulation differed from Dicer deficient regulatory T
cells that showed decreased suppression of multiple cytokines and general loss of

20

suppressive capacity (Liston et al. 2008; Lu et al. 2010). Macrophages from mice with a
genetic deletion of miR-146a show an exaggerated response with intra-peritoneal
lipopolysaccharide challenge, with elevated levels of serum TNF and decreased survival
rate. The mice develop spontaneous autoimmunity with age, displaying enlarged spleens
and lymph nodes, inflammation in peripheral organs, increased serum levels of IL-6, and
expression of activation markers on T cells. This autoimmunity resulted in a decreased
survival rate and the appearance of spontaneous tumors in secondary lymphoid organs
(Boldin et al. 2011).

Mice lacking miR-155 showed deficiencies in both T and B cells. For example, CD4 T
cells showed reduced expression of IFNG upon stimulation (Rodriguez et al. 2007; Thai
et al. 2007).

Additionally, mir-155 is necessary for the heightened responses of

regulatory T cells to IL-2 even though most suppressor functions are maintained in its
absence (Lu et al. 2009). Ago CLIP binding maps in WT and miR-155 deficient mouse
regulatory CD4 T cells were recently published and help to establish that roughly forty
percent of miR-155 binding sites do not display canonical seed matches (Loeb et al.
2012). These studies examine a different subset of T cells than is the focus of the work
described here, but suggest a need to understand other mechanisms of transcript targeting
for Ago binding aside from seed match pairing in lymphocytes.

Hematopoietic stem cells from the bone marrow were transduced with retrovirus to
ectopically express miR-181a. When these cells reconstituted the bone marrow of sublethally irradiated hosts, while the percentage of mature B cells nearly doubled, the
number of CD8 T cells was reduced more than ten-fold. Only small alterations were

21

observed in the CD4 T cell and myeloid compartments (Chen et al. 2004). miR-181a is
highly expressed early in T cell development and decreases with maturation. CD4 T cells
overexpressing miR-181a showed increased intracellular calcium fluctuations and IL-2
production with antigen stimulation, and required less peptide present on APCs to reach
their maximal response, demonstrating that they were more sensitive to TCR stimulation.
The opposite effect was seen in T cells with reduced miR-181a expression. These
responses were shown to be mediated in part by the regulation of CD28 expression, but
also by downstream components of the TCR signaling pathway (Li et al. 2007). Liu et al.
utilized the increase in the development of double positive cells with overexpression of
miR-181a-1 in vitro as a screen for functional microRNA activity.

Sequential

mutagenesis of the miR-181 stem loop demonstrated that while sequences in the mature
microRNA were important for T cell development, the regulation of distinct miR-181
family members was dictated by their pre-microRNA loop sequences (G. Liu et al. 2008).
Although the absolute expression levels of miR-181 are lower in double positive cells
than other stages of development, it represents a larger percentage of the microRNA pool
in these cells and this mediates the regulatory control of targets such as CD69 to regulate
T cell development (Neilson et al. 2007).

Many studies have focused on the role of the miR-17-92 cluster in B cells due to its
overexpression in human B cell lymphomas. This is due to transcriptional up-regulation
of the cluster by c-MYC. The oncogenic capacity of these microRNAs is greatly due to
the targeting effects of miR-19a and miR-19b (Mu et al. 2009). Mice deficient in the
miR-17-92 cluster die shortly after birth. Wild type mice reconstituted with miR-17-92
deficient bone marrow showed drastic reductions in total lymphocyte counts due to
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impaired B cell development, while the T cell compartment appeared grossly unaffected
(Ventura et al. 2008). miR-17-92 is highly expressed during lymphocyte development
and is decreased in mature cell populations including CD4 and CD8 single positive cells.
Overexpression of miR-17-92 in lymphocytes led to lymphoproliferative disease,
autoimmunity, and death.

Interestingly, CD4 T cells overexpressing miR-17-92

proliferated with CD3 stimulation at similar levels to control CD4 T cells stimulated with
both CD3 and CD28 indicating that the aberrant microRNA expression may have
functionally mimicked CD28 co-stimulation (Xiao et al. 2008). miR-17-92 expression is
temporally regulated with T cell activation and is needed for expansion of CD8 T cells
after antigen encounter (T. Wu et al. 2012). By examining mice with T cells deficient for
the miR-17-92 cluster, these microRNAs were shown to promote Th1 responses and
suppression of tumor growth in melanoma challenged mice. Furthermore, miR-19b was
demonstrated to rescue the production of IFNG in CD3/CD28 stimulated deficient cells
with retroviral transduction of that microRNA (Jiang et al. 2011).

The Combinatorial Control of Ago and HuR

As reviewed above, HuR and Ago both positively and negatively regulate gene
expression by transcriptional and translational control and are both critical to the
regulation of healthy immune responses. We have previously demonstrated the ability to
use high-throughput sequencing crosslinking immunoprecipitation (HITS-CLIP) to
establish a precise and genome-wide map of Ago-microRNA-mRNA ternary interactions.
Interestingly, this map showed that Ago binds to mRNA targets at very specific sites, on
average only 2.6 regions per Ago regulated transcript. This specificity is hard to explain
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solely by the reliance of a microRNA-mRNA interaction determined by a microRNA
seed sequence of as few as six nucleotides of complementarity. Furthermore, AgomRNA binding sites did not appear to have a general sequence preference, suggesting
that additional RNA-binding proteins may be required to determine mRNA accessibility
to Ago (Chi et al. 2009). Many Ago binding sites have also been identified without
exactly matching canonical microRNA seed sequences. While some of these regulatory
sites represent microRNA mediated targeting through non-classical seed pairings, some
cannot be explained by microRNA direction alone (Chi et al. 2009; Chi, Hannon, and
Darnell 2012; Leung et al. 2011; Loeb et al. 2012).

3’UTRs are abundant in both microRNA binding sites and ARE.

This creates a

concentrated region for the possible combinatorial control of target mRNAs by Ago and
other RNA-binding proteins. Ago and microRNA are important in the regulation of AUrich elements (ARE) through their interactions with other RNA-binding proteins such as
HuR (Meisner and Filipowicz 2010). Accordingly, a recent systematic analysis indicated
that the efficacy of miRNA mediated silencing was attenuated by the presence of AREs
near predicted miRNA target sites, suggesting that ARE-binding proteins may globally
influence recruitment of Ago-miRNA complexes (Jacobsen et al. 2010). Much work
studying the interactions of Ago and HuR have focused on specific target transcripts.
While these may be informative for the specific examples, the differences in the outcome
of their combinatorial control indicate the need for more systematic study of their coregulation.
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For example, CAT-1 protein levels increase in response to stress without a corresponding
change in transcription. In normal cellular conditions, miR-122 mediates the subcellular
localization of the CAT-1 mRNA to P-bodies. Upon activation of a stress response, HuR
was demonstrated to bind to the 3’UTR of CAT-1 via ARE and reverse its microRNAmediated repression. Binding by HuR led to the exit of CAT-1 from P-bodies and its
association with active polysomes, resulting in an increase in CAT-1 translation. The
mechanism mediating the interaction between Ago and HuR on the CAT-1 mRNA is
unknown, but because the target sequence sites for each protein are not directly adjacent,
the authors speculate that the proximity of their interaction may be enhanced by the RNA
secondary structure, possibly bringing the sites closer together than indicated by their
sequence, or by HuR oligomerization along the 3’UTR to disrupt Ago-miR-122 binding
(Bhattacharyya, Habermacher, Martine, Closs, and Filipowicz 2006a; 2006b).

Conversely, HuR was shown to be necessary for the microRNA let-7 mediated repression
of c-Myc. HuR associated with c-Myc in RNA-immunoprecipitation experiments. By
diminishing levels of HuR in Hela cells by siRNA or overexpressing recombinant HuR
protein, HuR was observed to negatively correlate with c-Myc mRNA and protein levels
suggesting repression of c-Myc by HuR.

Using synthesized biotinylated mRNA

fragments and chimeric GFP-reporter constructs, specific regions of the 3’UTR were
identified as mediating the interaction between HuR and c-Myc. Let-7 was predicted to
bind a region adjacent to the proposed HuR binding site. Decreasing functional let-7
with antagomiRs, or increasing its levels by transfection of synthesized precursor duplex
RNA, increased or decreased c-Myc expression respectively. HuR was shown to be
necessary for Ago2-let-7 binding to the c-Myc 3’UTR and the co-immunoprecipitation of
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HuR with Ago was RNA dependent, although this immunoprecipitation did not utilize
crosslinking and the interaction could have been formed after cell lysis (Kim et al. 2009).
It is possible that the opposite affects of Ago and HuR interaction for this transcript are
due to differences in the proximity of the binding sites for each protein, cell lines, cellular
states, or that the interactions are more complex than only the involvement of these two
regulators.

Although myeloid cell proliferation, survival, and differentiation were maintain in mice
deficient in HuR in the myeloid compartment, steady state mRNA and microRNA levels
were disrupted in these cells. The angiogenic pathway was implicated as being regulated
by HuR expression and the strength of ARE in the 3’UTR correlated with the down
regulation of these potential targets.

In searching for regulated mRNA with ARE

adjacent to putative microRNA binding sites, the Vegf-a mRNA was recognized as
having reduced levels of both transcript and protein in the knock out cells, containing a
previously identified binding site of HuR from PAR-CLIP, and a bioinformatics
predicted ARE-adjacent site for miR-200b which was increased in the HuR deficient
macrophages. Vegf-a mRNA was shown to immunoprecipitate with both Ago and HuR.
In reporter systems, the intact miR-200b site was necessary to mediate reduction of
luciferase expression with miR-200b transfection and concurrent HuR knockdown further
mediated this repression. An antagomiR blocking miR-200b only de-repressed Vegf-a
reporters if HuR was present and more Vegf-a mRNA was shown to associate with Ago2
in the absence of HuR. In a mouse tumor challenge, although wild type and myeloid
HuR knock out mice had similar myeloid invasion of the tumor microenvironment, the
tumors displayed defects in their vasculature and angiogenesis, and tumor growth was
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attenuated due to tumor cell apoptosis. Morpholino knock down of elavl1 zebrafish or
miR-200b mimic injection resulted in severe vascular development in the subintestinal
vein (SIV), while elavl1 mRNA rescued the defects from miR-200b overexpression.
Interestingly, using a suboptimal dose of either intervention resulted in fairly normal
vasculature, but when both were applied simultaneously, the majority of zebrafish had
defective SIV, supporting the antagonistic role of Ago and HuR in regulating vegfaa that
had been demonstrated in vitro (Chang et al. 2012).

Utilizing in vitro systems and reporter constructs, Ago-miR-19 demonstrated repression
of RhoB in an HuR dependent manner.

This repression was relieved during UV-

irradiation of keratinocytes leading to the apoptosis of these stressed cells (Glorian et al.
2011). In other cell culture studies using reporter constructs and recombinant protein
expression, HuR binding sites were shown to be necessary to mitigate Ago-let-7
mediated cleavage of IL-1B mRNA. The transfection of oligonucleotides specific for the
intervening sequences between the microRNA and HuR binding sites blocked Ago
repression of this transcript suggesting that oligomerization of HuR may be necessary for
its interaction in suppressing Ago cleavage (Kundu et al. 2012).

Previous Studies Using CLIP to Explore Co-Regulation of Ago and HuR Targets

Recent studies using Ago and HuR CLIP experiments have investigated the potential coregulation of mRNA by these RNA-binding proteins on a genome-wide scale. HuR
binding sites were recently identified in unstressed HeLa cells using PAR-CLIP. The
largest group of target sites was found in the 3’UTRs of transcripts, but around a third of
binding sites were in intronic regions of the message. These target sequences were
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highly evolutionarily conserved. In comparing HuR binding sites with Ago regulation
identified by PAR-CLIP in HEK293 cells, a preference for binding in areas of Ago
targeting was not observed. With knockdown of HuR in the HeLa cells, miR-7 was
shown to have increased expression levels that inversely correlated with the levels of
HuR. HuR binding sites in the intron and surrounding exons containing the microRNA
sequence were proposed to influence the levels of this microRNA, although no direct
mechanism was explored (Lebedeva et al. 2011).

HuR PAR-CLIP was also done in HEK293 cells with epitope-tagged protein.
Reproducible binding sites, determined by the crosslinking index of each sequenced tag,
were found predominantly in the introns and 3’UTRs of target mRNAs, suggesting that
pre-mRNA processing may be related to target stability. The authors suggest that the
PAR-CLIP data reflects both stable and transient HuR-mRNA interactions and that
targets identified by immunoprecipitation without crosslinking may reflect more stable
binding events as evidenced by HuR knockdown leading to a more profound affect on
identified targets’ mRNA stability in targets identified in the RIP-chip method.

In

comparing data from Ago PAR-CLIP from the same cell line with HuR PAR-CLIP
binding sites, significant overlapping patterns of regulation were observed for the two
proteins, suggesting the potential for competition of these proteins for effective binding
to targets and subsequent regulation. Still, the mRNA level changes seen with HuR
knockdown could be explained with or without the presence of overlapping or adjacent
microRNA binding sites. The authors suggest that this indicates a model of HuR using
physical competition for access to binding sites to mitigate microRNA-mediated
repression (Mukherjee et al. 2011).
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Accordingly, previous CLIP experiments comparing Ago and HuR regulation have been
completed in steady state cell culture systems and may not represent their binding
patterns in biologic systems or in dynamic cellular state changes. While PAR-CLIP has
been demonstrated to produce reliable binding site information for Ago and HuR proteins
in addition to the HITS-CLIP methods, the necessity for incorporating a photo-activatable
nucleotide analog into cells for PAR-CLIP analysis limits its utility in the study of
biologic systems (Kishore et al. 2011). In only one of the two described studies, Ago and
HuR binding maps were compared from the same type of cell line, nevertheless, they
were not the same biologic samples and in one case used an epitope tagged version of
HuR for immunoprecipitation in the HEK293 cells, which would not have been present in
the previous Ago studies to which they compare their results (Mukherjee et al. 2011).
Therefore, studying the dynamic regulation of Ago and HuR within a biologically
meaningful context is critical to the understanding of these important RNA regulators.

Perspectives

The adaptive immune response has been studied in great mechanistic detail and many of
the molecular processes involved T cell activation have been resolved. However, the
regulatory mechanisms mediating these complex systems in the context of rapid cellular
stress responses and disease are still not largely understood. Lymphocytes are required to
respond quickly to rapid changes they confront within their host.

When a T cell

encounters its cognate antigen, cytokine production must be carefully regulated to
instigate immediate induction of the inflammatory response, but also be transient to
ensure the protection of surrounding tissue. Therefore, although nascent transcription is
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large component of this response, it is logical that much of protein expression be
controlled at a post-transcriptional level. The Ago and HuR RNA-binding proteins have
been shown to be critical for normal lymphocyte development and the regulation of their
phenotypes. While their mRNA targets and binding sites has been vastly explored in the
literature, analysis of their regulation in biologic settings is limited. For these reasons,
we have undertaken to study the role of Ago and HuR regulation during CD8 T cell
activation by CD3 and CD28 stimulation in normal human donor CD8 lymphocytes. We
accomplished this by overlaying genome-wide HITS-CLIP binding maps, for Ago and
HuR, with translational profiles of the cells as they relate to transcriptional abundance.
Using these dynamic regulatory maps, we gain insight into the mechanisms governing T
cell stimulation.
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CHAPTER 2. Experimental Procedures

Peripheral Blood Isolation

Blood cells were collected by peripheral blood draw or leukapheresis under a Rockefeller
University IRB-approved protocol with informed consent.

PBMC were isolated by

density gradient centrifugation over Ficoll-Hypaque (Pharmacia).

Cell Culture

Cells were maintained at 37°C in 5% CO2. Human T cells were maintained T cell Media
(AIM V Medium (Invitrogen) supplemented with 1% pooled human sera). Mouse T cells
and other non-adherent cells were maintained in R10 medium (RPMI 1640 medium
(Mediatech) supplemented with 10% FBS (Hyclone), 2mM Glutamax (Gibco), sodim
pyruvate, non-essential amino acids, 15 mM Hepes buffer, 50 μM β-mercaptoethanol,
and gentimycin). Ascites cells were maintained in Growth Medium (equal volumes
MCDB105 medium (Sigma) and M199 medium (Invitrogen) supplemented with 10%
FBS, and penicillin-streptomycin_. All adherent cell lines mentioned were maintained in
D10 medium (DMEM high glucose (Mediatech) containing all of the same supplements
as R10).

Negative Selection of CD8 T cells

Human PBMC were incubated with a cocktail of biotin-conjugated antibodies specific for
markers on non-CD8 T cells from a CD8+ T cell Isolation Kit and then bound by antibiotin magnetic beads supplemented with anti-CD19, anti-CD56, anti-CD4 and anti-
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CD14 MACS beads (Miltenyi Biotech).

Cells were washed and run through two

magnetic columns collecting the flow through to isolate cells not bound by antibody.

Positive Selection of CD8 T cells

Human PBMC were incubated with anti-CD56 MACS beads (Miltenyi). These cells
washed and then were depleted by running the cells through two successive magnetic
columns collecting the flow through to isolate cells not bound by CD56 antibody. The
cells were then incubated with anti-CD8 MACS beads (Miltenyi), were washed, and
loaded onto a magnetic column to isolate antibody bound cells. After washing the
column, the positive cells were eluted by plunging the column. This selection process
was repeated on a second column to ensure cell purity. Mouse positive selection uses the
same protocol without the CD56 depletion.

To rest human T cells, cells were

resuspended at 2x106/ml and 5-10 ml was put in a 50 ml conical tube (Denville
Scientific) with loose caps at 37°C overnight.

After the resting period, cells were

harvested and filtered through a 70 µm cell strainer to remove dead cells and any debris
and the cells were collected by centrifugation.

CD3/CD28 Stimulation

T cells were plated at ~18x106/ml in R10 medium with 25 µl/106 T cells washed
CD3/CD28 mouse or human T-Activator Dynabeads (Invitrogen). Cultures were agitated
every 12 minutes to aid in the dispersal of stimulatory beads to each T cell. After one
hour, cells were harvested and processed for future analysis.
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Flow Cytometry Surface Staining

All surface antibodies were purchased from BD Biosciences. Cell surface expression of
markers were measured using fluorescently-conjugated antibodies according to the
manufacturer’s instructions.

Cells were resuspended in 100 µl FACS buffer: PBS

supplemented with 1% PHS, 1% FBS (HyClone), and for mouse cells 5% goat serum.
Mouse cells were then Fc blocked for 10 minutes using 1 µg of anti-CD16/CD32
(FcγRII/III). For both human and mouse cells, 1 µg of each antibody was added directly
to the cells. Human cells were incubated for 10 minutes at room temperature in the dark
and mouse cells were incubated for 15 minutes at 4°C. Cells were washed twice with
FACS buffer and collected immediately on a BD FACScaliber machine and analyzed
using Flowjo software (Treestar).

Reverse Transcription and Quantitative PCR Analysis

Total RNA was extracted from CD8 T cells using an RNeasy Mini Kit with on-column
DNAse treatment (Qiagen) and eluted in 20 µl of RT-grade H2O. RNA was then reverse
transcribed using the iScript cDNA Synthesis Kit (BioRad) as per manufacturer’s
instructions. cDNA was amplified by qPCR using iTaq SYBR Green Supermix with
ROX (Biorad) on an iQ5 Multicolor Real-Time PCR Detection System (Biorad) using a
58°C annealing temperature and both melt curves and -RT controls were performed.
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Primers

Human IFNG
Forward: TCAGCTCTGCATCGTTTTGGGTTC
Reverse: TCCGCTACATCTGAATGACCTGCAT
Human TNF
Forward: CTGCCTGCTGCACTTTGGAGTGAT
Reverse: TGGGCCAGAGGGCTGATTAGAG
Mouse Ifng
Forward: CAGCAACAGCAAGGCGAAAAAGG
Reverse: TTTCCGCTTCCTGAGGCTGGAT
Mouse Gapdh
Forward: TGAACGGGAAGCTCACTGGCAT
Reverse: TCAGATGCCTGCTTCACCACCT

Western Blot

T cells were lysed in PXL by three cycles of freezing and thawing. DNA was removed
from lysate by DNase treatment at 37°C for 5 minutes. Samples were spun at 14,000rpm
for 10 minutes at 4°C and the supernatant was harvested to a new tube. NuPAGE loading
sample buffer and reducing agent (Invitrogen) were added to 1x concentrations in the
lysate and samples were heated for 15 minutes at 70°C. Lysate was run on a 8% (Ago) or
10% (HuR) NuPAGE Bis-Tris gel (Invitrogen) in MOPS Buffer and transferred to
Protran BA85 nitrocellulose (Whatman) or Immobilon-FL PVDF (Millipore) by standard
methods.

For nitrocellulose membranes, membranes were blocked for 1hr at room
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temperature in 5% non-fat dry milk (Carnation) in PBS followed by addition of primary
antibody for 1 hour at room temperature or overnight at 4°C. Blots were washed 3x10
minutes with Western blot wash buffer (23mM Tris, pH 8.0, 190mM NaCl, 0.1% w/v
BSA, 1 mM EDTA, 0.5% Triton X-100, 0.02% SDS) after each antibody incubation.
HRP-conjugated secondary antibodies (Jackson Immunochemicals) were used at
1:10,000 dilution in 5% milk/PBS for 1 hr at RT, washed as before, and HRP signal was
detected by Enhanced ChemiLuminescence (Western Lightning detection kit, Perkin
Elmer) and detected on film (Kodak MR). For Immobilon-FL membranes, membranes
were blocked for 1 hour at room temperature in Odyssey Blocking Buffer (LI-COR)
followed by the addition of primary antibody in LI-COR Antibody Buffer (50 mM TrisHCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20, 2% BSA and 0.02% Sodium Azide), for 1
hour at room temperature or overnight at 4°C. Blots were washed 4x5 minutes in TBST
after each antibody incubation. Fluorescently-conjugated secondary antibody (Goat antimouse IgG IRDye, 827-08364, LI-COR) was used at 1:30,000 Dilution in LI-COR
Antibody Buffer for 45 minutes rocking at room temperature shielded from light by foil.
The blots were washed 3 times as before and then once with TBS without tween.
Fluorescent signal was detected on the Odyssey LI-COR machine.

Ago and HuR HITS-CLIP

Bead Preparations for Immunoprecipitation

Protein A beads were vortexed and an aliquot was washed 3x in PBS with 0.02% Tween20. Beads were pre-coated with rabbit anti-mouse IgG (Jackson ImmunoResearch, 315005-008 at 2.3 mg/ml) as a bridging antibody (1 µl antibody per 2 µl beads for HuR or 1
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µl antibody per 8 µl beads for Ago) for 35 minutes rotating at room temperature. Beads
were washed 3x in PBS with 0.02% Tween-20. HuR or Ago antibody was then loaded to
the beads. For HuR 1.7 µg/µl beads of 19F12 or 3A2 was added (Santa Cruz, (Gallouzi
et al. 2000; Wang et al. 2000)). For Ago, 3 µl of 2A8 ascites (provided by Dr. Zissimos
Mourelatos (Nelson et al. 2007)) is added per 400 µl beads. For irrelevant antibody
controls, equivalent amounts of 7G1-1 antibody was added (Memorial Sloan-Kettering
Cancer Center Monoclonal Antibody Core Facility, (Brown et al. 2001)). For Ago CLIP
with Protein G beads, beads are washed in the same way, but no bridging antibody is
needed and 3 µl 2A8 is added per 200 µl beads. Beads were rotated for 2 hours at 4°C to
bind antibody. Generally, for HuR CLIP, we used roughly 20 µl of beads per 10 million
CD8 T cells, and for Ago CLIP, 40 µl beads per 10 million CD8 T cells.

After

incubation with the antibodies for immunoprecipitation, the beads were washed once in
PBS with 0.02% Tween-20 and three times in lysis buffer containing complete protease
inhibitor mini EDTA free tablets (1 tablet/10 ml buffer) (Roche).

T cell Lysate Preparation

T cells were UV crosslinked as indicated on a bed of ice three times at 200 mJ/cm2 (254
nm UV light) in a minimal volume of PBS with swirling between each irradiation, using
a Stratalinker 2400 (Stratagene). Lymphocyte lysate was prepared by adding a volume of
1 ml PXL lysis buffer (1X PBS [tissue culture grade; no Mg2+, no Ca2+, GIBCO], 0.1%
SDS, 0.5% Na-DOC, 0.5% NP-40) with complete protease inhibitor and the buffer was
pipet multiple times to mix and resuspend cells in the buffer. T cells were rested on ice
for ten minutes with vortexing 15 seconds every 2 minutes to ensure complete lysis. The
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lysate was then DNase treated with RQ1 RNase-free DNase (Promega) for 5 minutes
shaking in the Thermomixer R at 37°C. 5 µl of a 1:100 (high) or 1:10,1000 (low) RNase
A solution was added to each sample as indicated and the lysate was incubated in the
Thermomixer R for 5 minutes shaking at 37°C. The lysate was spun at 14,000 rpm for 30
minutes at 4°C to clear the lysate and the supernatant was harvested to a new tube for
immunoprecipitation.

Samples were then rotated with primary antibody-loaded beads at 4°C for 2 hours.
Following IP beads were washed sequentially (1 ml washes) twice with 1X PXL lysis
buffer, twice with 5X PXL (5X PBS [tissue culture grade; no Mg2+, no Ca2+, GIBCO],
0.1% SDS, 0.5% Na-DOC, 0.5% NP-40), twice with high stringency buffer (15 mM TrisHCl, pH 7.5, 5 mM EDTA, 2.5 mM EGTA, 1% Triton X-100, 1% Na-deoxycholate
(DOC), 0.1% SDS, 120 mM NaCl, 25 mM KCl), high salt buffer (15 mM Tris-HCl, pH
7.5, 5 mM EDTA, 2.5 mM EGTA, 1% Triton X- 100, 1% Na-DOC, 0.1% SDS, 1 M
NaCl) and twice with low salt buffer (15 mM Tris- HCl, pH 7.5, 5 mM EDTA) followed
by two washes with NT-2 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2,
and 0.05% NP-40) and two washes with PNK buffer (50mM Tris-HCl, pH 7.5, 10 mM
MgCl2, 0.5% NP-40). After each capture on the magnet beads, the beads were
resuspended by end-over-end rotation. Throughout the washes tubes were treated in a
random order to diminish the chance of artifacts. Throughout the CLIP protocol 1.5 ml
SlickSeal microfuge tubes (National Diagnostics) were used to reduce non-crosslinked
RNA binding to tubes.
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Dephosphorylation of RNA, 3’ Linker Ligation, and Rephosphorylatoin of 5’ end of RNA
Tags

Immunoprecipitations were treated with calf intestinal phosphatase to remove the 5’
phosphate from RNA crosslinked to Ago and HuR (RNA tags) so that the RNA could not
circularize during ligation, an otherwise predominant competing intramolecular reaction.
Beads were resuspended in 60 µl of 1X dephosphorylation buffer and 3 units of CIAP
(Roche) with RNAsin Plus RNase Inhibitor (Promega) and incubated in the Thermomixer
R at 37°C for 20 min, programmed to shake at 1000rpm for 15 s every 2 min. This was
followed 1 ml washes, once with PNK Buffer, twice with PNK buffer with EGTA
(10mM Tris pH 7.5, 20mM EGTA, 0.5% NP-40) and twice again with with PNK buffer
(no EGTA).

For Ago CLIP, to ligate a
puromycin-

blocked
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P-labeled RNA linker to the 3’ end of the RNA, the

linker

(L32,

5’-OH-GUGUCAGUCACUUCCAGCGG-3’-

puromycin, Dharmacon) was first labeled using T4 phosphonucleotide kinase (PNK, New
England Biolabs, NEB). 50 pmol of L32 RNA, 15 µl 32P-γ-ATP, 1 µl RNAsin and 2 µl
of T4 PNK in 1X PNK buffer were incubated at 37°C for 30 min, an additional 0.02 ml 1
mM ATP to drive the reaction to complete and was incubated 5 min. Radiolabeled linker
was spun through a G-25 column (Amersham) to remove free ATP. 30 pmol of the
labeled 3’RNA linker was added to a 60 µl T4 RNA ligase reaction (Fermentas),
according to kit instructions, and on-bead ligation reactions were incubated at 16°C for 1
hr in a thermomixer programmed to shake at 1000rpm for 15 sec every 4 min. After 1 hr,
80 pmol of cold L32 RNA linker with 5’ phosphate was added to each tube and incubated
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overnight. For HuR CLIP, only the cold L32 RNA linker with 5’ phosphate was used for
ligation overnight.

Following linker ligation, the beads were washed three times with PNK buffer. To
rephosphorylate the 5’ end of the RNA for 5’ linker ligation, 80 ul of T4 PNK mix (6 ul
of 1 mM ATP, 4 ul T4 PNK enzyme [NEB], 1 ul RNasin in 1X T4 PNK buffer [NEB],
total volume 80ul) was added to each tube and incubated at 37°C in the Thermomixer R
for 20 min at 1000 rpm shaking for 15 sec every 4 min. For HuR CLIP, this step was
done in the presence of 32P-γ-ATP for 20 minutes and then 1 mM cold ATP was added to
drive the reaction to completion for 5 additional minutes at 37°C. Beads were washed
three times with 1 ml PNK buffer.

SDS-PAGE Separation of RNA-binding Protein:RNA Complexes

After last PNK buffer wash, each tube of beads was resuspended in 30 ul NuPAGE
loading buffer (LDS, Invitrogen) brought to 1x concentration with PNK buffer and
containing reducing agent for Ago CLIP. The beads were incubated in the Thermomixer
R at 70°C for 10min shaking at 1000 rpm. Supernatants were taken off the beads and run
on Novex NuPAGE 10% Bis-Tris gels for HuR and 8% for Ago (Invitrogen) in MOPS
running buffer (Invitrogen) for 2 hr at 175V and transferred to Protran BA85
nitrocellulose (Whatman) using a Novex wet transfer apparatus (Invitrogen). After
transfer, the nitrocellulose was quickly rinsed with RNase-free PBS, blotted with
Kimwipes, wrapped in plastic wrap and exposed to Biomax MR film (Kodak).
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Recovery of Complexes, Protease Digestion, and 5’ Linker Ligation

Nitrocellulose membranes were aligned carefully with the exposed film and filter excised
fro the low RNase immunoprecipitation lanes at a size directly above the overdigested
band as indicated in Figure 4.3 and Figure 5.2 with a scalpel. Each band of nitrocellulose
membrane was further cut into smaller pieces and proteinase K treated (0.2 ml of a 1:5
dilution of proteinase K (4 mg/ml, Roche) in PK buffer (100 mM Tris-Cl pH 7.5, 50 mM
NaCl, 10 mM EDTA)) in the Thermomixer R at 37°C, shaking at 1100 rpm for 20
minutes. Then 0.2 ml of PK buffer with 7M urea solution was added and incubated for
another 20 minutes at 37°C shaking at 1100 rpm. Finally, 0.4 ml of RNA phenol (pH 6.8,
Applied Biosystems/Ambion) and 0.13 ml of 49:1 CHCl3:isoamyl alcohol were added
and incubated at 37°C, shaking at 1100 rpm for additional 20 min. Tubes were spun at
20,000g in a desktop microcentrifuge at room temperature. Glycogen (0.8 ul, Applied
Biosystems/Ambion), 50 ul 3M NaOAc pH 5.2, and 1 ml of 1:1 ethanol:isopropanol were
added to the aqueous phase in a fresh tube and RNA was precipitated overnight at -20°C.

RNA was pelleted, washed twice with 75% ethanol. The pellet dried and dissolved in 6
ul RNase-free H2O. RNA ligation to add the 5’ linker (RL5D: 5’-OHAGGGAGGACGAUGCGGr(N)r(N)r(N)r(N)G3’-OH) was performed with 1 µl 10X T4
RNA ligase buffer (Fermentas), 1 µl BSA (0.2 µg/µl), 1 µl ATP (10mM), 0.1 µl T4 RNA
ligase (3U, Fermentas), and 20 pmol of RL5D RNA linker in a total volume of 10 µl in
the Thermomixer R at 16°C for 5 hrs. To the ligation reaction, 79 µl H2O, 11 µl 10X
RQ1 DNase buffer, 5 µl RQ1 DNase (Promega) and 5 ul RNasin (Promega) were added
and incubated at 37°C for 20 min. 300 µl H2O, 300 µl RNA phenol (Ambion) and 100 µl
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CHCl3 were added, vortexed, spun and the aqueous layer taken. RNA was precipitated
with 50 ul 3M NaOAc pH 5.2, 0.5 µl glycogen (Ambion) and 1 ml 1:1
ethanol:isopropanol overnight at -20°C.

RT-PCR and High-Throughput Sequencing of PCR Products

RNA was pelleted, washed, dried as before, and resuspended in 10 µl of RNase-free H2O.
2 µl of resuspended RNA was used as a –RT control and was brought to the same volume.
The RNA was mixed with 2 µl of primer P32 (3’ DNA primer 32, 5’CTTCACTCACCTCGCAACCG-3’, Operon) at 5 pmol/µl, and 3 µl 3mM dNTPs, and
incubated at 65°C for 5 min in the Thermomixer R, chilled, and spun briefly. 1 µl 0.1M
DTT, 4 µl 5X SuperScript RT buffer, 1 µl RNasin, and 1 µl SuperScript III (Invitrogen)
were added and incubated at 50°C for 45 minuntes, 55°C for 15 minutes, 90°C for 5
mininutes and then moved onto ice. PCR reactions were performed immediately with 27
µl Accuprime Pfx Supermix (Invitrogen), 0.75 µl P51 (5’ DNA primer 51, 5’AGGGAGGACGATGCGG-3’, Operon) at 20 pmol/µl, 0.75 µl P32 primer, 20 pmol/ul
and 2 µl of the RT reaction, incubated at 95°C for 2 minutes and then cycled for 20-35
cycles using a program of 95°C for 20 seconds, 58°C for 30 seconds, and 68°C for 30
seconds. A 10% denaturing polyacrylamide was poured and the entire PCR reaction was
loaded along with 3 µl of Amplisize Molecular Ruler (Biorad). To visualize DNA, the
gel was immersed in a 1:10,000-fold dilution of SYBR Gold (Molecular Probes) in TBE
for 10 minutes.

Routinely, aliquots of the reaction were removed at various cycle

numbers and product excised from the lowest cycle number giving visible product.
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Remaining RT reaction was then brought up to this minimal cycle number, gel purified
and the products were pooled with the smaller reactions. Acrylamide bands containing
DNA of 60-100nts were excised and DNA purified by crushing in diffusion buffer (0.5M
ammonium acetate, 10mM Mg acetate, 1mM EDTA, 0.1% SDS), incubating at 50°C for
30 min at 1200 rpm, and filtering through Whatman GF/D filters in Nanosep columns
(VWR). DNA was recovered from filtrate using Qiaquick gel purification buffers and
columns (Qiagen) and eluted in 30 µl TE. An additional PCR reaction was performed
using the following fusion primers to permit sequencing on the Illumina platform.

SP5fusion:
5’AATGATACGGCGACCACCGACTATGGATACTTAGTCAGGGAGGACGATGC
GG3’
SP3fusion:
5’CAAGCAGAAGACGGCATACGACCGCTGGAAGTGACTGACAC3’

PCR amplification was performed using Accuprime Pfx (Invitrogen) and ranged between
6 and 12 cycles. The product was then run on a 2% NuSieve agarose gel and purified
using Qiaquick spin columns (Qiagen). A total of 10-30 µl of DNA (quantified using the
Quant-IT kit (Invitrogen)) at 10 nM was submitted for sequencing. The sequencing of
CLIP tags was performed using the sequencing primer SSP1 on an Illumina HiSeq.

SSP1:
5’CTATGGATACTTAGTCAGGGAGGACGATGCGG3’
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Data analysis was done using the Galaxy platform (Hillman-Jackson et al. 2012) and
using R Statistical Analysis Software (http://www.R-project.org).

Preparation of samples for RNA Sequencing analysis

RNA was prepared from CD8 T cells using the High Pure RNA extraction kit (Roche) as
per manufacturer’s instructions and the standard Illumina TruSeq protocol was followed
to prepare samples for high-throughput sequencing.

Ribosomal Profiling and mRNA Sequencing

T cell Lysate Preparation and Sucrose Gradients

CD8 T cells were treated for 8 minutes with 100 µg/ml cycloheximide at 37°C. Treated
cells were harvested and collected by centrifugation. Lysates were prepared in Lysis
Buffer (10 mM Tirs-HCl, pH 7.4, 5 mM MgCl2, 100 mM KCl), which was supplemented
freshly before lysis with 1% Triton X-100, 2 mM DTT, 100 µg/ml cycloheximide, 500
U/ml RNasin Plus (Promega), and complete protease inhibitor mini EDTA free tablets (1
tablet/10 ml buffer) (Roche). The lysate in a volume of 600 µl was homogenized gently
four times with a 26-gauge needle at 4°C. The lysate was then clarified by centrifugation
at 14,000 rpm for 10 minutes on a desktop microcentrifuge at 4°C. The supernatant was
collect and 6 µl 10 mM CaCl2 was added to a final concentration of 1 mM. 1000 U/ml
micrococcal nuclease was added to T cell lysate and was incubated rotating at room
temperature for 25 minutes. 9.6 µl 0.5 M EGTA was added and the lysate volume was
adjusted to 1.1 ml with lysis buffer for layering on sucrose.
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Equal volumes of supernatants were loaded onto a 10%–50% w/v linear density gradient
of sucrose in Lysis Buffer without the added supplements and prepared using a Gradient
Master 107 (BioComp), in 14x3x89 mm polyallomer ultracentrifuge tubes (Beckman
331372). Gradients were centrifuged at 35,000 rpm for 3 hours at 4°C in a Beckman
SW41 rotor and sixteen fractions of 0.72 ml volume were collected with continuous
monitoring at 254 nm using an ISCO UA-6 UV detector.

Isolation of Ribosomal Protected Fragment RNA

The pooled material from sucrose fractions 6-8 was spun through Ultra-4 centrifugal
filters with Ultracel-100 membranes (Amicon) at 1900g for 30 minutes at 4°C. 1.2 ml
ice-cold Release Buffer (20 mM HEPES-KOH, 100 mM KCl, 1 mM EDTA, 2 mM DTT,
20 U/ml SUPERaseIn (Ambion)) was added to the membrane and incubated on ice for 10
minutes. The filters were then spun again at 1900g for 15 minutes at 4°C with a new 15
ml collection tube. The filtrate was supplemented with SDS to 1% and treated with
proteinase K (200 µg/ml) for 30 minutes at 42°C. The RNA was extracted by acid
phenol:chloroform (pH 4.5, Ambion) with 360 µl Phenol, 120 µl 49:1 CHCl3:isoamyl
alcohol. The samples were vortexed and the aqueous layer was separated by spinning at
14,000 rpm in a desktop microcentrifuge for 10 minutes at room temperature. The
aqueous layer (~400 µl) was supplemented with 40 µl 3M NaOAc pH 5.5, 1 µl Glycogen,
and 1 ml 100% EtOH. The solution was inverted and left at -20°C overnight for the
RNA to precipitate.
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Isolation of Poly-A RNA and Partial Alkaline Hydrolysis

Matching aliquots of CD8 T cells also treated with cycloheximide as described above
were resuspended in 1 ml Trizol and the RNA was chloroform extracted with 200 µl 49:1
CHCl3:isoamyl alcohol. The solution was mixed and incubated for 3 minutes at room
temperature followed by centrifugation at 14,000 rpm in a desktop microcentrifuge for 15
minutes at room temperature. The aqueous layer was transferred to a new tube and
supplemented with 1 µl Glycogen and 500 µl Isopropanol. The RNA was precipitated at
-20°C for 2 hours. The RNA was pelleted by centrifugation at 14,000 rpm in a desktop
microcentrifuge for 20 minutes at 4°C. RNA pellets were washed twice with 80% EtOH
and then air dried for 10 minutes on the bench top. RNA was resuspended in 30 µl H2O
and heated at 65°C for 2 minutes and placed on ice. The Dynabeads mRNA Purification
Kit (Invitrogen) was used to select for poly-A RNA as per manufacturers instructions
using (145 µl Oligo (dT)25 beads per RNA sample from 25x106 T cells). Poly-A selected
RNA was eluted from the beads in 75 µl PBS heated at 80°C for 2 minutes and
transferred to a new tube. 3.75 µl 1M NaOH was added to the sample, mixed well and
spun down. It was then incubated at 37°C for 30 minutes to fragment RNA shaking 15
seconds at 1250 rpm every 1.5 minutes in the Thermomixer R. 3.75 µl 1M HCl was
added to quench the base and 0.825 µl 1M HEPES added to buffer the solution. 1 µl
Glycogen was added followed by 1 ml 100% EtOH. The solution was inverted and left at
-20°C overnight for the RNA to precipitate.
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PNK Treatment and Size Selection

Both the ribosomal protected fragment (RPF) and alkaline hydrolyzed poly-A selected
(mRNA) were pelleted by centrifugation at 14,000 rpm in a desktop microcentrifuge for
20 minutes at 4°C. RNA pellets were washed twice with 80% EtOH and then air dried
for 10 minutes on the bench top. RNA was resuspended in 30 µl H2O supplemented. To
rephosphorylate the 5’ end of the RNA, the RNA was treated with PNK (4 µl PNK
enzyme, 2 µl SUPERasin, 4 µl PNK Buffer) for 1 hour at 37°C, 75°C for 10 minutes and
then moved to ice. 20% polyacrylamide Urea gel was poured and the entire RNA sample
was loaded along with microRNA marker (New England Biolabs, N2102S), low range
ssRNA Ladder (New England Biolabs, N0364S), and RNA 32-mer oligonucleotide (also
PNK treated to match running conditions of sample). To visualize RNA, the gel was
immersed in a 1:10,000-fold dilution of SYBR Gold (Molecular Probes) in TBE for 10
minutes. Gel fragments were cut from gel at ~35 nucleotides for RPFs and between ~3555 nucleotides for mRNA, as indicated in Figure 7.8. 400 µl RNA gel Extraction Buffer
(300 mM NaOAc, 1 mM EDTA, 0.1 U/ml SUPERasin) was added to each gel slice
which was crushed in buffer with the plunger of a 1 ml syringe. Crushed slices were then
frozen on dry ice for 30 minutes to help dissociation. The crushed gel was then rotated in
buffer overnight at 4°C after which the RNA solution was filtered through Whatman
GF/D filters in Nanosep columns (VWR). 2 µl Glycogen was added and 1 ml EtOH was
used to precipitate RNA at -20°C for at least 2 hours or overnight.

46

Poly-A Tailing Reaction

Protein-G Dynabeads were prepared by washing three times in Antibody Binding Buffer
(ABB) (1X PBS, pH 7.4 with 0.02% Tween-20). Beads were resuspended in 225 µl/50
µl beads ABB with 25 µl/50 µl beads Denhardt’s Solution (Sigma). The beads were
blocked rotating at room temperature for 45 minutes to 1 hour. RNA was pelleted by
centrifugation at 14,000 rpm in a desktop microcentrifuge for 20 minutes at 4°C. RNA
pellets were washed twice with 80% EtOH and then air dried for 10 minutes on the bench
top. 6.25 µl H2O was added to RNA pellet and it was left on ice to go into solution aided
by tapping of the tube and then the material was spun down. RNA was denatured at
65°C for 5 minutes and then placed immediately on ice. RNA was added to a reaction
poly-A tail reaction mixture of 1 µl 10X E-PAP Buffer (NEB), 1.5 µl 1 mM ATP, 1.5 µl
RNAsin Plus (Promega), and 1 µl 3U/µl E-PAP (NEB) in a PCR tube. The RNA was
polyadenylated at 37°C for 10 minutes, 65°C for 20 minutes, and then moved to ice.

Reverse Transcription Reaction

Protein-G Dynabeads blocking in ABB and Denhardt’s Solution were washed 3 times
with ABB. For 250 µl original bead volume, we added 100 µl ABB, 25 µl Denhardt’s
Solution, 125 µl anti-BrdU antibody (Santa Cruz, sc-32323) and rotated at room
temperature for a minimum of 45 minutes. The poly-A tailed RNA was spun down and
2.5 µl of each sample was pooled together for a final volume of 10 µl for –RT control.
The RNA was supplemented with 1 µl H2O, 1 µl 0.752 M Tris, 1 µl each of dATP, dCTP,
dGTP (8.2 mM, Invitrogen) and 1 µl Br-dUTP (8.2 mM, Sigma). 1 µl of 25 µM primers
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was added to each tube (NV20T-RT1 for RPF samples and NV20T-RT 2 for mRNA
samples) and 0.5 µl of each were added to the –RT control.

NV20T-RT1:
5’pGACATCGTNNNNNNGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGATTTTTTTTTTTTTTTTTTTTVN
NV20T-RT2:
5’pGCACTGTTNNNNNNGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGATTTTTTTTTTTTTTTTTTTTVN

The samples were quickly spun down and incubated at 75°C for 3 minutes. A prewarmed mixture of 1 µl 82 mM DTT, 1 µl 10U/µl RNAsin Plus (Promega) and 1 µl
Superscript III (or H2O for –RT control) were added to each sample and the reverse
transcription reaction was incubated at 48°C for 45 minutes, 55°C for 15 minutes, 85°C
for 5 minutes and then moved to ice.

cDNA Purification: Immunoprecipitation I

Protein-G Dynabeads labeled with anti-BrdU antibody were washed three times in IP
Buffer (0.3x SSPE, 1mM EDTA, 0.5% Tween-20). 1 µl 2U/µl RNase H (Invitrogen)
was added to each reverse transcription reaction and incubated at 37°C for 20 minutes to
digest RNA and then placed on ice. 10 µl H2O was added to the reaction and then it was
spun through a G-25 column (Amersham) to remove free nucleotides. The flow through
was adjusted to a final volume of 100 µl with H2O and then incubated at 70°C for 5
minutes and at room temperature for 2 minutes. 25 µl of original slurry volume of
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Protein-G beads in 100 µl IP Buffer was added to fresh tubes and the supernatant was
removed. cDNA was added to the beads and the beads were resuspended by tapping,
trying to keep everything at the bottom of the tube. Beads were rotated for 30 minutes at
room temperature to immunoprecipitate the cDNA via the incorporated Br-dUTP. The
beads were then washed with 900 µl of each buffer for 3 minutes at room temperature.
First, they were washed once with IP Buffer with Denhardt’s (4.5 ml IP Buffer/0.5 ml
Denhardt’s), then twice with low salt buffer (15 mM Tris- HCl, pH 7.5, 5 mM EDTA)
with 2% Denhardt’s, twice with high stringency buffer (15 mM Tris-HCl, pH 7.5, 5 mM
EDTA, 2.5 mM EGTA, 1% Triton X-100, 1% Na-deoxycholate (DOC), 0.1% SDS, 120
mM NaCl, 25 mM KCl) with 2% Denhardt’s, and twice with IP Buffer without
Denhardt’s. The last wash was completely removed from the beads and 50 µl 100 µM
BrdU (Sigma) in IP Buffer was added to competitively elute the cDNA off of the beads.
Beads were resuspended in solution by tapping and rotated for 30 minutes at room
temperature. The beads were placed on the magnet and the eluate was collected and spun
through a G-25 column. The flow through was adjusted to 150 µl total volume with H2O.
This cDNA solution was stored overnight at 4°C.

cDNA Purification: Immunoprecipitation II

After leaving the samples overnight, the immunoprecipitation was repeated. The cDNA
solution was quickly vortexed and spun down. It was incubated at 70°C for 5 minutes
and at room temperature for 2 minutes. 25 µl of original slurry volume of Protein-G
beads in 100 µl IP Buffer was added to fresh tubes and the supernatant was removed.
cDNA was added to the beads and the beads were resuspended by tapping, trying to keep
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everything at the bottom of the tube.

Beads were rotated for 30 minutes at room

temperature to immunoprecipitate the cDNA via the incorporated Br-dUTP. The beads
were then washed with 900 µl of each buffer for 3 minutes at room temperature. First,
they were washed once with IP Buffer with 10% Denhardt’s, twice with low salt buffer
with 2% Denhardt’s, twice with high stringency buffer with 2% Denhardt’s, and twice
with IP Buffer without Denhardt’s. The last wash was completely removed from the
beads.

cDNA Circularization and Relinearization

20 µl CircLigase reaction mixture (2 µl CircLigase 10X Reaction buffer, 4 µl 5 M
Betaine, 1 µl 50 mM MnCl2, 0.5 µl (50U) CircLigase ssDNA Ligase II (Epicentre), and
12.5 µl H2O) was added to the beads which were tapped into solution. This reaction was
incubated at 60°C for 1 hour in the Thermomixer R to circularize the cDNA. The beads
were collected and washed twice in low salt buffer with 2% Denhardt’s, twice with high
stringency buffer with 2% Denhardt’s, and twice with APE1 wash buffer (50 mM
Potassium Acetate, 20 mM Tris-Acetate, 10 mM Magnesium Acetate, pH 7.9). The last
wash was removed from the beads completely and the cDNA was relinearized using an
APE1 cut site with 2 µl 10X Reaction Buffer (NEB4), 1.25 µl 10U/µl APE1 (NEB), and
16.75 µl H2O. This reaction was incubated for 1 hour at 37°C in Thermomixer R
shaking at 1300 rpm for 15 seconds every 30 seconds. The beads were again washed
twice in low salt buffer with 2% Denhardt’s, twice with high stringency buffer with 2%
Denhardt’s, and twice in Phusion Wash Buffer (50 mM Tris pH 8.0).
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PCR Amplification and High-Throughput Sequencing

To amplify the cDNA, PCR was done with Phusion Polymerase. First, 37.5 µl H2O, 10
µl 5X Phusion HF Buffer, and 1 µl 10 mM dNTPs wre added to the beads. This was
incubated at 98°C for one minute shaking at 1200 rpm in the Thermomixer R to elute the
cDNA from the beads. This was quickly placed on the magnet and the eluate was
collected to a a PCR tube with an optically clear cap. This solution was supplemented
with PCR primers and DNA polymerase (0.5 µl 20 µM DP5 PAT, 0.5 µl 20 µM DP3
PAT, and 0.5 µl Phusion DNA Polymerase (NEB). SYBR Green I was diluted from
10,000X to 50X in Phusion Wash buffer and 0.5 µl was added to the PCR reaction and
mixed by pipetting. Tubes were placed in the iQ5 Multicolor Real-Time PCR Detection
System (Biorad) and pushed in place using a Kimwipe so as not to touch the lid. The
tubes were incubated at 98°C for 30 seconds and then cycled at 98°C for 10 seconds,
60°C for 15 seconds, and 72°C for 20 seconds until the RFU signal reached ~800-1000.
Note that the display is a cycle behind the detection so the tubes need to be removed
when the display signals ~400-500 to account for doubling.

10 nM solution was

submitted for sequencing and data analysis was done using the Galaxy platform
(Hillman-Jackson et al. 2012) and using R Statistical Analysis Software (http://www.Rproject.org).

DP5 PAT:
5’-AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGACG
DP3 PAT:
5'-CAAGCAGAAGACGGCATACGA
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Illumina Small RNA Sequencing Primer:
5’ -CGACAGGTTCAGAGTTCTACAGTCCGACGATC

Mice

Wild-type C57BL/6 mice (stock number 000664), Lck-Cre mice (stock number 003802),
and A2.1 transgenic AAD mice (stock number 003475) were purchased from The
Jackson Laboratory. CD4-Cre mice (stock number 4196-F/M) were purchased from
Taconic Farms. HuRfl/fl mice were obtained from Dr. Dimitris Kontoyiannis (Katsanou et
al. 2009). HuD knock out mice were obtained from Dr. Hideyuki Okano (Akamatsu et al.
2005).

Ocular Blood Draw

Mouse peripheral blood was obtained by ocular blood draw with heparinized capillary
tubes. 5 drops were taken into 10 milliliters PBS.

Flow Cytometry Intracellular Staining

For intracellular staining, cells were incubated for 20 minutes at 4°C in the
Fixation/Permeabilization solution from the Cytofix/Cytoperm kit (BD Biosciences).
Cells were then permeabilized by washing in the BD Perm/Wash Buffer (PWB). Cells
were stained in PWB with the indicated primary antibodies, for example HuR specific
mouse monoclonal antibody 3A2, for 1 hour rocking on ice and covered in foil. Cells
were washed twice and then incubated with anti-mouse IgG (Fc-specific) polyclonal goat
F(ab')2 fragment conjugated with DyLight 649 (Jackson Immunoresearch) at a dilution of
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1:1000 in PWB for 30 minutes rocking on ice and covered in foil. After this incubation,
cells were washed twice in PWB and once in FACS Buffer.

Cells were collected

immediately on a BD FACScaliber machine and analyzed using Flowjo software
(Treestar).

Single Linker Ligation CLIP

This protocol was used for Ago CLIP in HuR Wild-Type and cKO Mice. Samples were
prepared as described in the standard CLIP methods starting with T cell lysate
preparation through the recovery of protein-RNA complexes and protease digestion,
except that a different 3’ linker sequence was used which matches the Illumina small
RNA sequencing primer.

SRA3:
5'-P UCGUAUGCCGUCUUCUGCUUG 3'-puromycin

No 5’ linker ligation is used in this protocol and instead it follows the same cloning
strategy as detailed in the ribosomal profiling and mRNA sequencing methods section
starting at the reverse transcription step. The only modifications from the ribosomal
profiling methods are that different reverse transcription primers were used matching the
3’ linker sequence instead of the stretch of poly-A’s and it was indexed as indicated for
each sample. The PCR and sequencing primers were the same as for ribosomal profiling
and mRNA sequencing.
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Index 1a GCAT:
5’pGNNNNNNNNGATGCGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA
Index 2a GTCA:
5’pGNNNNNNNNGTGACGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA
Index 3a ACTG:
5’pGNNNNNNNNGCAGTGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA
Index 4a AGCT:
5’pGNNNNNNNNGAGCTGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA
Index 6a TCGA:
5’pGNNNNNNNNGTCGAGATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGAAG
ACGGCATACGA

Adenovirus production

Recombinant adenoviruses expressing GFP, β-galactosidase, or HuD-GFP were produced
by transduction of HEK293 cells (ATCC) and purified using the Adenopure Kit
(Puresyn) according to the manufacturer’s instructions. Viral titers were assessed by
infection of HEK293 cells with serial dilutions of purified virus followed by
determination of the number of virally infected cells after 20 hours by fluorescence or XGal staining.
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Adenovirus Immunizations

6-8 week old mice were injected with 100 µl purified adenovirus (109 PFU/ml)
intradermally and treated with pertussis toxin (Sigma) intraperitoneally at days 0 and 2.

Mouse T cell in vitro Stimulation
Around 3x107 splenocytes, or half a spleen per flask, from adenovirus-immunized mice
were incubated at 37°C in upright T25 culture flasks (Corning) in R10 with 0.5 µM
peptide for 7 days. For further rounds of re-stimulation, splenocytes were plated in 24
well plates (2-6x105 splenocytes per well) with peptide-pulsed feeder cells in R10 with 50
CU/ml recombinant human IL-2 (Chiron). Feeder cells were prepared from spleens of
naïve syngeneic mice by pulsing with 0.5 µM peptide for 1 hour at room temperature and
irradiating at 3,000 Rads before plating.

T cell Receptor Codon Optimization, Synthesis, and Cloning

Sequences of previously cloned T cell receptors were codon optimized and synthesized
by GeneArt (Santomasso et al. 2007). Synthesized constructs contained restriction sites
for insertion into pGEM4Z/GFP/A64 vector kindly provided by Dr. Eli Gilboa
(Boczkowski et al. 1996).

In vitro Transcription of RNA for Electroporation

mRNA encoding GFP from pEGFP-N1 (Clontech) and mRNAs encoding TCR α and β
chains were prepared from PCR products made using gene specific primer pairs
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containing the T7 RNA polymerase promoter sequence. mMESSAGE mMACHINE High
Yield Capped RNA transcription Kit (Ambion Inc. Austin, TX) was used to in vitro
transcribe RNA according to the manufacturer’s instructions.

The RNA was then

purified using an RNeasy Mini Kit (Qiagen) and purified RNA was resuspended in
RNase free water at 1-3 mg/ml.

Electroporation of in vitro transcribed RNA
One vial of 108 PBMC was thawed into 100 ml of complete Stemline medium (CSM)
(Stemline T cell Expansion Medium (Sigma) supplemented with 5% FBS (Hyclone),
Glutamax (Invitrogen), and gentamycin). Upon thawing, PBMC were stimulated with
IL-2 (300 IU/ml, Chiron Corp) with 50 ng/ml OKT3 for 3 to 4 days. After stimulation,
CD8 T cells were isolated by positive selection. The purified CD8+ T cells were cultured
in CSM with 300 IU/ml IL-2 without OKT3 for 10-17 days for expansion before
electroporation and kept at a concentration of 106/ml. The stimulated CD8 lymphocytes
were resuspended in OPTI-MEM (Invitrogen) medium at a final concentration of 25x106
cells/ml. Cells and cuvettes were pre-chilled on ice for at least five minutes before
electroporation. Lymphocytes were mixed at a concentration of 2 µg in vitro transcribed
RNA per 1x106 lymphocytes and electroporated in a 2 mm gap cuvette using an ECM830
Electro Square Wave Porator (Harvard Apparatus BTX) at 500 Volts/500 μs. Warm
media was added immediately to the cuvette and cells were transferred to fresh CSM with
no IL-2 or OKT3 and rested for at least 6 hours.
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Tetramer Staining

Human cells were stained in Human FACS buffer (PBS supplemented with 1% FBS
(Hyclone), and 1% PHS). Mouse T cells were incubated for 10 minutes using 1 µg of
anti-CD16/CD32 (FcγRII/III) in Mouse FACS buffer (the same as for human cells but
also supplemented with %5 goat serum). For tetramer staining, 105-106 human cells were
incubated with 1:20 dilution of tetramer for 20 minutes at room temperature in the dark.
Antibody to CD8 was then added for an additional 10 minutes. The cells were then
washed twice in FACS buffer and collected immediately on a BD FACScaliber and
analyzed using Flowjo software (Treestar).

Primary Ascites Cultures

Received freshly isolated ascited fluid in sterile containers from the operating room. The
fluid was incubated with an equal volume of Growth Medium in a flask at 37°C with 5%
CO2 and not disturbed for 3-4 days. After this incubation period, the media was changed
every 2-3 days until the flasks were confluent, which was typically between 7-10 days.
To passage cells, the adherent cells were washed once in PBS and then trypsinized using
a minimal volume of 0.06% w/v trypsin/EDTA (Cellgro) for 2-3 minutes at 37°C.
Growth medium was then added to the disrupted cells and transferred to two new flasks.
Stocks of ascites cells were frozen in RPMI (Mediatech) supplemented with 10% human
serum albumin, and 10% DMSO (Sigma-Aldrich).
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Preparation of Primary Murine Kidney Epithelial Cells (KECs)

Kidneys from adult mice were mashed using the back of a syringe and pipetted until a
single cell suspension was obtained. The cell suspension was passed over a 70 µm cell
strainer and washed in D10 medium before plating in 10 cm dishes. Cultures were fed by
replacing D-0 on days 4 and 7. On day 7, recombinant mouse IFNG (R&D Systems) was
added at 10 units/ml medium. On day 8, 10 µl recombinant adenovirus at 109 PFU/ml
was added to each cell culture dish and the cells were harvested on day 9 for use in an
IFNG ELISPOT assay.

Cell Lines

T2 cells are a human lymphoblast cell line deficient in TAP function containing abundant
HLA-A2 molecules on the cell surface that can be loaded with exogenous peptide (Salter,
Howell, and Cresswell 1985). EL4 cells are a murine lymphoblast cell line. Other cell
lines used include: Adenovirus (Ad)-5 transformed cell line HEK293 (CRC 1573;
ATCC), the cervical carcinoma cell line HeLa (CCL- 2, ATTC), the ovarian carcinoma
cell line COV413 provided by Dr. Victor Engelhard. For IFNG treatments, recombinant
mouse IFNG (R&D Systems) was added at 10 units/ml medium for 48 hours prior to use
in assay.

Peptides

All peptides for cdr2, HuD, β-gal and Ova were purchased from American Peptide
Company.
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Tumor Killing Assay
T cells were resuspended at 1x106 cells/ml and target cells were resuspended at 1x105
cells/ml. 1 ml of T cells and target cells were plated together in a 6-well dish. The cells
were co-cultured overnight.

Cells were then harvested and TO-PRO 3 Iodide

(Invitrogen) was used to stain dead cells as per manufacturer’s instructions. Blank
calibration beads (BD Biosciences) were added to the tube before flow cytometry
collection to normalize acquisition between samples. Cells were collected immediately
on a BD FACScaliber and analyzed using Flowjo software (Treestar).

Murine and Human IFNG ELISPOT Assays

Enzyme-linked immunospot (ELISPOT) assay was used to quantify the number of
antigen-specific IFNG producing lymphocytes in response to different target cells.
Briefly, nitrocellulose-bottomed 96-well plates (MultiScreen HA, Millipore) were coated
overnight at 4°C with anti-IFNG monoclonal antibody (clone AN18 at 5 μg/ml for mouse,
clone 1-DIK at 10 μg/ml for human; both from Mabtech). Wells were washed three
times with PBS and blocked for 2 hours with R10 medium at 37°C. For direct ex vivo
mouse ELISPOTs, CD8 T cells were isolated by positive selection from spleens using
MACS purification (Miltenyi Biotec) and 2x105 CD8 T cells were co-cultured with 5x104
target cells. For ELISPOTs with T cell clones or otherwise in vitro stimulated cells, 1x104
CD8 T cells were cocultured with 5x104 target cells. For human ELISPOTs with RNA
electroporated human lymphocytes, 1x105 CD8 T cells were co-cultured with 5x104
target cells.

All co-culture conditions were performed in triplicate wells.

After

incubation for 20 hours at 37°C, the plates were washed 6 times with PBS supplemented
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with 0.05% Tween-20. Biotinylated IFN-γ mAb (clone R4-6A2 for mouse, Pharmingen;
clone 7-B6-1 for human, Mabtech), the conjugate (avidin-peroxidase complex;
Vectastain avidin-biotin complex method Elite Kit; Vector Laboratories) and AEC
substrate (Sigma) were then used for spot development according to the manufacturer’s
instructions. After development, red spots on the membrane represent IFNG released by
individual T cells and are reported as spot- forming-cells per 106 cells. The ELIPSOT
plate quantification was performed in a blinded fashion by an independent evaluation
service (Zellnet Consulting) using an automated ELISPOT reader (Carl Zeiss) with KS
Elispot 4.8 software.

CD107a assay
105 tumor cells were placed into one well of a 24-well plate along with an equal number
of TCR-electoporated or mock-electroporated CD8+ T cells in a total volume of 1
milliliter R10. 20 µl of FITC-conjugated CD107a antibody and 1 μl of GolgiStop
(Beckton Dickenson, San Jose, CA) were added to the well according to the
manufacturer’s instructions. The co-culture was incubated for 4 h at 37°C followed by
washing and flow cytometry.

HuD peptide 321 specific CD8 T cell Cloning

6-8 week old mice were injected with 100 µl purified adenovirus-HuD at 109 PFU/ml
intradermally and treated with pertussis toxin (Sigma) intraperitoneally at days 0 and 2.
On day 13 spleens were removed. The red blood cells were lysed with ACK buffer
(Biofluids) and splenocytes were plated for in vitro stimulation as described. CD8
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isolated T cells from IVS cultures were plated in an entire 96 well plate at a concentration
of 3, 1 and 0.3 cells per well with 5x106 HuD peptide 321 pulsed irradiated feeder cells
and 10 U/ml recombinant human IL-2 (Chiron) in a final volume of 200 µl R10. After
one week, plates with less than 33% positive wells were expanded by transferring each
well into a separate well of a 24-well plate containing 106 HuD peptide 321 pulsed
irradiated splenocytes and 10 U/ml recombinant human IL-2 in a final volume of 1 ml.
Clones were maintained by weekly stimulations with irradiated feeders and expanded 6
fold. Adapted from (Galfrè and Milstein 1981).

In Vitro CTL Chromium Release Assay

For target cell preparation, 106 EL4 cells in 100 µl R10 were labeled with 10 µM peptide
plus 100uCi 51Cr for 1 hour at 37°C, shaking every 10 minutes. EL4 cells were then
washed 3 times in 1 ml R10 and resuspended at 105/ml. 5x103 EL4 cells were plated per
well in a round bottom plate with serial dilutions of T cells. Plates were spun at 300 rpm
for 5 minutes to sediment cells and incubated at 37°C for 4.5 hours. To harvest and
measure radioactivity from the CTL assay, 100ul of supernatant from each well was
pipetted into a sample plate for gamma measurement with 100 µl gamma scintillation
fluid.

Titermax Immunization

C57BL/6 mice were injected in the footpad with a single peptide emulsified in Titermax
adjuvant. To form the peptide emulsion, 75 µl of peptide at 10 mg/ml in 50% DMSO was
added to 75ul ddH2O.

This solution was then added to a sterile eppendorf tube
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containing 150ul Titermax adjuvant. The tube was then vortexed for 30 minutes on high
to form an emulsion of Titermax and peptide. The peptide emulsion was drawn into an
insulin syringe and 50 µl (approximately 125 µg of peptide) was injected per animal.
After 7 days, the animal was sacrificed and the right popliteal and inguinal lymph nodes
were removed. Lymph nodes were ground between two sterile frosted glass slides to
obtain a single cell suspension.

Bone Marrow Chimeras

Bone marrow recipient mice were given two doses of 450 Rads whole body gammairradiation to sub-lethally deplete bone marrow. Bone marrow was collected from donor
mice by extracting cells from the tibia and femur. Red blood cells were lysed with ACK
buffer (Biofluids) and the bone marrow cells were depleted of CD90.2 positive mature
lymphocytes by MACS selection. 5x106 bone marrow cells were transferred into the
irradiated hosts in the retro-orbital cavity and then were left to rest for two months to
allow for bone marrow reconstitution before challenge.
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CHAPTER 3. The Efficiency and Activation of Purified Lymphocytes
Using Different Isolation Techniques
Introduction

Cluster of differentiation eight (CD8) T cells are circulating lymphocytes that monitor
and selectively kill infected, transformed, or damaged cells. Generally, in virtually all
cells, intracellular proteins are presented as peptides extracellularly to the immune system
in major histocompatibility complex (MHC) I molecule complexes.

Each T cell

expresses a unique T cell receptor that can bind a particular peptide-MHC complex. In
this way, T cells can initiate an immune response in an epitope and MHC-restricted
manner. Typically, non-self proteins that indicate that a cell has been compromised, such
as viral proteins, will be detected on the cell surface by CD8 T cells and targeted for
killing.

In order to study the impact of the dynamic stimulus of T cell activation on RNA
regulation within the T cell, we developed a system to analyze T cells in a resting state as
well as after stimulation. Our plan, as discussed in Chapter I and in subsequent chapters,
was to compare and contrast HuR and Argonaute (Ago)-microRNA regulation in these
cells.

To activate a polyclonal population of T cells without antigen dependency,

antibody coated beads were used to mimic the signaling that a CD8 T cell would
encounter from a cognate antigen-presenting cell (APC). The first signal from the APC
is directed towards the T cell receptor-CD3 complex that can be mimicked with an antiCD3 antibody.

Second, for complete activation and proliferative responses, co-

stimulation is needed through the CD28 co-receptor molecule on the surface of
lymphocytes. By using beads coated with antibodies against CD3 and CD28 the T cells
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encounter both signals on a surface approximately the size of an APC, resulting in T cell
activation.

We developed a quantitative RNA-based assay as a surrogate to monitor the activation
response of the lymphocytes. In this assay, we measured the induction of two cytokine
transcripts, IFNG and TNF, by isolating T cell RNA and performing reverse transcription
for quantitative PCR (qPCR) analysis. Stimulation of CD8 T cells with CD3 and CD28
agonists leads to a dramatic increase in the expression of IFNG and TNF mRNA
(Lindstein et al. 1989; Thompson et al. 1989; Wang et al. 2006). These cytokines are
critical to the activation response because both help to mediate effector functions of CD8
lymphocytes. For example, IFNG produced after T cell activation stimulates Janus
Tyrosine Kinase (JAK) signaling and can directly inhibit viral replication and induce the
starvation of intracellular pathogens. IFNG can also induce the production of antigen
processing machinery, which in turn increases the presentation of pathogenic antigen to
the lymphocytes (Levy and Darnell 2002; Shuai and Liu 2003; Stark et al. 1998). TNF
stimulates the transcription of a wide array of cytokines and chemokines by cells in the
local environment of the activated T cell. In this way, IFNG synergizes with TNF to
activate and recruit white blood cells to propagate the inflammatory response and aid in
the clearance and killing of infected material (Boehm et al. 1997; Janeway and
Medzhitov 2002; Rock and Goldberg 1999).

Therefore, these two transcripts were

analyzed because of their early transcriptional induction with T cell activation and
because they had been previously shown to be regulatory targets of HuR (Brennan and
Steitz 2001; Mazan-Mamczarz et al. 2003; Wang et al. 2006).
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Several prior studies were used to support this activation method and chosen time of one
hour of stimulation. For instance, the RNA binding protein HuR translocates from the
nucleus to the cytoplasm in peripheral T cells by 45 minutes of in vitro stimulation with
CD28 monoclonal antibodies.

One hour of activation also showed a consistently

measurable change in the cellular status of lymphocytes by a detectable induction of
immediate early genes (Lindstein et al. 1989; Thompson et al. 1989; Wang et al. 2006).
Ago and HuR have also been shown to mediate rapid effects on mRNA localization and
stability. For example, these proteins can rapidly shuttle in and out of stress granules, to
mediate translational silencing and potentially degradation of bound mRNAs
(Bhattacharyya, Habermacher, Martine, Closs, and Filipowicz 2006a; 2006b; Leung and
Sharp 2007; 2010). Therefore, we chose to examine this early time point of T cell
activation to investigate the direct dynamic regulatory control of RNA by Ago and HuR.

In this chapter we develop methods to purify a sufficient quantity and quality of human
lymphocytes for subsequent HuR, Ago and RNA profiling experiments. We explore and
optimize two main methodological issues: the yield and purity of T cells from isolation
procedures, and the impact of the isolation procedures themselves on T cell activation.
Purification of sufficient T cell numbers for these studies depended upon the
requirements for RNA analyses.

As will be detailed in subsequent chapters, high-

throughput sequencing of RNA isolated by crosslinking immunoprecipitation (HITSCLIP) studies and ribosomal profiling studies are variable in their sensitivity, depending
on the abundance and avidity of RNA-protein interactions and RNA levels in
polyribosomes. Hence one variable we explore in this chapter is the impact of T cell
activation on the levels of Ago.
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In general, these studies suggest that sufficient numbers of cells for analysis may require
isolation of 20 million peripheral lymphocytes for each activation state of a paired sample
for HITS-CLIP analysis and additional material for other RNA profiling experiments.
Achieving such yields from a peripheral human blood draw would be difficult. Therefore,
we turned to leukapheresis, a protocol we have utilized within the laboratory to purify
PMBCs from patients with paraneoplastic neurologic disorders (Albert et al. 1998). This
protocol yields large numbers of peripheral blood mononuclear cells (PBMC), returning
the remainder of the blood back to the donor. For the purposes of the current study, we
were approved by the Rockefeller University Hospital Institutional Review Board to
obtain leukapheresates from normal healthy human volunteers.

In these studies, it was important to assess whether our protocol to isolate peripheral
blood lymphocytes for analysis perturbed their activation state. Hence we compared
different isolation protocols for purifying T cells from PBMC. Typically, these protocols
use antibodies against cell surface markers to isolate different cellular populations. Two
different approaches were assessed. In one, T cells of interest were directly purified with
antibodies to the T cell co-receptor CD8 molecule. One concern here is that such
purification might crosslink the receptors and initiate downstream signaling and
activation of the T cells. Therefore we compared this protocol with ones in which we
isolated CD8 T cells by negative selection, using a mix of depleting antibodies specific
for other cell surface markers present on all unwanted peripheral lymphocytes. We
assessed whether using negative selection could produce sufficient yield and purity of
CD8 T cells while leaving the T cells naïve.
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Results

Purification of CD8 T cells by Negative Selection

We first examined whether negative selection of CD8 T cells could be efficiently
accomplished from 100-250 milliliters of peripheral blood collected from normal
volunteers. Heparinized and phosphate buffered saline (PBS)-diluted blood was purified
over a Ficoll gradient to separate the PBMC from plasma and from a pellet of
erythrocytes and granulocytes.

The number of circulating peripheral cells per unit

volume was dependent on the donor but 240-960 million PBMC were isolated in each
case. T cells were then isolated by negative selection, by incubating the PBMC with a
biotin-conjugated antibody mixture directed at non-CD8+ cells for depletion. To ensure
maximal purity of this isolation, we depleted cells using additional antibodies specific to
B cells (CD19), NK cells (CD56), CD4 T cells, monocytes and macrophages (CD14).
Using anti-biotin magnetic beads, non-CD8+ cells were bound to a magnetic column and
CD8 lymphocytes were collected as the flow-through of the column.

This yielded

between 7 and 40 million freshly purified CD8 T cells per donor.

The isolated cells were analyzed for purity by flow cytometry. Between 90% and 95% of
the isolated cells were CD8 T cells based on expression of CD8 and the T cell lineage
marker CD3. By forward and side scatter profiles we determined the viability of these
cells to be greater than 95% (Figure 3.1). We concluded that purification of CD8
lymphocytes by negative selection is effective for purifying small numbers of cells from
peripheral blood and allowed isolation of a population of at least 90% pure CD8 T cells.
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Figure 3.1 Purity of CD8 T Cells Purified by Negative Selection. Representative CD8
T cells purified from PBMC of normal human donors by negative selection. (A) Forward
and side scatter determined by flow cytometry. The percentage of live cells (97.6%) is
noted in the gated population. (B-E) Stains indicated on each axis and percentages of
cells for the indicated lineages are noted for each quadrant.

68

Purification of CD8 T cells by CD56 Depletion followed by CD8 Positive Selection

To purify larger numbers of CD8 lymphocytes more efficiently, we explored the
purification of CD8 T cells from PBMC by positive selection. When isolating the cells
by positive selection of the CD8 marker on the cell-surface of T cells, we found that the
resulting lymphocytes contained a significant percentage of CD8+ CD56+ Natural Killer
(NK) T cells. Therefore, to remove this population of cells in subsequent purifications,
we first depleted NK T cells using CD56 antibody-conjugated magnetic beads.

We found that depletion of CD56+ cells followed by positive selection of CD8+ cells
yielded enhanced purity of CD8 T cells as compared to negative selection (Figure 3.2).
The average purity determined from five preparations of normal donor cells from
leukapheresis and screened by flow cytometry was 97% CD8 T cells. The non-CD8+
cells contaminating the preparation typically correspond to 2% each of CD4 T cells and
CD8+ CD56+ NK T cells. There is typically less than 0.5% contamination by CD14+
monocytes or macrophages, and by CD19+ B cells (Table 3.1).

Furthermore, we found that this purity was preserved when processing larger amounts of
cells from leukapheresis of normal healthy volunteers rather than relying on peripheral
blood draw. We collected between 120 and 150 milliliters of leukapheresate from normal
donors and layered and centrifuged this material through a Ficoll gradient. From this
volume of material we were able to isolate 2-6 billion PBMC from each donor, which
was roughly one hundred times more material than from a standard peripheral blood draw.
After depletion of CD56 positive cells and selection of CD8 positive cells as described
above, we were able to elute 400-800 million CD8 T cells. After resting the cells
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Table 3.1 Purification of CD8 T cells from Normal Human Donor Leukapheresis.
Five normal healthy donors were leukapheresed. CD8 T cells were purified by CD56
depletion and CD8 positive selection. Leukapheresates collected and resulting cell
populations isolated are described. Abbreviations: leukapheresate (Leuk.), peripheral
blood mononuclear cells (PBMC).

Leukapheresate

Volume
(ml)

Total Selected Rested
PBMC
CD8
CD8
(x 109) (x 106) (x 106)

Live
Cells
(%)

CD8+
T cells
(%)

CD4+
T cells
(%)

CD56+

CD19+

CD14+

NK T cells

B cells

Monocytes

(%)

(%)

(%)

Donor 1

150

3.5

560

410

96.2

97.4

3.19

1.39

0.19

0.20

Donor 2

150

2.0

420

277

97.4

98.5

1.06

1.11

0.18

0.64

Donor 3

140

6.0

780

560

95.8

97.6

3.24

2.49

0.29

0.54

Donor 4

120

3.0

496

261

97.1

96.9

1.39

2.00

0.31

0.37

Donor 5

140

2.6

595

455

95.6

92.7

1.87

0.39

0.11

0.03

Average
+/Standard
Deviation

140
+/- 12

3.4
+/- 1.5

570
+/- 140

393
+/- 125

96.4
+/- 0.8

96.6
+/- 2.3

71

2.15
1.48
0.22
0.36
+/- 1.01 +/- 0.81 +/- 0.08 +/- 0.25

overnight in media, we recovered 250-600 million live CD8 T cells. Therefore, we
concluded that purifying lymphocytes by positive selection followed by resting them
overnight was an efficient method to isolate large numbers of pure populations of normal
human CD8 lymphocytes.

Assessment of CD8 T cell Activation

We assessed the degree to which the two isolation protocols activated the CD8 T cells.
The lymphocytes were analyzed for activation by isolation of total RNA from the cells
and assessing levels of TNF and IFNG mRNA, two transcripts that are rapidly induced
from low baseline levels to high levels within one hour of T cell activation (Lindstein et
al. 1989; Thompson et al. 1989; Wang et al. 2006). To address whether T cell activation
occurred during the process of cell isolation, normal donor samples were processed by
either positive or negative selection in parallel and then evaluated immediately for their
activation status, or after resting the cells overnight. CD8 T cell RNA was isolated and
reverse transcribed. cDNA was used to measure the abundance of TNF and IFNG
normalized to levels of GAPDH by qPCR, as a surrogate for the level of T cell activation.
GAPDH mRNA levels did not vary significantly between resting and activated T cells.

Cells that had been isolated by positive selection had increased levels of TNF and IFNG
mRNA as compared to those isolated by negative selection (data not shown).
Interestingly, the levels of T cell activation in cells that had been positively selected and
rested overnight returned to the low baseline levels seen in T cells isolated by negative
selection without resting (Figure 3.3). It is likely that cells isolated by positive selection
either revert to a resting state overnight or die overnight and are lost from analysis. We
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Figure 3.3 CD8 T Cell Activation qPCR Analysis. IFNG and TNF mRNA in resting
and activated CD8 T cells was analyzed by qRT-PCR. (A) IFNG or TNF mRNA levels
were normalized to GAPDH. Plotted is the fold change of these transcripts in CD3/CD28
stimulated CD8 T cells relative to resting CD8 T cells mRNA for five normal human
donor samples prepared either by negative selection (NS) or positive selection (Donor).
(B) Ct values for GAPDH mRNA were subtracted from the Ct values for IFNG mRNA
(dCt) for resting or CD3/CD28 stimulated CD8 T cells for each donor. Gray bars
indicate the average dCt value for each group of T cells. (C) Ct values for GAPDH
mRNA were subtracted from the Ct values for TNF mRNA (dCt) for resting or
CD3/CD28 stimulated CD8 T cells for each donor. Gray bars indicate the average dCt
value for each group of T cells.
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conclude that where large numbers of cells are needed, it is preferred to take advantage of
the increased efficiency and purity of the positive selection process and rest the cells
overnight to return them to a quiescent state. We observed that processing the cells for
plating and harvesting them for one hour in media without CD3/CD28 stimulus after
resting the cells also induced small but measurable amounts of cytokine production (data
not shown).

Thus, to maximize the signal seen by activating the cells with the

CD3/CD28 stimulus, ‘resting’ cells were collected and processed for the subsequent
assays without any further manipulation or incubation.

We also examined whether the level of activation with CD3 and CD28 stimulation would
be altered by either isolation method or by resting the lymphocytes overnight. We found
that the cells reached a similar level of activation after an hour stimulus with the
CD3/CD28 beads if they had been isolated by either negative selection or positive
selection with resting overnight (Figure 3.3). We concluded that the cells were able to
achieve a maximal activation state with CD3/CD28 stimulation after either method of
purification. Consequently, the large difference in the fold change seen with activation of
negatively selected or positively selected and rested CD8 T cells was due to a difference
in the amount of TNF and IFNG transcript present in the resting T cells rather than a
marked difference in the absolute amount of activation of the cells with one hour of
stimulation.

To maximize the purity of the isolated sample while preserving the resting state of the
cells, we concluded that the T cells should be isolated by CD56 depletion and positive
CD8 selection and then rested overnight. Following the resting period, non-stimulated
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cells would be immediately processed and frozen for subsequent assays while another
aliquot of cells would first be stimulated for an hour in culture with CD3/CD28 beads.

Ago protein levels with T cell activation

To determine if the levels of Ago increase during T cell activation, a pilot experiment of
a stimulation time course was done for a series of time-points ranging from no
stimulation to 72 hours of activation with CD3/CD28 beads. We separated lysates by
SDS-PAGE and visualized Ago protein by western blot. We analyzed a fixed number of
cells after different periods of time in culture with or without activation. This showed
that while there was no significant induction of Ago with one hour of stimulation, the
levels of Ago protein per cell did increase with time in culture as noted at the 16-hour
time point. This induction stayed constant for cells grown in media alone, but continued
to increase with time when stimulated with CD3/CD28 beads. It was also seen that the
Ago signal on a western blot of 300,000 T cells was comparable to that of less than 2% of
a mouse cortex (Figure 3.4). From this observation we estimate that the amount of Ago
in a mouse cortex is roughly equivalent to that in 20 million human CD8 T cells. We
conclude that on the order of 10-100 million lymphocytes may be necessary for
subsequent Ago HITS-CLIP assays and that activation of T cells for one hour does not
significantly change the amount of Ago material available for analysis.

Discussion

In this chapter, we established a system for analysis of the effects of T cell activation on
RNA regulation.

This entailed several aspects of investigation beginning with the
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Figure 3.4 Ago Protein Levels with CD8 T Cell Activation in vitro. (A) Cellequivalent aliquots of CD8 T cells were analyzed by western blotting for Ago (with
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establishment of methods to reproducibly obtain purified populations of CD8
lymphocytes from normal human donors. We examined the effects of these T cell
purification methods on the activation state of the resulting lymphocyte populations using
the qPCR assay we developed to compare levels of activation with and without
stimulation. Finally, we examined the corresponding abundance of Ago proteins after
CD3/CD28 interrogation of the T cells.

One hour of stimulation with CD3/CD28 beads was chosen for our assays because at this
time point there was a dramatic increase in both TNF and IFNG mRNA and by this time
it has been shown that HuR has already partially shuttled from the nucleus to the
cytoplasm with stimulation (Lindstein et al. 1989; Thompson et al. 1989; Wang et al.
2006). Because Ago and HuR have been implicated in regulating rapid changes in
mRNA localization and stability, such as the movement of targeted transcripts in or out
of stress granules or active polysomes, we chose to investigate an early time point in the
lymphocyte activation process (Bhattacharyya, Habermacher, Martine, Closs, and
Filipowicz 2006a; 2006b; Leung and Sharp 2007; 2010). It was hypothesized that at one
hour of stimulation, a sufficient number of cells would be present in the activated status
and that the regulation of the HuR and Ago could be determined during the initiation of
the activation response and induction of the new transcriptional program.

It would be interesting to examine the regulation by HuR and Ago at even earlier time
points in this signaling cascade.

However, since each cell may not be activated

simultaneously, the status evaluated biochemically at one hour can be seen as the sum of
events leading up until this time. Later time points could also be interesting to study, but
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we thought it might be more straight forward to see direct effects of these regulators at an
earlier time rather than a later one. Hao and Baltimore described that the inflammatory
response of macrophages in response to TNFα could be grouped into three sets of genes.
Those that peaked in expression at half an hour after activation, after two hours of
activation, and genes that increased more steadily with the stimulus and peaked at 12
hours after activation (Hao and Baltimore 2009).

We thought that looking at the

regulation of RNA at one-hour post T cell activation might provide interesting insight
into the regulation of these rapidly changing transcripts as different groups of genes are
being simultaneously induced and silenced during the inflammatory sequence (Hao and
Baltimore 2009; Hargreaves, Horng, and Medzhitov 2009; Ramirez-Carrozzi et al. 2009;
Smale et al. 2012).

We examined the efficiency of purifying CD8 T cells using different protocols. We
found that we could generally achieve greater purity of the cell populations with positive
selection than negative selection and could expect roughly 95% purity of CD8
lymphocytes. Interestingly, we found that the T cell purification process had a significant
impact on cell activation. Positive selection of CD8 lymphocytes left the cells in a more
activated state than by negative selection as determined by our assay measuring TNF and
IFNG transcription by qPCR. We hypothesize that binding of antibody to the CD8 coreceptor may have led to crosslinking of other cell surface receptors that mediate
downstream signaling in the lymphocytes leading to the induction of immediate early
genes. Fortunately, we found that this activation during the purification process could be
overcome by resting the cells in culture overnight. This achieved a reversal of the
activation of these transcripts that was seen with purification. Furthermore, cells could
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be activated to comparable levels with stimulation by CD3/CD28 beads after the resting
period as seen with the stimulation of freshly negatively selected lymphocytes.

It was important to first establish general mechanisms of regulation with T cell
stimulation as described in this work to understand any processes unique to specific
responses.

Nevertheless, the protocol we established suggests that this purification

method could be extended to study more specific populations of T cells. Antigen-specific
cells can be purified by fluorescent-activated cell sorting using labeled synthetic MHCtetramers. Our data suggest that if this extended isolation process led to activation of the
cells, it is possible that they could be rested to return them to a quieter state in vitro prior
to stimulation. In this way, the molecular processes mediating such responses such as
anti-viral, anti-tumor, or autoimmune reactions and the differences in signaling mediating
them could be studied. In these systems, using an APC could introduce difficulties
distinguishing the responses of stimulators and responders in the subsequent assays.
Thus, we thought using a cell-autonomous method for stimulation might decrease
background and allow for analysis of earlier time points of cellular regulation without
further purification of the lymphocytes from stimulators. Nevertheless, we understand
that stimulation with CD3/CD28 beads is a very strong agonist and that it can activate
different subsets of cells simultaneously, which may be pre-programmed for different
responses, confusing the subsequent results.

Because Ago HITS-CLIP is less efficient than HuR in yield of the radiolabeled RNA coprecipitated with each protein (data not shown), it was thought that stimulating the cells
might increase this signal and help to decrease the number of cells needed for analysis.
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The levels of Ago did increase with T cell stimulation in culture, but not within the
timeline that was pursued for further experiments. The size of the cells in culture also
increased with activation and expansion and this difference in cellular volume could
explain the increase in Ago with stimulation. HuR expression has also been shown to
increase with T cell stimulation and the induction of the cell cycle, still as in the case of
Ago expression, it is unlikely that this would have a significant effect on these
experiments due to the short time course of stimulation (Atasoy et al. 1998; Sakai et al.
2003).
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CHAPTER 4. Determination of HuR in vivo Binding Sites
in Resting and Activated T cells

Introduction

Lymphocytes are required to rapidly respond to changes within their host, such as during
an encounter with antigen. Therefore, it is logical that much of their protein expression
be regulated at the translational level. RNA-binding proteins can help to regulate mRNA
translation in a number of ways. These include the regulation of mRNA turnover,
localization, and access to ribosomes, mechanisms that are not mutually exclusive. For
example, RNA-binding proteins can harbor latent transcripts in cytoplasmic granules as a
means regulating their stability and ability to be translated. In this state, transcripts can
be translated almost instantaneously, which is congruous with the rapid responses seen
from lymphocytes. Alternatively, RNA-binding proteins can also rapidly shuttle in and
out of stress granules, presumably in conjunction with bound mRNAs, to mediate
translational silencing and potentially degradation (Anderson 2010).

Within T cells, rapid changes in the production of proteins such as cytokines is known to
involve RNA-binding proteins. The expression of cytokines in T cells needs to be
transient in order to avoid damage to cells in the surrounding microenvironment after an
antigen-specific response. RNA-binding proteins can ensure this by targeting cytokine
mRNA transcripts for rapid degradation or repressing cytokine translation (Anderson
2008). To better understand the immune response in lymphocytes, and as a surrogate
system for understanding general principles of dynamic RNA-binding protein regulation
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of mRNA translation, we have undertaken a large-scale approach to analyze the posttranscriptional regulation of T cell cytokines.

We hypothesize that HuR plays a critical role in shaping the immune response with
cluster of differentiation eight (CD8) T cell activation. HuR has been shown to regulate
cytokine production in T cells, including regulating interleukin (IL)-13, IL-4, interferon
gamma (IFNG), and tumor necrosis factor (TNF) (Brennan and Steitz 2001; J. G. Wang
et al. 2006; Yarovinsky et al. 2006). HuR is thought to promote stabilization of cytokine
mRNA transcripts upon T cell activation by binding to AU-rich elements (ARE) in the 3’
untranslated region.

HuR binding can either promote or inhibit translation due to

cooperative and competitive interactions with other RNA-binding proteins. Together the
bound proteins determine the fate of the transcript (Anderson 2008; Casolaro et al. 2008;
Fan and Steitz 1998; Myer, Fan, and Steitz 1997). Most research to date investigating the
targets and effects of HuR binding has been studied in vitro with reporter constructs or by
over expressing HuR, leading to non-physiologic conditions.

Furthermore, there is

evidence that RNA-binding proteins can associate with transcripts after a cell has been
lysed for immunoprecipitation leading to false targets of regulation (Mili and Steitz 2004).
Thus, previous studies examining HuR function during T cell activation using RNA
immunoprecipitation without crosslinking may not represent in vivo interactions between
HuR and RNA and do not point to discreet binding sites within the RNA molecule.
Moreover, HuR binding sites have been mapped using the photoactivatable
ribonucleoside crosslinking and immunoprecipitation (PAR-CLIP) approach, but its
requirement for incorporating a photo-activatable nucleotide analog into RNA limits is
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use to cell culture systems that may not preserve biologically meaningful binding sites or
dynamic changes in cellular states (Mukherjee et al. 2011).

Here we have employed more rigorous biochemical techniques for analyzing RNAprotein interactions in live cells to the study of lymphocyte dynamics. We have used a
powerful platform technology developed in the lab, high-throughput crosslinking
immunoprecipitation (HITS-CLIP) (Figure 4.1).

In this procedure, live cells are

ultraviolet (UV) irradiated to crosslink protein to bound RNA. Crosslinking allows us to
harshly wash immunoprecipitated RNA-protein complexes to remove cross-reacting or
co-precipitating contaminants. The RNA is partially digested so that full transcripts will
not be bound to the protein, but rather only RNA “tags” which are radioactively labeled.
After gel-purifying the RNA-protein complexes, the protein can be digested and ligated
RNA linkers are used to reverse transcribe the CLIP tags. High-throughput sequencing
enables us to identify genome-wide targets of the protein of interest (Licatalosi et al.
2008; Ule et al. 2003; 2005). In this chapter we develop HITS-CLIP to examine HuRRNA interactions in resting and activated CD8 T cells from normal human donors.

Results

Immunoprecipitation of HuR from T cell Lysate

In order to begin an experiment utilizing HITS-CLIP, it is necessary to develop a means
of purifying the RNA binding protein of interest after crosslinking it to its RNA targets in
cells.

Most commonly used such purifications consist of immunoprecipitation.

To

examine whether HuR could be efficiently immunoprecipitated from normal human
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donor T cells, we developed an IP protocol using a mix of two mouse monoclonal
antibodies (mAbs) to HuR to increase avidity to the protein (Harlow and Lane 1988). We
first bound a bridging rabbit anti-mouse mAb to protein A Dynabeads and then mixed the
beads with two mouse HuR mAbs, clones 3A2 and 19F12 (Gallouzi et al. 2000; W.
Wang et al. 2000). As a negative control, an aliquot of protein A Dynabeads was bound
with the same bridging antibody and an irrelevant mAb to a mouse protein.

The

antibody-bead complexes were incubated with the isolated primary T cell lysate, and,
after a series of washes in different stringency buffers, the immunoprecipitated proteins
were eluted from the beads. The eluted proteins were separated on a sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS PAGE) gel and transferred to a
nitrocellulose membrane.

The membrane was blotted with HuR mAb 3A2 and a

secondary HRP-conjugated donkey anti-mouse antibody (Figure 4.2).

A strong immunoreactive band was evident in the HuR mAb immunoprecipitation at the
molecular weight of HuR (~36 kD; Figure 4.2, Lane 5). Moreover, we observed a
reduction

of

protein

at

this

molecular

weight

in

the

supernatant

of

the

immunoprecipitation (Figure 4.2, Lane 3) relative to the input sample (Figure 4.2, Lane
1).

As expected, we did not see an immunoreactive band in the irrelevant mAb

immunoprecipitation (Figure 4.2, Lane 4) and the quantity of HuR was not significantly
depleted in that supernatant (Figure 4.2, Lane 2). Together, these data indicated that the
HuR antibody specifically immunoprecipitates a protein of the size expected of HuR.
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Figure 4.2 HuR Immunoprecipitation.
Human CD8 T cell lysate was
immunoprecipitated for HuR (with monoclonal HuR specific 3A2) or using irrelevant
antibody (mouse monoclonal FMRP specific 7G1) and analyzed by western blotting for
HuR (with monoclonal HuR specific 3A2). Equivalent aliquots of T cell lysate input to
immunoprecipitation, supernatant from immunoprecipitation, or immunoprecipitated and
eluted material were analyzed as indicated. Film exposures for 30 seconds or 5 minutes
are shown.
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Pilot HuR HITS-CLIP Experiment on Human T cells expanded in Culture with IL-2

The HITS-CLIP methods were used to investigate what RNA targets HuR binds in
activated T cells.

In preliminary experiments, we assessed whether HuR could be

immunoprecipitated with crosslinked RNA in CD8 T cells expanded and growing in
culture with IL-2. The T cells were crosslinked, lysed, and the RNA was partially
digested prior to the immunoprecipitation to shorten the RNA “tags” that would be bound
to HuR. HuR crosslinked to RNA targets was immunoprecipitated using the mixture of
monoclonal antibodies specific to HuR bound to protein A Dynabeads. To optimize the
stringency of the assay, IPs were washed with a series of high stringency buffers
containing differing amounts of detergents and salt concentrations. RNA tags were then
ligated to 3’ linkers for later PCR amplification and labeled with polynucleotide kinasemediated incorporation of radioactive ATP. The material was separated by SDS-PAGE
and transferred to a nitrocellulose membrane (Figure 4.3A, Lanes 2,4). Protein-RNA
complexes were cut from the membrane, the protein was digested and the RNA extracted.
After adding 5’ linkers and performing an RNase-free DNA digestion to remove any
contaminating DNA, RNA tags were reverse transcribed, PCR amplified, and highthroughput sequenced (Figure 4.3B,C).

This first HuR CLIP pilot experiment produced nearly 9 million pre-filtered CLIP tags, of
which roughly 6 million could be mapped to the human genome unambiguously. More
than 300,000 were determined to be unique binding events, which is a large data set of
mapped HuR regulation. Approximately half of the tags mapped to deep intergenic
regions and a third were intronic sequences. Only 1% of the tags mapped to coding
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Figure 4.3 HuR CLIP: mAb Specific to HuR.
(A) Autoradiogram of
immunoprecipitation results from human CD8 T cells expanded in culture in IL-2 and
crosslinked.
Lysate was immunoprecipitated with irrelevant antibody (mouse
monoclonal FMRP specific 7G1-1) in lanes 1 and 3, or with HuR antibodies (mouse
monoclonal HuR specific 3A2 and 19F12) in lanes 2 and 4. Lysate treated with high
RNase A concentrations in lanes 1 and 2, and low RNAse A concentrations in lanes 3 and
4. 3’linker was added to RNA and then labeled by PNK with 32P-γ-ATP, protein-RNA
complexes were separated on SDS-PAGE, transferred to nitrocellulose and imaged by
autoradiography. 32P-labeled RNA was evident in HuR immunoprecipitation but not in
irrelevant control immunoprecipitation. Dots indicate regions of nitrocellulose processed
for RNA purification. (B) After protease digestion of the radioactive RNA-protein
complexes, 5’ linker was added and products amplified by RT-PCR; products of the
expected size, 100-150 nucleotides, were seen after 26 cycles from HuR CLIP. (C) Final
PCR products after amplification of CLIP tags with high-throughput sequencing
compatible primers.
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sequence with the remaining tags falling in the region surrounding the genes and in the 5’
and 3’ untranslated regions of genes (data not shown).

Although these data only represent one experiment, a large proportion of the genes that
had the most tags in this data set matched CLIP tag maps from other neuronal Hu protein
family members in the mouse brain that are being studied by other members of the
laboratory in other systems, suggesting that the data are robust and that HuR targets are
evolutionarily conserved.

Radioactive RNA Signal on the Autoradiogram is Specific to the HuR Antibodies

To ensure that the labeled RNA signal seen on the autoradiogram was specific to HuR
and not due to an artifact of the protein A beads or the bridging antibody used to bind the
monoclonal antibodies for HuR. In addition to labeling protein A beads with the bridging
antibody and the two HuR monoclonal antibodies, we had prepared another aliquot of the
protein A beads with bridging antibody and used another mouse monoclonal antibody
that was specific to a mouse protein and should not specifically recognize any proteins in
human T cell lysate.

Following immunoprecipitation with the irrelevant antibody bound beads, there was no
radioactive signal from the lysate prepared with either high RNase concentration (Figure
4.3, Lane 1) or low RNase concentration (Figure 4.3A, Lane 3). As a control, we cut
from the membrane at the same molecular weight as in the HuR immunoprecipitation and
continued to prepare the two RNA samples in parallel. The amplified cDNA products
from the HuR immunoprecipitation were visible on the gel beginning around 24 PCR
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cycles. In the control sample, the cDNA was not visible until later cycle numbers and the
characteristic smearing pattern of the RNase treated samples was not apparent from the
irrelevant immunoprecipitation (Figure 4.3B).

We isolated DNA from the lane

containing products from 26 PCR cycles for both the HuR and the irrelevant antibody
immunoprecipitation. Additionally we prepared DNA from the upper and lower bands in
the irrelevant immunoprecipitation that were visible at 32 PCR cycles.

In the control PCR reactions with the irrelevant antibody purification material from 26
cycles of the first PCR, we were not able to amplify products to add the sequencing
compatible sequences. The contaminating bands that had been visible with later PCR
cycles from the irrelevant immunoprecipitation were not overlapping in size with the
smear seen from the HuR immunoprecipitation (Figure 4.3C). Thus, we concluded that
the RNA material isolated with the HuR immunoprecipitation was specific to the mix of
HuR monoclonal antibodies.

Radioactive signal on the Autoradiogram is Sensitive to RNase A Digestion

During the CLIP experiment, we rely on radiolabeling of the RNA to visualize the
material associated with the protein during immunoprecipitation. To ensure that the
signal is from RNA, we treated the cellular lysate prior to immunoprecipitation with
different concentrations of RNase A to show sensitivity to this digestion. With a high
concentration of RNase, the RNA should be almost entirely degraded and the signal seen
on the autoradiogram should be roughly that of the protein alone.
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A discrete signal at around 38 kDa was visible on the autoradiogram with over digestion
of the sample (Figure 4.3, Lane 2). In this lane, there are other bands at higher molecular
weights, such as near 80 kDa, which is not present in the irrelevant antibody control, so is
therefore specific to immunoprecipitation with the HuR monoclonal antibodies. We
speculate that this could represent a dimer of HuR because it is running at double the
molecular weight of the protein alone. However, it is also possible the band represents a
contaminating RNA-binding protein. To ensure that these complexes do not contaminate
the samples, we were careful to cut below this size when purifying RNA for cloning.

Digestion of the T cell lysate with a lower concentration of RNase A trims HuR-bound
transcripts to RNA fragments. The small length of the RNA fragments will allow for
precise determination of the RNA-binding site footprint of HuR rather than identifying
the entire transcript as a target of regulation. These digested fragments will not be
uniform in size and will therefore appear as a smear of RNA signal above the expected
size of the protein. In Figure 4.3, lane 4, we observed the labeled signal initiating above
the size of the collapsed band in the over digested sample in lane 2. Thus, the radioactive
labeling pattern on the membrane is RNase A sensitive, demonstrating that the labeled
material immunoprecipitated with HuR is RNA.

Radioactive RNA Signal on the Autoradiogram is Dependent on Crosslinking

In order to study native in vivo binding interactions between HuR and RNA, we rely on
crosslinking live cells to covalently link the RNA binding protein to its targets. The UV
irradiation should only crosslink interactions that are on the order of a single angstrom in
distance.

With sufficiently stringent washing protocols, we can dissociate non-
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crosslinked RNA from immunoprecipitating with the protein of interest and deplete reassociation artifacts of the protein with RNA during the immunoprecipitation.

To confirm that radiolabeled protein-RNA complexes are UV-dependent, we used both
crosslinked and non-crosslinked samples as the input to immunoprecipitation. Using
crosslinked samples, we were able to see labeled signal in both the high and low RNase
treated samples at the expected size of HuR or a smear above that size respectively. But,
without crosslinking, we were unable to detect an RNA signal (Figure 4.4). Therefore,
the RNA signal is dependent on the in vivo crosslinking and not due to random
association of the protein and RNA available during immunoprecipitation. Furthermore,
the lysis and washing conditions are sufficient to dissociate all measureable RNA signal
from immunoprecipitated HuR.

HuR CLIP in Mouse CD8 T cells

The HuR protein is highly conserved between human and mouse. In addition to the
human lymphocytes, we crosslinked mouse T cells to determine if we could detect an
RNA signal from immunoprecipitation of murine HuR. We purified CD8 T cells from
mouse spleen by negative selection similarly to the protocol outlined for human
peripheral blood cells. Briefly, spleens were quickly extracted from sacrificed C57BL/6
mice. The spleens were mashed with the back of a syringe in ice cold PBS until a single
cell suspension was achieved. These cells were harvested into a tube and spun down.
The cells were then incubated in a suspension of PBS, fetal bovine serum, and magnetic
beads with antibodies conjugated to a mix of non-CD8 T cell surface markers. Non-
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Figure 4.4 HuR-RNA Complexes are Crosslinking Dependent. Autoradiogram of
immunoprecipitation results from human CD8 T cells expanded in culture in IL-2 and
prepared with or without crosslinking. Lysate was immunoprecipitated with HuR
antibodies (mouse monoclonal HuR specific 3A2 and 19F12). 32P-labeled RNA was
evident in HuR immunoprecipitation with crosslinked lysate, but not from noncrosslinked lysate.
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CD8+ cells were bound to a magnetic column and CD8+ cells were collected as flowthrough, with roughly 90% purity (Figure 4.5).

Cross-linked and non-cross-linked cells were processed for HuR CLIP as described
above. As seen with the material from the human immunoprecipitation, with a high
concentration of RNase A treatment of the lysate, the labeled RNA bound to HuR
collapsed to a band at the expected size of the protein. With lower amounts of RNase
added to the lysate, a smear of RNA was seen above the expected size. Unfortunately, in
this experiment, even the low concentration of RNase yielded products that appeared
slightly over digested, although there was still ample signal for subsequent cloning.
Importantly, the RNA signal was crosslinking dependent, as no signal was observed in
the lane on the membrane that derived from non-crosslinked T cell lysate (Figure 4.5).
We were encouraged that the results we were able to see in the human samples were not
species specific.

Numbers of T Cells Necessary for HuR CLIP

The first human HuR T cell CLIP experiment previously described was performed on
cells that had been expanded in culture. Although this is a valid method to produce large
numbers of T cells, prolonged activation in vitro is likely to undermine the physiologic
relevance of the system. To assess the number of lymphocytes required for HuR CLIP,
we titrated the amount of crosslinked T cell lysate that was used as input for HuR
immunoprecipitation.

The RNA bound to HuR was radiolabeled and visualized by

autoradiogram after being separated by SDS-PAGE and transferred to nitrocellulose. We
could visualize a strong signal from immunoprecipitated RNA from the lysate of 0.5
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Figure 4.5 HuR Mouse CD8+ T Cell CLIP. (A) CD8 T cells purified from splenocytes
of wild-type C57BL/6 mice and purified by negative selection. CD3 and CD8 staining
determined by flow cytometry. Percentages of cells are noted in each quadrant. (B)
Autoradiogram of immunoprecipitation results from resting and CD3/CD28 stimulated
mouse CD8 T cells prepared with or without crosslinking.
Lysate was
immunoprecipitated with HuR antibodies (mouse monoclonal HuR specific 3A2 and
19F12). 32P-labeled RNA was evident in HuR immunoprecipitation with crosslinked
lysate from resting and activated mouse lymphocytes, but not from non-crosslinked lysate.
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million normal human T cells, almost twenty-fold less than we used for the pilot
experiment described above (Figure 4.6). This will allow for the use of fresh samples
that have not been distorted by cell culture conditions. With the ability to use low
numbers of cells for the identification of HuR-bound RNA, these methods may be
applied to the investigation of antigen-specific lymphocyte responses from patient
samples or other cellular populations of interest. Still, the complexity of the pool of
sequenced RNA may be proportional to the amount of starting material due to our current
dependence on PCR amplification of cloned tags, so the initiation of the protocol from
larger cell numbers would be preferred.

HuR HITS-CLIP from Five Normal Donor Resting and Activated CD8 T cells

As described in the previous chapter, CD8 lymphocytes were isolated from normal
human donors and prepared for analysis by HITS-CLIP. Briefly, five healthy normal
donors were leukapheresed and the material was layered onto and spun through a Ficoll
gradient. The resulting layers of collected PBMCs were depleted of CD56+ cells and
then positively selected for CD8+ cells.

The eluted CD8 lymphocytes were rested

overnight in media. The following morning, T cells were harvested and aliquots of
lymphocytes were crosslinked immediately or after being stimulated in culture for one
hour with CD3/CD28 beads. The T cells were crosslinked with UV-B irradiation. The
purity of the cells was determined by flow cytometry to be greater than 90% CD8
lymphocytes, and analyzing TNF and IFNG mRNA levels by RT-qPCR confirmed the
activation status (Table 3.1). The cells displayed between roughly 300 and 600 fold
inductions of TNF mRNA and 1000 to 8000 fold inductions of IFNG mRNA (Figure 3.3).
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Figure 4.6 HuR CLIP CD8+ T Cell Titration. Autoradiogram of immunoprecipitation
results from human CD8 T cells expanded in culture in IL-2 and crosslinked. Aliquots of
lysate corresponding to 10 million (C,D), 5 million (A,B,E), 1 million (F), 0.5 million (G),
or 0.1 million T cells (H), were immunoprecipitated with HuR antibodies (mouse
monoclonal HuR specific 3A2 and 19F12) (B, D-H) and irrelevant antibody (mouse
monoclonal FMRP specific 7G1-1) (A,C). 32P-labeled RNA was evident in HuR
immunoprecipitation from lysate starting at 0.5 million T cells.
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For three of the five donors, the T cell lysates were prepared and used first for Ago HITSCLIP experiments described in the Chapter 5. HuR was then immunoprecipitated from
the same lysates to perform comparisons with identical starting material. However, this
approach raised the potential concern that carry-over from the Ago experiment could
contaminate HuR HITS-CLIP data. To address this possibility, HuR HITS-CLIP for the
other two donor samples was performed without prior Ago depletion. Additionally,
different, uniquely indexed RNA linkers were used for these two additional donors so
that potential contamination of sequenced RNA tags with tags from previous experiments
could be unambiguously assessed. HuR HITS-CLIB was performed as described above.

Overview of RNA Tag Statistics

In total, we sequenced material from five normal donor CD8 T cell samples activated for
one hour with CD3/CD28 beads and from four paired resting samples. From each sample
we were able to get between 9 and 38 million sequencing reads from each highthroughput sequencing run.

Because of the PCR amplification and saturation of

sequencing of samples, the number of total reads did not necessarily dictate the final
counts of unique mappable reads. For example, the largest number of processed usable
RNA tags came from a sample that had a starting number of only 13.6 million total reads,
while the smallest number of unique mappable reads, from a sample sequenced in its own
lane, started with 28 million total reads. To process this large amount of data, first we
removed all duplicate copies of reads, leaving only one of each exact sequence. This
reduced the total number of reads to between 1.8 to 10.4 million sequences. These
sequencing reads were then mapped to the hg18 build of the human genome.
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The

percentages of sequences mapping to unique positions within the genome ranged from 41
to 70% (Table 4.1).

In preparing the sequencing libraries, we used ligated RNA linkers to clone and amplify
the RNA bound to HuR. Within the sequence of the 5’ RNA linker, we included a four
base random degenerate code, which can consist of 256 different possible sequences.
Different degenerate barcodes would therefore be ligated to each individual piece of
RNA to be cloned from the same genomic location. This barcode is meant to distinguish
between identical cross-linked tags that were independently isolated and ligated to linker,
which are biologically informative, from likely PCR amplified duplicates, which are not.
This also gives us the ability to monitor contamination between the preparations of
different sequencing libraries. These barcodes allowed us to collapse sequences that
mapped to exactly the same start and stop site in the genome and also contained the
identical barcode; we term these collapsed products unique mappable reads or CLIP tags.
Each sample produced between 400,000 and 1.2 million unique mappable reads (Table
4.1).

In addition to the four nucleotide degenerative barcode, for the three samples prepared
from fresh T cell lysate, we used an additional two-nucleotide index within the 5’ linker.
These additional bases allowed us to distinguish the sequences from each sample when
the final material was pooled and sequenced together. For these samples, together the
sequencing produced over 500,000 unique mappable reads which then collapsed to
roughly 150,000 unique reads per sample (Table 4.1).

In Table 4.1, the colors

highlighting each individual donor sample will be used to indicate sequencing reads from
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Table 4.1 HuR CLIP Tag Statistics.

Resting
HuR

Total Reads

Total Reads
(One Copy)

Mappable
Reads
(One Copy)

Unique
Mappable
Reads

% Total Reads
(One Copy)

Donor 1

34,680,120

8,423,102

3,934,897

658,968

7.82

Donor 2

37,475,646

10,390,637

4,593,807

706,821

6.80

Donor 3

28,162,328

5,254,520

2,538,822

400,103

7.61

Multiplex:

30,671,330

1,914,692

1,190,522

515,861

Donor 4

---

---

---

143,101

Activated
HuR

Total Reads

Total Reads
(One Copy)

Mappable
Reads
(One Copy)

Unique
Mappable
Reads

% Total Reads
(One Copy)

Donor 1

13,595,577

3,029,521

2,093,555

1,154,523

38.11

Donor 2

11,851,138

2,297,658

1,412,266

587,257

25.56

Donor 3

9,047,999

1,848,374

1,105,861

539,178

29.17

Donor 4

---

---

---

175,523

Donor 5

---

---

---

141,819
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that donor in the CLIP tag representations in subsequent figures from the genome
browser. This enables us to distinguish the results between the donors and compare the
binding events between activation states for each donor.

In total, we cloned 1.9 million unique tag reads for the resting T cells and 2.6 million in
the activated state. These CLIP experiments were the first to produce such large numbers
of data and represent an expansive network of HuR regulation of RNA in the resting and
activated states of CD8 lymphocytes.

Reproducibility of Binding between Biologic Replicate Samples

We were interested in focusing on sites of regulation where the binding events were
abundant and reproducible between the different donor samples.

To do this, we

developed a program to cluster CLIP tags. We designated tags as belonging to a cluster
if their genomic locations overlapped by at least 5 nucleotides. Next we specified that
within each cluster there must be 5 tags overlapping in at least one nucleotide genomic
position, termed a peak height of at least 5. For this analysis, we excluded nine clusters
that had over 1,000 reads because they seemed to skew the correlations to be higher and
we were not sure if these were specific binding events. To determine the reproducibility
of binding between the data sets produced from the different samples, we calculated the
absolute value of the Pearson correlation coefficient of the number of tags per cluster
between each donor in both the resting and activated states shown in Figure 4.7.

We found very high correlations, r of greater than 0.9 between the datasets for the donors
processed from the same activation state and prepared from the same kind of lysate
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Figure 4.7 Pairwise Correlation of HuR CLIP Clusters. Upper half of table: Pair-wise
scatter plots displaying the number of tags per cluster of HuR CLIP tags contributed to
the cluster by each resting (r) or activated (a) donor sample as indicated. Lower half of
table: absolute value of the pair-wise Pearson correlation coefficient of the number of
tags contributed to each cluster by each resting or activated donor sample. The size of
text is scaled to the correlation value. Clusters needed to contain a minimum of 5
overlapping tags at one nucleotide position to be included in either analysis.
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(either supernatant from prior Ago immunoprecipitation or fresh T cell lysate). There
was slightly lower correlations between samples processed from the same kind of lysate
but in different activation states, ranging from r=0.84-0.89 which may represent the
differences in HuR binding with and without T cell activation. The correlations were a
little lower still for comparing samples processed from Ago supernatant to those from
fresh T cell lysate. This may represent some difference in the lysates due to the Ago
immunoprecipitation in one and not the other, but we think it is more likely that the
differences are due to the sequencing depths between these samples. Because we started
with lysate from a larger number of cells for those prepared from the Ago supernatant, we
were able to clone a larger number of unique reads (ranging from 400,000 to over 1
million reads). The samples from fresh T cell lysate were not only just from smaller
numbers of starting material, but were also multiplexed and sequenced on in the same
lane of the sequencer which resulted in less than 200,000 unique reads for those samples.
Moreover, as the sequencing depth was lower, it is more likely that a tag from those
experiments will not be represented in any given cluster, lowering the correlation
coefficient. Even with these caveats, the correlation coefficient between any two samples
was at least r=0.68 which represents great reproducibility of binding.

For further analysis, we also specified that there be at least three of the five donor
samples represented in each cluster in either the resting or the activated state to demand
biologic reproducibility in each binding site. Additionally, for each cluster we required
that at least one tag be present from the multiplexed barcoding experiment to ensure that
the cluster was not due to an artifact of the Ago immunoprecipitation. With these criteria,
we determined over 24,000 sites of robust and reproducible HuR binding. Nearly 6,000
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of these clusters showed reproducible binding of at least biologic complexity of 3 and a
peak height of 5 in both the resting and the activated states. Interestingly, there were a lot
of clusters that changed dynamically with activation and were only present at this
stringency in either the resting state (3,481 clusters) or the activated state (14,657
clusters) (Figure 4.8). We were surprised to find more than 4-fold the number of robust
binding sites exclusively in the activated state as compared to the resting state with only a
third more unique reads. These results began to demonstrate the dynamic changes in
HuR binding that quickly occur with T cell activation.

Genomic Distribution of HuR Binding Sites

In order to gain a global view of HuR regulation, we determined the location of HuR
Clusters of biologic complexity 3 (including a tag from the indexed experiment) and peak
height of 5. We were surprised to find that half to two-thirds of reproducible HuR
binding sites fell in the intronic regions of target RNA molecules.

The next most

represented region of RNA was the 3’ untranslated region (3’UTR) or within 10
kilobases of stop codons, which most likely denote un-annotated 3’UTR regions of
transcripts (Licatalosi et al. 2008). These regions at the 3’ end of transcripts represented
21-30% of HuR clusters. Less than 10 percent of clusters fell within the 5’UTR, coding
sequence, or deep intergenic regions of the genome. These intergenic clusters may
represent un-annotated RNAs. The distribution of HuR binding along target transcripts
was not altered greatly between the data sets of regulation seen in resting T cells or
activated T cells. In clusters present in both the resting and the activated states, we saw a
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Resting
3,481

Activated

5,969

14,657

Figure 4.8 HuR Clusters Activation State Distributions. Venn diagrams show the
overlap between HuR target clusters in the indicated activation states with the number of
clusters including 3 biologic donor samples and a peak height of at least 5 CLIP tags
shown.
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larger proportion of binding in the 3’UTRs of transcripts than in either state alone (Figure
4.9).

Top Hexameric Sequences Represented in HuR Binding Dataset

To investigate whether there was a conserved motif in the binding sites across different
clusters that were biological complexity of 3 and had a peak height of 5, we calculated
the number of times each hexameric sequence appeared within the HuR binding sites.
We compared the counts for all of the HuR binding sites together, for resting and
activated sites separately, and also for binding sites that were reproducible in both the
resting and activated state. For all cases, the top hexamer seen in the data sets was
UUUUUU (Table 4.2). One interesting observation was the high frequency of both
GUGUCA and UGUCAG in the data. These overlapping sequences were the third and
fourth highest ranked hexamers in clusters present in both the resting and activated state.
It was also interesting that these were less represented in the resting alone dataset and
even more so in the activated dataset. This may represent different binding preferences
of the protein in different cellular states. As expected, uracil was the most frequently
represented base followed closely by adenine and then cytosine and guanine at a lower
rate (Figure 4.10).

These data correlate well with previously reported binding

preferences for Hu proteins. HuR has been shown to bind U-rich elements in previously
reported targets of regulation and previous work from our laboratory showed similar
binding sites for the neuronal Hu family members (de Silanes et al. 2004; Ince-Dunn et al.
2012; Kishore et al. 2011; Mukherjee et al. 2011).
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5‘UTR Exon
3‘UTR Exon
A

CDS Exon
Downstream 10K
B

9%

Intron
Deep Intergenic
C

3% 4%

7%
7%

7%

5%

6%

6%

5% 4%

6%

18%
14%

23%

53%

63%

HuR Resting

HuR Resting & Activated

62%

HuR Activated

Figure 4.9 HuR Clusters Genomic Distribution. Distribution of clusters, comprised of
at least 3 biologic donor samples in the resting and or activated state and a peak height of
at least 5 CLIP tags, among HuR target transcripts represented by pie chart.
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Table 4.2 Top Hexameric Sequences in HuR Clusters. Listed are the top 25 hexamers
found in all HuR clusters representing at least three biologic donors in one activation
state (biologic complexity three: BC3) and having at least five tags in the peak position of
binding (peak height five: ph5). Hexamers were sorted by comparing the ratio of the
observed to the expected frequency of each hexamer within CLIP tags. The ranking and
absolute count of each hexamer within subsets of clusters BC3 and ph5 for the resting,
activated state, or both are shown.

!

Overall
Rank

Hexamer

Observed
Count

Observed
Frequency

Observed/
Expected
Frequency

Resting:
Rank
(Count)

Activated:
Rank
(Count)

Both:
Rank
(Count)

1

UUUUUU

18006

0.00699

28.6

1 (2166)

1 (10191)

1 (5649)

2

AAAAAA

8875

0.00344

14.1

2 (1233)

2 (5016)

2 (2626)

3

UUAUUU

6912

0.00268

11.0

3 (857)

3 (4030)

5 (2025)

4

UAUUUU

6663

0.00259

10.6

5 (765)

4 (3884)

6 (2014)

5

UUUAUU

6433

0.00250

10.2

4 (788)

5 (3711)

8 (1934)

6

AUUUUU

6303

0.00245

10.0

7 (672)

6 (3673)

7 (1958)

7

UUUUUA

5967

0.00232

9.5

6 (681)

7 (3383)

9 (1903)

8

UGUUUU

5388

0.00209

8.6

10 (606)

8 (3177)

12 (1605)

9

UUUUAU

5375

0.00209

8.5

9 (613)

9 (3114)

11 (1648)

10

UUUUAA

5362

0.00208

8.5

12 (602)

10 (3033)

10 (1727)

11

UUUUCU

5087

0.00197

8.1

8 (628)

12 (2937)

15 (1522)

12

UUUGUU

5047

0.00196

8.0

15 (580)

13 (2903)

14 (1564)

13

UUGUUU

5007

0.00194

8.0

17 (567)

11 (2966)

17 (1474)

14

UUUUGU

4981

0.00193

7.9

16 (572)

14 (2828)

13 (1581)

15

UUUCUU

4747

0.00184

7.5

11 (603)

15 (2705)

18 (1439)

16

UUUAAA

4614

0.00179

7.3

20 (504)

16 (2623)

16 (1487)

17

GUGUCA

4561

0.00177

7.3

13 (595)

46 (1676)

3 (2290)

18

UUUUUC

4477

0.00174

7.1

22 (499)

17 (2613)

20 (1365)

19

UUCUUU

4387

0.00170

7.0

14 (589)

18 (2433)

21 (1365)

20

AUUUUA

4281

0.00166

6.8

21 (501)

20 (2430)

22 (1350)

21

UUUUUG

4246

0.00165

6.7

24 (459)

18 (2472)

23 (1315)

22

CUUUUU

4245

0.00165

6.7

23 (490)

22 (2381)

19 (1374)

23

UGUCAG

4231

0.00164

6.7

18 (536)

52 (1551)

4 (2144)

24

UUAAAA

4143

0.00161

6.6

26 (438)

21 (2400)

24 (1305)

25

UCUUUU

3936

0.00153

6.3

19 (506)

24 (2238)

27 (1192)
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29%

35%
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Figure 4.10 Nucleotide Frequency in HuR Clusters. The percentage of each
nucleotide (adenine, cytosine, guanine, uracil) present in HuR CLIP clusters comprised of
at least 3 biologic donor samples in the resting and or activated state and a peak height of
at least 5 CLIP tags, represented by pie chart.
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HuR Binding Changes with Activation

To help give context to HuR binding patterns and changes with activation, we did
RNAseq on other aliquots of resting and activated T cells from the same pools of
lymphocytes used for HITS-CLIP, absent UV-crosslinking. This allowed us to overlay
HuR regulation with the expression levels of target transcripts using calculated values of
reads per kilobase per million (RPKM) for each RNA transcript. Then, for each cluster
we assigned a score for the relative HuR binding and transcript abundance in the resting
and activated states.

As diagramed in Figure 4.11, we pooled the HuR CLIP tags from both the resting and
activated state together and required that the tags overlapped at least 5 nucleotide
positions to be included in a cluster. For this analysis, we specified that clusters had to be
at least of biologic complexity 4 in the resting and or activated state and have a minimum
combined peak height of 10 tags between the resting and activated states together. For
each cluster we calculated the percentage of tags that originated from the activated state
out of the total number of resting and activated tags in that cluster. Finally, we grouped
binding sites into bins of whether the HuR binding and transcript expression in the
activated state was greater than, roughly equal to, or less than the resting state based on
cutoffs at 40 and 60 percent. We required that transcripts have a minimum of an RPKM
of 15 in either the resting or activated state for inclusion in this analysis to ensure that the
read depth changes for each transcript with activation was evaluable.

Interestingly, more than two-thirds of HuR binding sites shifted in binding intensity
dramatically with T cell activation, with about 28% of these binding changes mirroring
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CLIP Cluster:

Clustered Ago: Resting and Activated
Clustered HuR: Resting and Activated
(Tags Overlapping 5nt)

Donor 3A
Donor 4R

Peak
Height:
10

Donor 1A
Donor 3A
Donor 2R
Donor 3A

Donor 3R

Donor 3R
Donor 1A

Donor 2R

Donor 5R

Donor 3R
Donor 4R

Donor 3R

5UTR

CDS

CDS

CDS

CDS

Scoring System:
%Act: %Tags or Reads in Activated State:

Rest < Act : %Act ≥ 60%
Rest ≈ Act : 40% < %Act < 60%
Rest > Act : %Act ≤ 40%

3UTR

Resting:
9 Tags, BC4
Donor 4R

Donor 3A
Donor 2R

Donor 3R
Donor 3R
Donor 2R

ex: 5/(5+9)*100 = 35.7%: Rest > Act

Donor 1A
Donor 3A

Donor 4R

Donor 3R

Activated:
5 Tags, BC2

Donor 3R

Donor 3A
Donor 1A

Donor 5R

Figure 4.11 Cluster Scoring System. Schematic representing the cluster scoring system.
CLIP tags for each protein were clustered based on overlapping genomic positions of at
least 5 nucleotides. Clusters were included in the analysis if they were comprised of at
least 4 donor samples in the resting and or activated state and had a peak height of at least
10 tags between both activation states. The number of tags in each state was calculated
and the percentage of tags in the activated state out of the total number of tags in that
cluster from both states was calculated. Clusters were binned into whether the binding
increased (>60% activated tags), decreased (<40% activated tags), or showed little to no
significant change (between 40% and 60% activated tags) with T cell activation.
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changes in transcript abundance.

Overall, 45% of the binding distribution of HuR

between the resting and activated state for the cluster could be explained by parallel
distributions in gene expression for that transcript.

In only 7% of clusters did the

transcript abundance shift between activation states without a dramatic change in HuR
binding, although HuR binding was seen to shift in 45% of clusters without a substantial
change in gene expression. Interestingly, it was a small minority of clusters, less than 3%,
in which HuR binding and transcript abundance changed dramatically in opposite
directions (Table 4.3A). The transcripts with the top changes in cluster binding between
resting and activated lymphocytes are listed in Table 4.3B.

The most impressive changes in HuR regulation were seen in the activated state of early
activation genes and markers. While these transcripts had very low transcript expression
in the resting state and very weak levels of HuR binding, within the one hour of
stimulation, HuR appeared to coat these transcripts. One example of this is the EGR3
transcript that showed the most striking HuR change with CD3/CD28 stimulation. As
shown in Figure 4.12, there are only a few HuR tags at the end of the annotated 3’UTR in
the resting state, the coding region and UTRs of EGR3 are littered with robust clusters
with activation. It was unexpected that these changes would be seen so dynamically with
only an hour of stimulation of the lymphocytes. We also see that the binding extends
beyond the annotated 3’UTR for EGR3 and may represent a longer isoform than is
represented in the RefSeq database.

Another top HuR target with T cell activation is the IFNG transcript. As seen in Figure
4.13, there are only a few HuR binding sites mapped to IFNG in the resting state in
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Table 4.3 Combining HuR CLIP with RNAseq. (A) This table shows the number of
clusters binned in each category based on the scoring system outlined in Figure 4.11. (B)
This table lists the transcripts with the largest changes in cluster binding between resting
and activated states. First are HuR clusters with the largest decreases in binding with T
cell activation, then the largest increases in binding, and finally clusters where HuR
binding most opposes the changes in transcript abundance.

A
5112

598

3670

844

RPKM
Rest > Act
RPKM
Rest ≈ Act
RPKM
Rest < Act

679

1591

2742

HuR

HuR

HuR

Rest > Act Rest ≈ Act Rest < Act
187
488
4

284
1337
70

127
1845
770
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B
Clusters: HuR ⬇ Clusters: HuR ⬆
with CD3/CD28

Clusters: HuR

with CD3/CD28

Opposing RPKM
SP140

HSF2

EGR3

WDR22

NR4A3

ZHX2

PDE4D

FOSB

MAP3K7IP2

MAPK14

IFNG

ATF7IP

DARS

EGR1

ARL4C

INSIG2

CCL4

ARGLU1

ASH1L

NFKBIID

N4BP2L2

NAP1L4

EGR2

ZEB1

MGAT4A

CD69

WAC

BCL11B

FOS

RASGRP1
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Figure 4.12 HuR Binding on Human EGR3. The position of individual HuR unique
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on
the human EGR3 transcript. From top to bottom: chromosomal location, HuR CLIP tags
from activated CD8 T cells (colors represent each donor sample as shown in Table 4.1),
HuR CLIP tags from resting CD8 T cells, Gene diagram from RefSeq.
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Figure 4.13 HuR Binding on Human IFNG. The position of individual HuR unique
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on
the human IFNG transcript. From top to bottom: chromosomal location, HuR CLIP tags
from activated CD8 T cells (colors represent each donor sample as shown in Table 4.1),
HuR CLIP tags from resting CD8 T cells, Gene diagram from RefSeq.
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intronic regions and in the 3’UTR, but not more than biologic complexity of 2 or peak
height of 2. In contrast, almost the entire IFNG transcript is coated with robust HuR
binding clusters after an hour with CD3/CD28 stimulation. Most surprisingly, it appears
that HuR binds to the unprocessed pre-mRNA. This suggests that HuR may deposit on
the immature IFNG RNA co-transcriptionally and may accompany it from the nucleus to
the cytosol for processing.

Discussion

In this chapter we explored the regulation of RNA by HuR in CD8 T cells in the resting
and activated states from five normal human donors.

We were able to establish

conditions to effectively immunoprecipitate HuR from lymphocyte lysate and
demonstrated that the isolated RNA during CLIP was HuR monoclonal antibody specific,
crosslinking-dependent, and also achievable in mouse T cells. Using HITS-CLIP we
were able to define robust and reproducible binding sites across different human donors
samples that represented regulation in the resting and activated states of CD8
lymphocytes. We uncovered large sets of HuR regulatory sites that dynamically changed
within one hour of T cell stimulation.

We also demonstrated that only small numbers of T cells were needed to clone RNA
bound to HuR, therefore, this methodology may be easily applied to study more specific
populations of T cells. It could be possible to isolate antigen-specific T cells or other
small subsets of cellular populations and apply the HuR HITS-CLIP methods without
expansion of these cells in culture. This would allow for the molecular mechanisms of
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HuR control to be elucidated in physiologically relevant human donor cells for the study
of different disease states and for lymphocytes in an antigen specific manner.

We found that a majority of HuR binding sites was located in intronic regions of targeted
transcripts, followed by between 21 and 30 percent of binding falling in 3’UTR regions
of genes (Figure 4.9). Our finding that the vast majority of binding occurring in intronic
and 3’UTR regions of targeted genes corresponded to studies reporting HuR binding sites
determined by PAR-CLIP (Mukherjee et al. 2011). Interestingly, these binding patterns
contrast from those of the neuronal Hu proteins, which showed a binding preference to
the 3’UTR in nearly three quarters of highly reproducible clusters. This previous result
was seen for clusters of biologic complexity of 5 out of 6 sequenced samples, while lower
biologic complexity clusters showed a reduced preference towards the 3’UTR (InceDunn et al. 2012). It is therefore possible that the increased percentage of 3’UTR clusters
in T cells that were reproducible in both the resting and activated states is a reflection of
the enhanced robustness of these clusters as being at least a total of biologic complexity
of 6 and total peak height of 10 rather than a difference in the biology of this dataset.

Still, it is clear that the genomic distribution of binding appears to be different between
HuR and its neuronal family members. These binding patterns could represent multiple
possibilities. If the binding patterns are determined by the RNA sequence, then the
distribution of Hu binding sites might be different in the brain and T cells. Or there could
be other variables that influence HuR binding preferences such as the cooperative or
antagonistic interactions with other RNA-binding proteins, which might differ in
repertoire, abundance, and regulation in the two systems.
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Furthermore, differences

between the regulation of RNA in the steady state of the brain from the acutely activated
and proliferating T cells could account for differences seen in the proportion of intronic
binding.

Comparatively, there is more active transcription in these lymphocyte

populations and therefore likely more mRNA, leaving the possibility for increased cotranscriptional and intronic associations of HuR.

While we found that more than two-thirds of HuR binding clusters shifted in their
dominance between the resting and activated state, by combining this data with RNAseq
transcript abundance levels, we determined that much of the binding patterns can be
explained by gene expression levels. We saw that 45% of binding distribution between
the resting and activated states mirrored transcript abundance levels in these cells. Still,
in an additional 45% of clusters, HuR binding changes with activation were more
dramatic than changes in transcript abundance. This differs greatly from the reciprocal
scenario, where only 7% of genes that changed dramatically with T cell activation
showed roughly equivalent HuR binding in both states. It was very rare, in 3 percent of
clusters, for HuR binding to change in the opposite direction of a significant change in
transcript abundance (Table 4.3).

The largest changes in HuR binding were seen in early activation genes and markers of T
cell activation. Some of the largest differences in HuR tags between the resting and
activated states were seen in the EGR3 and IFNG mRNA. While robust binding was
seen along both of the transcripts, it was notable that for EGR3 while it appeared that
HuR bound solely exonic and UTRs, for IFNG it appeared to bind in intronic regions as
well. We were interested to find such robust HuR binding on the pre-processed transcript
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and consider that HuR appears to be deposited co-transcriptionally. Still, the largest
binding sites for both of these genes were seen in the 3’UTR. It would be interesting to
investigate the binding patterns of these and other genes at additional time points
following T cell stimulation. For example, it would be interesting to see if the HuR
binding resolved at later time points to include only processed mRNA sites or to the
3’UTR alone. Similarly it could be informative to study earlier time points to gain
insight into how these binding sites accumulate along the transcript. Nevertheless, at one
hour of activation, the view we are given of HuR regulation is most likely the population
average of activation time points leading up to one hour because it is unlikely that all of
the T cells encounter CD3 and CD28 antibody at time zero.

In this study, the activation and crosslinking was done at a short time point, so it would
be interesting in future studies to observe the binding of HuR to targets affects transcript
stability and translation at subsequent time points. It is possible that while HuR mirrors
transcript abundance with the new burst of transcriptional changes with CD3/CD28
stimulation that the presence or absence of HuR binding sites may help dictate the fate of
these transcripts as the activated biology resolves.
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CHAPTER 5. Determination of Ago in vivo Binding Sites
in Resting and Activated T cells

Introduction

As described in previous chapters, T cells must transition very quickly from a quiescent
state to an active state to perform various functions to maintain immunity within a host,
such as when they encounter cognate antigen and transmit signals through their T cell
receptors. Because of the rapid nature of these encounters, while they utilize regulated
gene expression at every level, the regulation of protein expression from pre-synthesized
mRNA provides the most rapid means of response. Such translational regulation occurs
in many ways, but a common feature is regulation by RNA-binding proteins that help
control the localization and stability of target transcripts, keep them poised for quick
translation into proteins, or help them be swiftly degraded to begin, reshape, or terminate
an immune response.

Transcripts encoding cytokines are good examples of such

remodeling because they are needed to initiate antigen-specific responses but need to be
terminated just as abruptly so that lymphocytes do not harm surrounding cells after
antigen encounter (Anderson, 2008). Understanding the post-transcriptional control of
RNA is essential to understanding the biology of the dynamic regulation of lymphocyte
activation.

Argonaute (Ago)-microRNA complexes provide one well-studied mechanism to regulate
translation of extant mRNAs, and there is emerging evidence that they may do so in a
dynamic manner. For example, the CAT-1 mRNA has been showed to localize to stress
granules by microRNA mediated repression. Upon amino acid starvation, HuR mediates
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de-repression from Ago by mobilization of this transcript from stress granules and into
active polysomes (Bhattacharyya, Habermacher, Martine, Closs, & Filipowicz, 2006a;
2006b). Vasudevan and Steitz showed that Ago and FXR1 associate together with the
TNF 3’ untranslated region (3’UTR) during serum starvation and recruit bound mRNA to
actively translating polysomes during the induction of cell cycle arrest (Vasudevan &
Steitz, 2007; Vasudevan, Tong, & Steitz, 2007). The localization of Ago to stress
granules upon the induction of stress conditions is microRNA mediated and rapidly
reversible in less than one minute.

It appears that Ago helps to exchange mRNA

localization between these cytoplasmic foci and actively translating ribosomes (Leung,
Calabrese, & Sharp, 2006).

Work from other groups has also demonstrated that

microRNA can be regulated to impact rapid changes within the retina and other neuronal
systems (Krol et al., 2010).

The abundance of microRNAs in different T cell lineages has also been studied
extensively, but has not taken into account the activation state of these cells or the
binding preferences of Ago therein (Landgraf et al., 2007; Monticelli et al., 2005; Salaun
et al., 2011; Wu et al., 2007). The genetic manipulation of specific microRNAs in mice
has demonstrated that many are necessary for the maintenance of a healthy immune
system, with ablation or overexpression of microRNAs showing various deleterious
results such as aberrant cell death, the induction of multiple autoimmune disorders, and
cancer (Xiao & Rajewsky, 2009). Mice lacking Ago2 in bone marrow derived cells
showed deficiencies in the development of the B cell and erythroid cell compartments
(O'Carroll et al., 2007). Dicer is essential for the production of mature microRNA and
mice deficient for this enzyme in the T cell lineage showed greatly impaired lymphocyte
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differentiation, with heightened defects in the development of CD8 T cells (Cobb, 2005;
Muljo et al., 2005). Zhang and Bevan examined the role of Dicer in mature mouse
cluster of differentiation eight (CD8) T cells and found that cells lacking Dicer were able
to respond more quickly to T cell activation in vitro including quicker expression of
CD69 and prolonged expression of this marker following withdrawal from the T cell
receptor stimulus.

They also found that certain microRNAs were increased after

stimulation in culture (Zhang & Bevan, 2010). Still, these analyses were on the order of
days in culture and did not represent the potential dynamic changes of Ago regulation
immediately following T cell stimulation ex vivo or the identification directly mapped
binding events.

We have previously demonstrated the ability to use high-throughput sequencing crosslinking immunoprecipitation (HITS-CLIP) to establish a precise and genome-wide map
of Ago-microRNA-mRNA ternary interactions (Chi, Zang, Mele, & Darnell, 2009). This
work examined Ago binding in the mouse brain in a steady state and did not explore the
dynamics of Ago regulation. Ago binding maps in WT and miR-155 deficient mouse
regulatory CD4 T cells were recently published, but these studies focus on a different
subset of T cells in mice and represent data from cells stimulated in culture for four days
(Loeb et al., 2012). Thus, to our knowledge studying the regulation of Ago in normal
human CD8 lymphocytes and with acute T cell stimulation has not been previously
examined. In this work we aim to map RNA-binding patterns of Ago in resting and
activated normal human CD8 T cells to decipher the mechanics of T cell activation and
probe the dynamic regulation of RNA.
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Results

Ago HITS-CLIP from Five Normal Donor Resting and Activated CD8 T cells

Five healthy normal volunteers were leukapheresed and the collected material was used
to purify CD8 T cells for HITS-CLIP, as described in previous chapters. Briefly, We
used a Ficoll gradient to isolate the PBMC from leukapheresate that were then depleted
of CD56+ cells using antibody bound magnetic beads and magnetic columns. The CD56
depleted PBMC were then subjected to CD8 positive selection and the resulting
lymphocytes were rested in media overnight. After resting, T cells were UV-B irradiated
to crosslink RNA to protein either immediately or after stimulation for one hour with
CD3/CD28 beads. As shown in Chapter 3, the cells were analyzed by flow cytometry to
confirm that their purity was greater than 90 percent (Table 3.1). Their activation status
was confirmed by analyzing RNA from a non-crosslinked aliquot of the T cells by RTqPCR for levels of TNF and IFNG (Figure 3.3). Each sample had between a 280 to 610fold induction of TNF mRNA and between 1250 to 7600-fold induction of IFNG mRNA.

For three of the donors, Ago immunoprecipitation was performed using protein A beads
with bound rabbit anti-mouse antibodies supporting a broader net of Ago specific
monoclonal antibody 2A8 (Harlow & Lane, 1988). For the other two, we used protein G
beads bound directly to the Ago antibody 2A8. We saw a reduced RNA signal in the
protein G immunoprecipitation as compared to with protein A. In pilot experiments, we
compared the signal to noise from both immunoprecipitation methods and found that
protein A samples contributed more unique CLIP reads than protein G samples, but that
CLIP tags from both methods clustered in many of the same genomic locations (data not
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shown). The correlations between the protein A and G immunoprecipitation methods
used in the lymphocyte Ago CLIP described in this chapter will be discussed below.
Thus, although the resulting data from the two methods produced differing amounts of
data, we included both in the analysis moving forward.

The HITS-CLIP protocol is schematized in Figure 4.1. Ago was immunoprecipitated
from CD8 T cell lysate that had been DNAse treated, to degrade DNA, and partially
RNase digested to reduce the size of RNA molecules in the samples to clonable
fragments and to determine the exact binding position of Ago on its target transcripts.
The protein-RNA complexes captured on the Ago antibody coated protein A beads or
protein G beads were then thoroughly washed on bead. The samples were heated to
remove the Ago-RNA complexes from the beads and dissociate free RNA. Next these
complexes underwent size selection after being run on an SDS-PAGE gel and being
transferred to a nitrocellulose membrane. As in HuR CLIP, free RNA not crosslinked to
Ago would not be expected to co-migrate with Ago on the gel and then subsequently to
the nitrocellulose and should have been removed during these rigorous processes.
Because of these purifications, there was no signal seen at the size of Ago bound to RNA
on the autoradiogram in non-crosslinked samples (Figure 5.1A). Thus, we concluded that
the isolation of mRNA was cross-linking dependent. Also, the signal seen from the AgoRNA complexes collapsed to the expected size of Ago bound to microRNA with over
digestion of the sample with a high concentration of RNase A (Figure 5.1A). This
showed that the signal seen above the molecular weight of RNA was RNase sensitive.
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A

B

Autoradiogram
P32-RNA Cross-linked to Ago
Purified by IP
No XL

High
RNAse

cDNA Products
PCR Amplified after
Linker Ligation

Low
RNAse
28 PCR
Cycles

225

300

150

mRNA

200

miRNA
mRNA

102

100
miRNA

76
50

Figure 5.1 Ago HITS-CLIP. (A) Autoradiogram of immunoprecipitation results from
human CD8 T cells prepared with or without crosslinking.
Lysate was
immunoprecipitated with HuR antibodies (mouse monoclonal Ago specific 2A8). 32Plabeled RNA was evident in Ago immunoprecipitation with crosslinked lysate, but not
from non-crosslinked lysate. With high RNAse treatment, the size of the RNA-protein
complexes approach the modal size of Ago. With a lower RNAse treatment, RNAprotein complexes of ~110 kD are visible, corresponding to the size of Ago-microRNA
complexes, and also ~130 kD, corresponding to the size of Ago bound predominantly to
partially digested mRNA. (B) PCR products amplified after linker ligation of microRNA
and mRNA products excised from the membrane shown in A.
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We isolated protein-RNA complexes from the nitrocellulose membrane at the size of Ago
bound to microRNA and also at a higher molecular weight of Ago bound to larger
fragments of mRNA. After this size selection, we digested Ago with Proteinase K and
cloned the RNA by ligating RNA linkers to either end of the isolated RNA. Then we
utilized reverse transcription and amplified the resulting cDNA samples by PCR for highthroughput sequencing (Figure 5.1B). During the PCR for the samples prepared from
protein A immunoprecipitation, we used small aliquots of the total sample to determine
the minimum number of cycles needed to visualize the resulting products on a UreaPAGE gel with SYBR gold staining without over amplification. Ideally, we want to
amplify these products for a minimum number of cycles to isolate enough material for
high-throughput sequencing, but to preserve the complexity of the cloned RNA
sequences. Once the minimal cycle numbers were established for each sample, those
PCR cycles were performed on the remaining aliquot of the sample and they were gel
purified. The products from each donor were pooled together to increase the complexity
of the samples to be sequenced.

Overview of RNA Tag Statistics

We sequenced samples produced from the CD8 lymphocytes of five healthy normal
donors in both a resting state and after being stimulated for an hour with CD3/CD28
beads.

Each Ago associated mRNA sample produced between 21 and 35 million

sequencing reads. We collapsed duplicate reads, to minimize the bias introduced from
PCR amplification. With only one representation of each sequence in the library, we had
between 4 and 10 million reads for each sample. This dramatic decrease is most likely
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due to both over sequencing of the sample and PCR duplication of CLIP tags. Each
sample was then mapped to its location in the hg18 build of the human genome (Table
5.1), yielding between 800,000 to 4.5 million uniquely mapping RNA CLIP tags.

The 5’ RNA linker contained a four nucleotide degenerative sequence. Comparing the
four-nucleotide barcodes allowed us to distinguish between unique Ago binding events
that occur on different mRNA molecules at the same position and yielded identical RNA
sequences and PCR duplications of a single Ago interaction. We removed duplicates that
had the same starting and ending genomic coordinates and the same four-nucleotide code
in the linker sequence. After this computation, the samples were reduced to under
100,000 reads for the protein G samples and between 300,000 and 1.25 million unique
CLIP tags for the protein A samples. The colors used to highlight each donor sample in
the table correspond to the colors of the tag representations in subsequent analyses on the
genome browser (Table 5.1). In this way, we can compare the data in each state from
matching donor samples and relate binding changes to the sequencing depth of each
sample. The Ago sample coloring also matches HuR CLIP data from the same donors,
presented in Chapter IV. These Ago HITS-CLIP analyses in lymphocytes in the resting
and activated state from five normal donors resulted in the generation of an extensive
dataset of Ago bound RNA.

Reproducibility of Binding between Biologic Replicate Samples

As with our analysis of HuR binding, we wanted to focus on Ago sites of regulation
where the cloned binding events were robust and reproducible between different donors.
To begin this exploration, we used a program to group CLIP tags that mapped to regions
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Table 5.1 Ago CLIP mRNA Tag Statistics.

Resting
Ago

Total Reads

Total Reads
(One Copy)

Mappable
Reads
(One Copy)

Unique
Mappable
Reads

% Total Reads
(One Copy)

Donor 1

32,542,843

8,079,941

3,655,774

556,098

6.88

Donor 2

26,822,766

6,789,815

3,525,705

690,355

10.17

Donor 3

29,655,003

9,280,766

4,407,580

1,009,902

10.88

Donor 4

34,142,134

6,983,614

1,671,612

75,346

1.08

Donor 5

31,620,159

4,443,870

791,461

24,852

0.56

Activated
Ago

Total Reads

Total Reads
(One Copy)

Mappable
Reads
(One Copy)

Unique
Mappable
Reads

% Total Reads
(One Copy)

Donor 1

32,467,147

8,807,525

4,026,449

1,301,022

14.77

Donor 2

21,768,315

4,433,931

1,699,750

305,414

6.89

Donor 3

21,658,925

4,930,455

2,425,804

1,218,059

24.70

Donor 4

30,981,793

4,959,913

1,147,922

50,879

1.03

Donor 5

28,363,457

4,605,741

965,624

46,980

1.02
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of the genome that overlapped at least 5 nucleotides. Within each cluster of tags, we
designated that in at least one position there be at least 5 tags overlapping the same
nucleotide. We calculated the number of tags overlapping at the peak nucleotide position
of each cluster and call this the peak height. To look at the correlation between the ten
samples, we excluded 8 clusters that had a sum of over 1,000 CLIP tags grouped together.
We did this to have a more conservative estimation of the correlation, because these
clusters improved the correlations and we were concerned that these were not accurate
depictions of Ago regulation.

To assess the reproducibility of our HITS-CLIP assay, we then calculated the absolute
value of the Pearson correlation coefficient between the numbers of tags per cluster that
originated from each normal donor from either resting or activated T cells (Figure 5.2).
For the samples prepared from protein A immunoprecipitation, we saw at least a
correlation of r=0.88 between samples from different donors in the same activation state.
These high correlations were slightly reduced, but very robust of at least r=0.77,
comparing protein A samples derived from activated T cells compared to resting T cells.
Because of the low read depth in the protein G prepared samples, the correlations
between them was lower than those from protein A, between 0.65 and 0.84. And they are
even lower when comparing protein G samples to protein A. These lower correlations
are most likely due to the lower probability of a unique read from the protein G samples
being present in a cluster formed by the larger numbers of reads from the protein A
samples. Still, there is the possibility that the different immunoprecipitation protocols
introduce bias into the samples.
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Figure 5.2 Pairwise Correlation of Ago CLIP Clusters. Upper half of table: Pair-wise
scatter plots displaying the number of tags per cluster of Ago CLIP tags contributed to
the cluster by each resting (r) or activated (a) donor sample as indicated. Lower half of
table: absolute value of the pair-wise Pearson correlation coefficient of the number of
tags contributed to each cluster by each resting or activated donor sample. The size of
text is scaled to the correlation value. Clusters needed to contain a minimum of 5
overlapping tags at one nucleotide position to be included in either analysis. !
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For more stringent analysis, we also specified that there be at least three of the five donor
samples represented in each cluster in either the resting or the activated state to demand
biologic reproducibility in each putative Ago binding site. With these conditions, we
defined over 38,000 sites of robust Ago mRNA binding. More than 40 percent of these
clusters had robust binding in both the resting and activated states. 28 percent of clusters
were present at this stringency level only in the resting state (10,839 clusters) and 41
percent of clusters were in the activated state alone (15,740 clusters) (Figure 5.3).
Interestingly, while there were more clusters with Ago binding sites in the activated state,
we saw less of a difference in the percentages of clusters distributed between resting and
activated states with Ago regulation than with HuR (Figure 4.8). In summary, these data
demonstrate the reproducibility of the Ago HITS-CLIP method between different normal
human donor samples.

Genomic Distribution of Ago Binding Sites

To examine the role of Ago in regulating mRNA in T cells, we next determined which
regions of target transcripts were represented by the Ago binding sites. We mapped
clusters that represented tags from at least three of the five donors and a peak height of 5
in either the resting state (Figure 5.4A), activated state (Figure 5.4C), or both (Figure
5.4B). As in the HuR dataset, we were surprised at the large number of robust clusters
that mapped to intronic regions of target transcripts. In all three groups we saw more
than two thirds of clusters mapping to intronic regions of regulation, while 3’UTR
binding represented a smaller, but significant portion of Ago regulation (13-15%). An
even smaller proportion of clusters mapped to the coding region and 5’UTR of genes.
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Resting
10,839

Activated

11,902

15,740

Figure 5.3 Ago Clusters Activation State Distributions. Venn diagrams show the
overlap between Ago target clusters in the indicated activation states with the number of
clusters representing 3 biologic donor samples and a peak height of at least 5 CLIP tags
shown.
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C
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9%

5%

5%

3%

6%

5%
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8%

8%

10%

71%

Ago Resting

67%

Ago Resting & Activated

70%

Ago Activated

Figure 5.4 Ago Clusters Genomic Distribution. Distribution of clusters, comprised of
at least 3 biologic donor samples in the resting and or activated state and a peak height of
at least 5 CLIP tags, among Ago target transcripts represented by pie chart.

133

Thus, the binding regions of Ago on target transcripts were reproducible between binding
states and lymphocytes may provide a strong model system to study the roles of Ago in
intronic RNA binding.

Ago bound MicroRNA Analysis

In addition to mapping Ago-binding events in mRNA target transcripts, we also cloned
and sequenced bound microRNA molecules from two donors in both the resting and
activated states. From these samples we mapped between 21 and 35 million microRNA
tags (Table 5.2). We identified 271 microRNA that were present in at least one of the
four sequenced samples, but the top 35 sequenced microRNAs represented over 98% of
the sequencing reads. These top microRNAs are listed in order of total sequencing
frequency in Table 5.3. The top microRNA found in the CD8 lymphocytes was miR142-3p. miR-142 is specific to the hematopoietic lineage and was shown previously to
be the most represented microRNA in T cells, confirming that our data correlates well
with previous findings (Landgraf et al., 2007).

To examine whether microRNAs changed in their binding status to Ago during T cell
activation we calculated the number of tags sequenced for each microRNA normalized to
the total read depth so that they could be compared between samples. We determined the
ratio of tags in the activated and resting state for each microRNA for both of the two
donors.

We included microRNAs that were more than 1.5 fold changed in either

direction but in the same direction with CD3/CD28 stimulation in both of the donor
samples. We included these small changes in microRNA fluctuations because these were
shown to be potentially biologically meaningful in many contexts, for instance, the light
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Table 5.2 Ago CLIP microRNA Tag Statistics.

Mappable
miRNA Reads
Resting Ago
Donor 3

29,655,003

Donor 4

34,142,134

Activated Ago
Donor 3

21,658,925

Donor 4

30,981,793
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Table 5.3 Ago CLIP: Top 35 microRNAs. Listed are the top 35 microRNAs
represented in the Ago CLIP microRNA dataset ranked by the total number of CLIP
reads for each microRNA from all four sequencing experiments pooled together.

Top 35
miRNA

Donor 3
Resting

Donor 3
Activated

Donor 4
Resting

Donor 4
Activated

Total
Reads

% Total
Reads

hsa-miR-142-3p
hsa-miR-30e

8,515,220
1,392,825

6,696,915
1,487,372

8,817,909
3,909,695

8,332,644
4,685,356

32,362,688
11,475,248

34.122
12.099

hsa-miR-27a

1,650,403

1,935,439

4,046,307

2,875,217

10,507,366

11.079

hsa-miR-26a

1,145,899

1,169,916

2,823,385

3,565,442

8,704,642

9.178

hsa-miR-146b-5p

609,620

567,185

2,054,043

1,937,224

5,168,072

5.449

hsa-miR-374a

603,602

754,739

1,834,183

1,845,924

5,038,448

5.312

hsa-miR-30d

553,358

714,481

1,490,311

1,700,847

4,458,997

4.701

hsa-miR-150

515,547

532,214

998,918

966,580

3,013,259

3.177

hsa-miR-19b

358,778

290,837

303,262

608,323

1,561,200

1.646

hsa-miR-181a

146,886

156,775

470,628

595,160

1,369,449

1.444

hsa-miR-374b

157,360

186,928

435,675

449,082

1,229,045

1.296

hsa-miR-101

236,535

245,996

333,864

400,586

1,216,981

1.283

hsa-miR-21

314,130

318,429

239,254

273,519

1,145,332

1.208

hsa-miR-20a

116,350

126,002

207,719

195,158

645,229

0.680

hsa-miR-16

118,932

117,031

189,527

193,081

618,571

0.652

hsa-miR-186

143,883

120,637

169,311

157,836

591,667

0.624

hsa-let-7i

121,066

116,858

115,255

140,371

493,550

0.520

hsa-miR-222

115,497

134,916

80,877

127,151

458,441

0.483

hsa-miR-29b

155,622

109,587

96,612

92,757

454,578

0.479

hsa-miR-17

68,345

72,967

124,358

127,512

393,182

0.415

hsa-miR-19a

92,935

74,627

56,256

106,223

330,041

0.348

hsa-miR-26b

67,407

61,673

67,048

88,771

284,899

0.300

hsa-miR-31

74,834

64,612

48,024

58,200

245,670

0.259

hsa-let-7g

70,368

63,330

45,329

48,572

227,599

0.240

hsa-miR-30b

48,111

62,490

53,251

62,742

226,594

0.239

hsa-miR-92a

51,946

48,263

45,599

64,291

210,099

0.222

hsa-miR-142-5p

59,166

58,643

39,219

44,112

201,140

0.212

hsa-miR-30a

29,167

25,415

39,905

46,708

141,195

0.149

hsa-miR-155

27,260

25,858

33,528

37,810

124,456

0.131

hsa-miR-181b

15,069

14,618

32,433

51,007

113,127

0.119

hsa-miR-30c

30,893

30,747

25,484

25,953

113,077

0.119

hsa-miR-106b

14,344

20,174

39,123

28,142

101,783

0.107

hsa-miR-140-5p

29,568

21,862

20,733

26,551

98,714

0.104

hsa-miR-146a

23,109

21,528

22,782

21,337

88,756

0.094

hsa-let-7a

25,371

23,861

15,695

16,880

81,807

0.086
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and dark adaptation of the retina (Krol et al., 2010). Finally, we ranked these changes by
taking the ratio of the sum of normalized reads in the activated and resting state for the
two donors together.

As enumerated in Table 5.4, there were 33 microRNA with

reproducible changes in Ago binding with T cell activation of at least 1.5 fold change.
Still, it is unclear whether these changes are biologically significant, because the most
highly abundantly sequenced microRNA in this list, miR-32, had a normalized rank of
68th out of the 271 sequenced microRNAs. As mentioned above, a very small number of
microRNAs represented the vast majority of sequencing reads and the microRNAs
ranked above miR-32 accounted for 99.7% of the total reads sequenced. While the
largest changes were among microRNAs with low levels of Ago binding, it is possible
that the identified fluctuations could represent the dynamic control of lymphocyte
activation acutely at one hour of CD3/CD28 stimulation.

Ago mRNA Binding Changes with Activation

As described in the previous chapter, RNAseq was done on non-crosslinked aliquots of
the same pools of cells that were prepared for HITS-CLIP. Using this data, we can give
context to the regulation by Ago and HuR by considering the transcript abundance of
target and non-target RNAs.

In this manner we were able to compare the dynamic

changes in both transcript binding by Ago and HuR with the dynamic changes in gene
expression seen with lymphocyte activation.

Using the same criteria as for HuR tags outlined in Figure 4.11, we clustered Ago CLIP
tags together from the resting and activated states of the five donors sequenced. For each
cluster we specified that the CLIP tags overlap at least 5 nucleotides in their genomic loci,
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Table 5.4 MicroRNAs Shifting More than 1.5 Fold with Activation. MicroRNAs are
ranked by the total number of CLIP reads for each microRNA from all four sequencing
experiments pooled together.

Donor 3
Donor 4
Donor 3
Donor 4
Activate
Activate
Resting
Resting
d
d
Tags
Tags
Tags
Tags

Act

Rest

Total
Reads

Donor 3
Donor 4
Donor 3
Donor 4
Act/
Activate
Activate
Resting
Resting
Rest
d
d
Norm.
Norm.
(Norm.)
Norm.
Norm.

hsa-miR-365
hsa-miR-941
hsa-miR-151-5p
hsa-miR-769-3p

0
0
0
1

24
36
1
37

0
0
0
3

46
18
4
43

70
54
5
84

0.00
0.00
0.00
0.03

0.79
1.19
0.03
1.22

0.00
0.00
0.00
0.17

2.74
1.07
0.24
2.56

------18.90

hsa-miR-99b
hsa-miR-548e
hsa-miR-1977
hsa-miR-132
hsa-miR-98
hsa-miR-200b
hsa-miR-192
hsa-miR-874
hsa-miR-503
hsa-miR-320b
hsa-miR-182
hsa-miR-940
hsa-miR-579
hsa-miR-32
hsa-miR-338-3p
hsa-miR-339-3p
hsa-miR-100
hsa-miR-1277
hsa-miR-135b
hsa-miR-130b
hsa-miR-548n
hsa-miR-548i
hsa-miR-362-3p
hsa-miR-1972
hsa-miR-331-5p
hsa-miR-212

10
0
4
97
74
630
611
105
35
184
0
0
0
4,459
217
149
47
5
131
144
2
3
56
0
2
112

63
363
80
761
271
2,306
1,718
498
55
287
255
41
46
2,594
46
62
0
0
1
35
0
1
0
1
1
0

20
58
23
201
80
330
1,135
733
31
82
112
23
43
3,872
503
169
68
75
465
95
3
1
27
74
31
43

72
35
38
360
162
504
1,701
1,118
58
143
11
1
13
2,383
258
74
36
24
154
25
1
0
10
11
0
0

165
456
145
1,419
587
3,770
5,165
2,454
179
696
378
65
102
13,308
1,024
454
151
104
751
299
6
5
93
86
34
155

0.34
0.00
0.13
3.27
2.50
21.25
20.61
3.54
1.18
6.21
0.00
0.00
0.00
150.43
7.32
5.03
1.59
0.17
4.42
4.86
0.07
0.10
1.89
0.00
0.07
3.78

2.07
11.95
2.63
25.05
8.92
75.92
56.56
16.39
1.81
9.45
8.39
1.35
1.51
85.40
1.51
2.04
0.00
0.00
0.03
1.15
0.00
0.03
0.00
0.03
0.03
0.00

1.11
3.21
1.27
11.14
4.43
18.29
62.90
40.62
1.72
4.54
6.21
1.27
2.38
214.59
27.88
9.37
3.77
4.16
25.77
5.26
0.17
0.06
1.50
4.10
1.72
2.38

4.29
2.09
2.26
21.45
9.65
30.03
101.36
66.62
3.46
8.52
0.66
0.06
0.77
142.00
15.37
4.41
2.15
1.43
9.18
1.49
0.06
0.00
0.60
0.66
0.00
0.00

4.40
4.37
3.47
3.23
2.68
2.68
1.89
1.88
1.82
1.67
1.46
1.11
0.96
0.62
0.48
0.45
0.40
0.33
0.31
0.26
0.25
0.21
0.18
0.17
0.02
0.00

hsa-miR-545
hsa-miR-744
hsa-miR-499-3p

2
3
1

0
0
0

16
14
15

0
0
0

18
17
16

0.07
0.10
0.03

0.00
0.00
0.00

0.89
0.78
0.83

0.00
0.00
0.00

0.00
0.00
0.00

138

that there be four of five donors represented in the resting and or activated state, and that
there be a position in the cluster where at least 10 tags from either activation state overlap.
We calculated the percentage of tags in each cluster that originated from activated cells
and then binned the clusters into whether the binding increased (>60 % activated tags),
decreased (<40% activated tags), or showed little to no significant change (between 40%
and 60% activated tags) with T cell activation. For the gene expression for each cluster,
we binned the RNAseq values into the same three groups with the same cutoffs
depending on the percentage of RPKM values from sequencing the activated T cells for
each gene. Furthermore, to ensure that the RNAseq data was interpretable, we specified
that the transcript have a minimum of an RPKM of 15 for inclusion in the subsequent
analysis.

As shown in the summarized results in Table 5.5A, nearly two thirds of robust Ago
clusters showed dramatic changes in binding patterns with T cell activation. Of these
dynamically changing Ago clusters, 37% reflected parallel changes in transcript
abundance in the cells.

Globally, more than half of Ago clusters had paired gene

expression changes with their binding changes. It was in only 7% of robust Ago binding
sites that gene expression changed between the resting and activated state without a
dynamic change in Ago binding and in less than 2% of clusters in which Ago binding and
gene expression shifted in opposite directions. Thus, we can conclude that while Ago
binding clearly shifts dramatically and dynamically with lymphocyte activation, much of
these differences at one hour of CD3/CD28 stimulation can be explained by changes in
transcript abundance.
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Table 5.5 Combining Ago CLIP with RNAseq. (A) This table shows the number of
clusters binned in each category based on the scoring system outlined in Figure 4.11. (B)
This table lists the transcripts with the largest changes in cluster binding between resting
and activated states. First are Ago clusters with the largest decreases in binding with T
cell activation, then the largest increases in binding, and finally clusters where Ago
binding most opposes the changes in transcript abundance.

A
1837

251

1215

371

RPKM
Rest > Act
RPKM
Rest ≈ Act
RPKM
Rest < Act

351

625

861

Ago

Ago

Ago

Rest > Act Rest ≈ Act Rest < Act
108
241
2

111
488
26

32
486
343
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B
Clusters: Ago ⬇

Clusters: Ago ⬆

Clusters: Ago

with CD3/CD28

with CD3/CD28

Opposing RPKM

WDR68

EGR2

IFI16

STX2

NR4A3

TAF15

BRWD1

EGR3

PLEC1

C6orf190

EGR1

ZC3H18

ENO2

NR4A2

SFRS8

MGAT4A

CD69

SRRM1

SLC4A7

IFNG

SESN3

FYB

MYC

ARGLU1

ARRDC3

IL2

NFATC2

UBQLN1

NR4A1

ANKRD10

Similarly to HuR, the biggest changes in Ago binding occurred with T cell activation in
early activation genes and markers (Table 5.5B). These transcripts had very minimal
expression in the resting state and virtually no Ago binding. After an hour of T cell
activation, Ago crosslinked throughout these transcripts in high abundance. Using the
same examples as for HuR binding, in Figure 5.5 we see Ago coating the coding region,
UTRs and downstream of the 3’UTR of the EGR3 transcript. We did not expect to see
such dynamic changes in binding within one hour of stimulation with CD3/CD28
antagonists. Similarly, Ago binding on the IFNG transcript increased dramatically with
lymphocyte activation (Figure 5.6).

Finally, Ago binding in some clusters decreased dramatically with lymphocyte activation.
One of the more dynamic examples of such changes was in the intronic region of FYB
(Figure 5.7). This example illustrates robust binding in the resting state that has less than
biologic complexity of two binding in the activated state. While the FYB gene decreases
slightly with T cell activation, it is binned with the group of genes that do not show
dramatic shifts in transcript abundance and shows more dynamic binding preferences by
Ago. As seen in Figure 5.4 the intronic regulation by Ago as seen in the IFNG transcript
is not limited to the activated state and is not necessarily linked to dramatic induction of
transcription within the T cell. In summary, we identified reproducible Ago binding
clusters in lymphocytes in both the resting and activated states. Many of these clusters
show dramatic quantitative changes in binding events with T cell stimulation and
generally the majority of binding patterns in each state mirror the RNA level of that
target.
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Figure 5.5 Ago Binding on Human EGR3. The position of individual Ago unique
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on
the human EGR3 transcript. From top to bottom: chromosomal location, Ago CLIP tags
from activated CD8 T cells (colors represent each donor sample as shown in Table 5.1),
Ago CLIP tags from resting CD8 T cells, Gene diagram from RefSeq.
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Figure 5.6 Ago Binding on Human IFNG. The position of individual Ago unique
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on
the human IFNG transcript. From top to bottom: chromosomal location, Ago CLIP tags
from activated CD8 T cells (colors represent each donor sample as shown in Table 5.1),
Ago CLIP tags from resting CD8 T cells, Gene diagram from RefSeq.
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Figure 5.7 Ago Binding in Human FYB Intron. The position of individual Ago unique
CLIP tags in biologic complexity two clusters plotted relative to their mapped position on
an intron of the human FYB transcript. From top to bottom: chromosomal location, Ago
CLIP tags from activated CD8 T cells (colors represent each donor sample as shown in
Table 5.1), Ago CLIP tags from resting CD8 T cells, Gene diagram from RefSeq.
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Discussion

In this chapter we examined the binding patterns of Ago in the resting and activated
states of CD8 lymphocytes from five normal human donors.

Using two different

immunoprecipitation configurations with protein A or protein G beads, we were able to
amass a large dataset of reproducible binding sites for Ago in T cells on mRNA and
microRNA. As alluded to above, we think the difference in complexity between the
protein G and protein A samples is due to a increased efficiency of the
immunoprecipitation using protein A and a bridging antibody to maximize the antigen
binding surface of the Ago monoclonal antibody. Also, using a larger proportion of the
isolated cDNA to be amplified and pooled from lower cycle numbers in the PCR
reactions helped increase the overall complexity of the sequenced material during the
protein A sample preparations.

We found many clusters of Ago binding in the resting state alone, both states, and a
slightly larger number of clusters in the activated state alone. This represents the first in
vivo dataset of mapped Ago regulation in human T cells with a physiologic biologic state
change and it was interesting to discover that Ago binding changes quite dramatically
within one hour of CD3/CD28 stimulation in CD8 lymphocytes. While the distribution
of binding within clusters and between transcripts did shift dramatically with T cell
activation, we did not see a global shift in the regions of transcripts that are bound by
Ago in the different states.

We were surprised to find that, while 3’UTR binding

represented a significant portion of Ago regulation (13-15%), the majority of robust Ago
clusters were found in intronic regions of transcripts. This contrasts with the maps
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previously determined in the lab for Ago function in the mouse brain, where only 12% of
clusters biologic complexity greater than or equal to two mapped to intronic sequences.
In the Ago brain map, about one third of clusters mapped to the 3’UTR regions of
transcripts and a quarter to coding regions, while less than half of those percentages did
in T cells (Chi et al., 2009).

This may represent differences in the biology of

lymphocytes, which unlike the brain are actively dividing cellular populations. Loeb et al.
also reported a lower percentage of Ago CLIP tags mapping to 3’UTR regions within T
cells. These studies used a polyclonal antibody specific to Ago2 for immunoprecipitation
and not a pan-Ago antibody as we did (Loeb et al., 2012). Thus we speculate that it is
possible that some of the increased intronic binding seen in our samples could be due to
regulation by the other Ago proteins in T cells or other binding preferences of the
antibodies in isolating populations of Ago within the T cells.

Similar to other studies measuring microRNA abundance in lymphocyte populations, we
found that miR-142 was the most represented in our CD8 T cells (Landgraf et al., 2007;
Salaun et al., 2011; Wu et al., 2007). While we were able to identify almost 300
microRNA bound to Ago in either the resting and activated states, similar to previous
work, we found that a small number of microRNA represented the vast majority of Agobound sequencing reads (Chi et al., 2009). The top 35 microRNA found in our T cell
dataset represented over 98% of the total reads. We identified 33 microRNAs that
changed in their Ago binding status between the resting and activated state and more than
1.5 fold with activation. Although these may be robust differences, it is unclear whether
these shifts in microRNAs that are representative of far less than 0.5% of Ago binding
could greatly influence the biology of T cells. Further analysis and studies are needed to
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determine if these shifts in these Ago bound microRNA help define the biology of the
resting and activated T cell phenotypes.

While we did not observe large differences in Ago-bound mature microRNAs cloned in
our CLIP experiments, we did observe an increase in binding in many microRNA host
genes and pre-microRNA transcripts (data not shown).

Previous studies have

demonstrated that the levels of many microRNAs can be regulated in the reaction to
different stress responses (Leung & Sharp, 2007). It would therefore be informative to
consider the Ago-bound microRNA repertoire with respect to the cellular pool of
microRNAs at later time points with activation to examine the kinetics of AgomicroRNA interactions and determine if and when there is a shift to reflect this changing
population of small RNAs in the cell.

As observed in HuR binding pattern changes with activation, although nearly two thirds
of Ago binding sites shift quantitatively with CD3/CD28 stimulation, the majority of Ago
binding changes are parallel to variations in transcript abundance. It was surprising to
find that Ago binding correlated well with transcript expression levels, because it is
typically assumed that increased Ago binding leads to decreased expression of its targets
(Bartel, 2009).

One possible interpretation is that the dynamic Ago binding map

determined here after one hour of T cell stimulation may be too short of a time course to
see the downstream effects of Ago binding in terms of transcript abundance. It would
therefore be informative to look at RNA levels, ribosomal occupancy, and protein levels
at later time points to elucidate the ultimate effects of Ago regulation during T cell
activation.
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With one hour of stimulation, the most dramatic shifts in Ago-binding patterns were in
early activation gene transcripts and T cell activation markers. Although in the EGR3
and IFNG transcripts, the largest clusters of Ago binding could be seen in the 3’UTR,
like for HuR, we observed binding throughout the entire transcript including intronic
regions. This was even more unexpected for Ago than HuR because it was assumed that
a majority of Ago regulation was occurring in the cytoplasm and on processed mRNA
transcripts rather than pre-mRNA. It was also surprising for these and other transcripts
that Ago coated the newly transcribed RNAs in a manner that does not appear to be
microRNA specific but rather that Ago may be deposited co-transcriptionally. This
differs from the binding seen by Ago in the brain where intronic clusters are less
represented. This may reflect differences between these two biologic systems (Chi et al.,
2009). These top Ago transcript targets overlapped impressively with HuR targets and
led us to investigate the potential combinatorial control of Ago and HuR in resting and
activated lymphocytes.
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CHAPTER 6. Exploring the Combinatorial Control of Ago and HuR
RNA Regulation During T cell Activation

Introduction

The instruction of transcriptional and translational control by (Argonaute) Ago and HuR
are both critical for immune function. As described in the previous two chapters, we
have used high-throughput sequencing crosslinking immunoprecipitation (HITS-CLIP) to
establish regulatory maps for both of these RNA-binding proteins in the resting and
activated states of cluster of differentiation eight (CD8) lymphocytes. Interestingly, we
saw similar binding changes in key Ago and HuR target mRNAs.

Therefore, we

undertook to study the combined regulation of these proteins during lymphocyte
activation.

The pronounced specificity of Ago targeting mRNA sites cannot be explained solely by
the presence of target sequences complementary to the six-nucleotide microRNA seed
region, because potential target sites far outnumber true Ago binding sites in the
transcriptome. Additionally, many Ago binding sites have been identified without having
clear microRNA pairings (Bhattacharyya, Habermacher, Martine, Closs, & Filipowicz,
2006a; 2006b; Chi, Hannon, & Darnell, 2012; Chi, Zang, Mele, & Darnell, 2009; Leung
et al., 2011; Loeb et al., 2012). Predicted microRNA target sites are abundant in AU-rich
elements (ARE), creating the possibility for combinatorial regulation of mRNA by Ago
and other RNA-binding proteins, such as HuR (Chang et al., 2012; Meisner & Filipowicz,
2010). Studies investigating the control of joint mRNA targets of both Ago and HuR
have signaled the importance of these interactions, but their focus on specific transcripts
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and varied outcomes on the regulation of these messages has indicated the need for more
systematic study of their combinatorial regulation.

For instance, CAT-1 protein levels can increase during stress responses without a
corresponding change in transcription. While the translational repression of this message
is mediated by Ago-miR-122 sequestration of CAT-1 to P-bodies, upon the activation of
a stress response, HuR binds this 3’UTR in ARE and allows for the association of CAT-1
with active polysomes. Thus, upon the induction of cellular stress, HuR mitigates Ago
repression of CAT-1 (Bhattacharyya, Habermacher, Martine, Closs, & Filipowicz, 2006a;
2006b; Kim et al., 2009). Furthermore, Ago and HuR were shown to compete for
regulation of Vegf-a and the balance of this regulation influenced the development of
angiogenesis in mice and zebrafish (Chang et al., 2012; Glorian et al., 2011; Kundu,
Fabian, Sonenberg, Bhattacharyya, & Filipowicz, 2012). Conversely, HuR was shown to
be necessary for microRNA let-7 mediated repression of c-Myc. Manipulation of HuR
and let-7 levels within HeLa cells showed that each negatively correlated with c-Myc
mRNA and protein levels. The binding region in the 3’UTR for HuR was shown to be
adjacent to a let-7 site and HuR was necessary for Ago binding to the 3’UTR to mediate
down regulation of c-Myc (Kim et al., 2009; Lebedeva et al., 2011). Other work
investigating the combinatorial control of Ago and HuR utilizing in vitro systems has
also elucidated further examples of Ago and HuR interdependence for the regulation of
RhoB and IL-1B mRNA (Glorian et al., 2011; Kundu et al., 2012; Mukherjee et al.,
2011).
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Recent work integrating Ago and HuR binding maps produced by PAR-CLIP has
produced conflicting results on whether their binding patterns are similar. In comparing
genome-wide HuR binding sites in HeLa cells with Ago maps identified in HEK293 cells,
a preference for binding in areas of Ago targeting was not observed (Lebedeva et al.,
2011; Mukherjee et al., 2011).

These differences may represent differences in the

regulation of these proteins between the cell lines explored. Mukherjee et al. compared
this same HEK293 cell Ago PAR-CLIP data with HuR PAR-CLIP binding sites from
HEK293 cells expressing a tagged HuR protein.

This group reported significant

overlapping patterns of regulation for the two proteins, suggesting a potential for
competition of these proteins for regulatory binding of target transcripts.

Still, the

mRNA level changes observed in these cells with HuR knockdown could be explained
with or without the presence of overlapping or adjacent microRNA binding sites. The
authors suggest that HuR may physically compete with Ago for access to binding sites to
regulate the fate of targets (Levy & Darnell, 2002; Mukherjee et al., 2011). Therefore,
more work is needed to understand the relationship of these RNA-binding proteins,
especially in the context of physiologic systems and dynamic cellular state changes. In
this section we study the Ago and HuR HITS-CLIP binding maps from resting and
stimulated human CD8 T cells to determine their roles in combinatorial regulation of
target mRNAs.
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Results

Ago and HuR HITS-CLIP Summary

As previously described, we purified CD8 lymphocytes from five healthy normal
volunteers. We crosslinked both rested cells and T cells that were stimulated for one
hour with CD3/CD28 beads. The purity of the cells was established to be over 90% CD8
T cells by flow cytometry and RT-qPCR analysis of TNF and IFNG levels confirmed the
activation state of non-crosslinked aliquots of the lymphocytes. The T cells showed a
280 to 610-fold induction of TNF mRNA and 1250 to 7600-fold induction of IFNG
mRNA. Using these CD8 T cells, we have amassed datasets from paired samples for
Ago and HuR CLIP and the summarized sequencing results are found in Table 6.1. As in
previous chapters, the color highlighting each donor for Ago and HuR sequencing
statistics in the table corresponds to the color of the tags represented on the tracks of the
genome browser. This allows us to compare the Ago and HuR tags from each donor
easily and relate the binding maps to the overall read depth of each sample as we examine
the regulatory patterns of the proteins on each target transcript.

Ago and HuR Bind EGR3 and IFNG

Because the transcripts with the largest dynamic changes in binding patterns for Ago and
HuR with T cell activation appeared to be very similar, we compared the binding maps of
the two proteins.

We began by examining the binding patterns on the previously

discussed EGR3 (Figure 6.1) and IFNG (Figure 6.2) transcripts. We found that the
binding patterns of Ago and HuR on these transcripts appeared very similar although they
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Table 6.1 HITS-CLIP Sequencing Summary.
Abbreviations: Ago
immunoprecipitation supernatant (Ago Sup), CLIP reads containing an additional 2nucelotide sequence in the linker region to identify them as coming from unique
experimental replicates (2 nt Index).
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Figure 6.1 Ago and HuR bind Human EGR3. The position of individual Ago and
HuR unique CLIP tags in biologic complexity two clusters plotted relative to their
mapped position on the human EGR3 transcript. From top to bottom: chromosomal
location, Ago CLIP tags from activated CD8 T cells (colors represent each donor sample
as shown in Table 6.1), Ago CLIP tags from resting CD8 T cells, HuR CLIP tags from
activated CD8 T cells, HuR CLIP tags from resting CD8 T cells, Gene diagram from
RefSeq.
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Figure 6.2 Ago and HuR bind Human IFNG. The position of individual Ago and HuR
unique CLIP tags in biologic complexity two clusters plotted relative to their mapped
position on the human IFNG transcript. From top to bottom: chromosomal location, Ago
CLIP tags from activated CD8 T cells (colors represent each donor sample as shown in
Table 6.1), Ago CLIP tags from resting CD8 T cells, HuR CLIP tags from activated CD8
T cells, HuR CLIP tags from resting CD8 T cells, Gene diagram from RefSeq.
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were not identical. Interestingly, while the amount of HuR binding exceeded that of Ago
on EGR3, the opposite was true for IFNG, where there was much more binding of Ago.
Because we were able to observe both patterns, and some of the HuR samples were not
prepared from Ago supernatant and with different RNA linkers, we were able to rule out
the concern that Ago depleted target sites from being clonable for HuR or that there was
contamination between samples.

Additionally, Ago and HuR bind with different

stoichiometry on individual target transcripts.

For both transcripts, the largest clusters of binding were found on the 3’ untranslated
regions (3’UTRs) and their binding sites overlap between the two proteins.

As

mentioned previously, it was interesting to observe the binding pattern of both Ago and
HuR on the IFNG transcript in both the intronic and coding regions. This suggested that
the two proteins might be deposited throughout the newly transcribed message either cotranscriptionally or at least prior to being processed to become a mature transcript.
Although HuR and Ago proteins are found in the nucleus, it was unexpected to find
robust binding events at such early stages of mRNA processing.

Overlapping Binding of Ago and HuR

In order to study the intersection of regulatory regions of Ago and HuR in more depth,
we computed the overlap of CLIP tag clusters on a genome-wide scale. The calculations
are diagrammed in Figure 6.3. To begin, we clustered together all of the resting and
activated tags for Ago and separately for HuR. We then specified that each Ago or HuR
cluster needed to contain reads from four out of five samples in the resting and or
activated states and that at least 10 tags from either state must overlap in one genomic
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Figure 6.3 Ago and HuR Cluster Overlap Parameters. Schematic representing cluster
and binding footprint definitions used as input into cluster overlap analysis. CLIP tags
for each protein were clustered based on overlapping genomic positions of at least 5
nucleotides. Clusters were included in the analysis if they were comprised of at least 4
donor samples in the resting and or activated state and had a peak height of at least 10
tags between both activation states. Cluster regions overlapping genomic repeats,
pseudogenes, ncRNA, or snoRNA were removed from analysis. The binding footprint of
each cluster was defined as including 32-nucleotides 5’ and 3’ of the peak position. Ago
and HuR clusters were designated as overlapping if their binding footprints overlapped at
least 1 nucleotide.
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position.

To make the analysis more stringent, we also removed clusters in low

complexity repeat regions, pseudogenes, non-coding RNAs and snoRNAs.

We

calculated the peak binding position of each cluster, where the most tags overlapped, and
defined a footprint for each cluster of 32 nucleotides up and downstream of the peak
location.

Finally, we identified clusters from Ago where the footprint of binding

overlapped with the footprint of HuR clusters. It was possible for more than one Ago
cluster to overlap an HuR cluster and vice versa.

We had roughly 2,500 Ago clusters and 7,500 HuR clusters of biologic complexity of 4
and peak height of 10 as input into the intersection analysis. Remarkably, we defined
over 1,000 intersecting regions that represented over 40% of Ago clusters and 14% of
HuR clusters. Figure 6.4 shows a histogram of the distance between the peak positions of
overlapping Ago and HuR clusters. Interestingly, not only do large numbers of Ago and
HuR clusters overlap within a small distance, but their peak positions are also highly
superimposable suggesting that in many cases Ago and HuR are binding in the exact
same positions on many transcripts. Our HuR CLIP samples processed from separate
lysate from Ago and with distinguishing indexing linker sequences provided a control
that

these

binding

similarities

were

not

an

artifact

of

having

done

the

immunoprecipitation from the same lysate or due to contamination from previous
experiments. Similar results were recently published showing a high degree of overlap
between Ago clusters in HEK293 cells and HuR clusters in HEK293 cells expressing an
epitope-tagged HuR, providing further support for our finding (Mukherjee et al., 2011).
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Figure 6.4 Histogram of Ago and HuR Cluster Overlap. Histogram of the number of
overlapping cluster footprints with a given distance from the peak position of the HuR
cluster to the peak position of the Ago cluster.
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To see whether the overlap of Ago and HuR regulation differed between activation states,
we repeated the cluster intersection calculations using HuR or Ago clusters that had
biologic complexity of 4 for each state without consideration of the biologic complexity
in the opposing state for that protein. In Figure 6.5, we demonstrate that Ago and HuR
clusters have high levels of overlap regardless of which states they originated from. We
see the same distribution pattern for individual T cell activations states as with all clusters
together; the most represented position of overlap is at the peak position of the clusters of
Ago and HuR. As in the previous analysis, we find that a higher proportion of Ago
clusters were found to overlap than HuR, but in both cases, this is most likely due to the
differences in the starting numbers of clusters for each protein as HuR had roughly threefold more clusters as input into the analysis.

Examining Dynamic Changes in Ago and HuR Binding within Overlapping Transcript
Regions

In order to understand the interactions between Ago and HuR in overlapping clusters, we
examined the binding changes in these intersecting regions with lymphocyte stimulation.
For each cluster, we calculated the log2 ratio of CLIP tags in the activated state to the
resting state. In Figure 6.6 these ratios are plotted for intersecting clusters of Ago versus
HuR. As shown in Chapters 4 and 5, the majority of Ago or HuR binding changes with T
cell activation mirror transcriptional changes in these levels.

Consistent with this

observation, the binding changes with activation were often in the same direction for Ago
and HuR. This could suggest agonism between Ago and HuR binding. For example, on
the IFNG transcript discussed previously, there is more binding seen in the activated state
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Figure 6.5 Ago and HuR Cluster Overlap in Resting and Activated States. Clusters
were defined as described in Figure 6.3, with the addition of each cluster being
designated as resting or activated if there was biologic complexity of four (BC4) in that
state. Histograms of the number of overlapping cluster footprints with a given distance
from the peak position of the resting or activated HuR cluster to the peak position of the
resting or activated Ago cluster. The number of intersecting clusters is indicated in each
panel. Y-axis denotes the number of clusters. X-axis is the distance (bp) from HuR peak
to Ago peak.
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Figure 6.6 Dynamic Ago and HuR Changes in Overlapping Clusters. Scatter plot of
the Log2 ratio of the number of activated tags and resting tags in an Ago cluster versus
the Log2 ratio of the number of activated tags and resting tags in an HuR cluster with a
footprint intersecting the Ago footprint.
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for both Ago and HuR than in the resting state, which reflects the levels of IFNG mRNA
in each T cell state. Still, although the changes on IFNG and other transcripts were
shifting in the same directions, there were many overlapping regions where Ago or HuR
binding changes were not directly proportional to each other with CD3/CD28 stimulation.
In the example of IFNG, Ago binding was increased more at one hour than HuR and the
opposite was observed for EGR3.

There were also many clusters represented in the upper left and lower right quadrants of
the graph where Ago and HuR binding changes were in opposite directions, suggesting
that the proteins could function antagonistically. For example, a region of overlapping
Ago and HuR regulation in the 3’UTR of IRF9 is highlighted in the upper left quadrant of
Figure 6.6. For these overlapping clusters, the amount of Ago binding increased with
activation, while the HuR binding decreased. This cluster is highlighted in the genome
browser representation of IRF9 in Figure 6.7. Interferon Regulatory Factor 9 (IRF9) is
part of the transcriptional regulatory machinery that activates gene expression through
Tyrosine Kinase (JAK) signaling in response to type I interferon interrogation of cell
surface receptors. IRF9 has been demonstrated to increase in response to IFNG which is
induced substantially with CD3/CD28 activation (Levy & Darnell, 2002). Thus, IRF9
might need to be dynamically controlled with T cell stimulation, although transcript
levels do not shift drastically. In this example it appears that while both proteins bind
robustly in both states, that the reduction of HuR binding with activation corresponds
with the induction of Ago binding. This suggests that the two proteins may be competing
for this site of regulation.
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Figure 6.7 Reciprocal Changes in Ago and HuR Binding in the Human IRF9 3’UTR.
The position of individual Ago and HuR unique CLIP tags in biologic complexity two
clusters plotted relative to their mapped position on the human IRF9 transcript. The
CLIP cluster showing dynamic reciprocal Ago and HuR binding changes is outlined in
the 3’UTR. From top to bottom: chromosomal location, Ago CLIP tags from activated
CD8 T cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags
from resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags
from resting CD8 T cells, Gene diagram from RefSeq.
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Another example of where the binding pattern shifted between T cell activation states in
an opposing manner for each protein is in the SATB1 transcript.

This cluster is

highlighted in the scatter plot in Figure 6.6 and the binding map is displayed in Figure 6.8.
The SATB1 protein regulates chromatin structure organization by recruiting histone
modifiers to its targets’ genomic loci and its gene regulation has been shown to be
important in T cell differentiation and proliferation (Burute, Gottimukkala, & Galande,
2012). While the binding sites for both Ago and HuR are robustly represented in both
activation states in this overlapping cluster, the number of HuR tags increases with T cell
activation while Ago binding decreases, indicating that they may compete for regulation
at this binding position.

Examining Ago and HuR Binding in the Context of Transcriptional Levels of Target RNA

In previous chapters, we examined the binding changes of HuR and Ago in the context of
the levels of target transcripts as determined by RNAseq. By comparing binding maps
with transcript abundance, we can begin to understand the cellular context for the
regulation by these RNA binding proteins and the dynamic state changes that occur
quickly with T cell stimulation.

As diagrammed in Figure 4.11, we designated each Ago or HuR binding site and each
transcript as being more represented in the resting state, more represented in the activated
state, or relatively unchanged between the two. This was accomplished by tabulating the
percentage of reads for each feature in the activated state as a proportion of the total
number of reads for that cluster or transcript. We applied cutoffs at 40 or 60 percent
representation in the activated state to bin each one into a category, as previously

165

1 kb
18366000

18365500
18365000
Ago CLIP BC2: Activated

18364500

Scale
:chr3

Ago CLIP BC2: Resting

HuR CLIP BC2: Activated

HuR CLIP BC2: Resting

RefSeq Genes

SATB1
SATB1
SATB1

Figure 6.8 Reciprocal Changes in Ago and HuR Binding in the Human SATB1
3’UTR. The position of individual Ago and HuR unique CLIP tags in biologic
complexity two clusters plotted relative to their mapped position on the human SATB1
3’UTR. The CLIP cluster showing dynamic reciprocal Ago and HuR binding changes is
outlined. From top to bottom: chromosomal location, Ago CLIP tags from activated CD8
T cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags from
resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags from
resting CD8 T cells, Gene diagram from RefSeq.
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described. Therefore, for each overlapping Ago and HuR cluster, the site is scored on the
relative amount of binding in the activated state compared to the total binding at that site
for both Ago and HuR, and the relative amount of transcript abundance in the activated
state compared to both states together. As in the other chapters, we also specified that
the RPKM of target transcripts be at least 15 in either the resting or activated state for
inclusion in this analysis. This ensured that there was robustly measured transcript
abundance for the targeted message in at least one of the states for it to be considered.
This reduced the number of clusters being analyzed to roughly 700 intersecting regions
out of the 1,000 regions defined above.

The results of this combinatorial analysis are summarized in Table 6.2. In more than
60% of clusters, Ago and HuR follow a similar pattern of binding with CD3/CD28
stimulation. In 60% of those clusters, Ago and HuR both follow the same trend as their
target transcript levels. More than one fifth of Ago and HuR overlapping clusters are
synchronized in having a more exaggerated change than that of the transcript level. In a
little over a quarter of clusters, while transcript abundance does not shift with T cell
activation, the binding of either Ago or HuR does dramatically shift binding patterns with
CD3/CD28 stimulation. These findings suggest that much of the dynamic change seen in
binding patterns for Ago and HuR are reflective of the transcriptional changes in the cell,
although in some cases the RNA-binding map may be even more responsive than
changes in steady state levels of transcript within the cell. It is rare that there is a change
in transcript level without some dynamic change in the binding of Ago and or HuR.
Interestingly, when transcript abundance increases with T cell activation, there are no
Ago and HuR intersecting clusters where either protein has more tags in the resting state.
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Table 6.2 Combining Overlapping Ago and HuR CLIP with RNAseq. (A) This table
shows the number of overlapping Ago and HuR clusters binned in each category based
on the scoring system outlined in Figure 4.11. (B) This table lists the transcripts with the
largest changes in cluster binding in the resting and activated states between Ago and
HuR.

A

B

Ago
Rest > Act
Ago
Rest ≈ Act
Ago
Rest < Act

HuR

HuR

HuR

Rest > Act

Rest ≈ Act

Rest < Act

21

40

0

25

33

0

4

10

Clusters with
Ago Opposing
HuR Binding
ARGLU1

0

C2orf64
FYB
GLS

13

21

0

32

124

4

4

69

11

HECA
IKZF1
RAP1A
SATB1

1

0

0

6

63

7

1

111

125

RPKM
Rest >
Act

RPKM
Rest ≈
Act

RPKM
Rest <
Act

RPKM
Rest >
Act

RPKM
Rest ≈
Act

RPKM
Rest <
Act

RPKM
Rest >
Act

RPKM
Rest ≈
Act

RPKM
Rest <
Act
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TBC1D1
TRAM1
TXNIP
USP25
WIPF1
ZBTB38

This might reflect that lymphocyte stimulation induced increases in gene expression of
transcripts that are not present in the steady state of a quiescent T cell.

The FYB transcript was among the top clusters with opposing changes in overlapping
Ago and HuR binding. FYB mRNA abundance was scored as relatively unchanged with
T cell stimulation. Therefore the dynamic shifts in Ago and HuR binding are not due to a
dramatic change in transcript level. While this is the same gene as discussed in Figure
5.6, the previously analyzed region only contained a robust binding site for Ago and
therefore was not included in the overlap analysis here. For all of the clusters of FYB
identified in either analysis, the binding of Ago was either relatively unchanged or
decreased with activation. Here we see overlapping HuR clusters where the binding
pattern is increased with T cell stimulation. In the two examples in Figure 6.9, there are
biologically reproducible binding sites for Ago and HuR in both the resting and activated
state that overlap. The quantitative direction of the binding changes, increased HuR
binding in the activated state with a decrease in Ago binding, suggest that although robust
binding is present in both states, the two proteins may compete for regulation between the
resting and activated states and seem to shift the predominantly bound protein in those
sites with stimulation.

Ago and HuR and microRNAs

To begin to probe whether the co-regulation of Ago and HuR was microRNA dependent,
we examined whether HuR associated with specific Ago-microRNA complexes. To do
this, we searched each Ago binding footprint for a microRNA seed match from the top
microRNAs sequenced in our Ago CLIP samples. In Figure 6.10A we plotted the
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Figure 6.9 Reciprocal Changes in Ago and HuR Binding in the Human FYB Gene.
The position of individual Ago and HuR unique CLIP tags in biologic complexity two
clusters plotted relative to their mapped position on the human FYB transcript in a coding
exon (A) or 3’UTR (B). From top to bottom: chromosomal location, Ago CLIP tags
from activated CD8 T cells (colors represent each donor sample as shown in Table 6.1),
Ago CLIP tags from resting CD8 T cells, HuR CLIP tags from activated CD8 T cells,
HuR CLIP tags from resting CD8 T cells, Gene diagram from RefSeq.
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Figure 6.10 Ago Clusters with Matches in each Seed Family. (A) Scatter plot of the
number of Ago clusters containing a seed family match for clusters with footprints not
overlapping HuR binding footprints versus clusters with footprints overlapping HuR
binding footprints. Overlaid is a solid line representing the linear regression of the points
with ninety-five percent confidence intervals in red. Additionally, a black dotted line is
displayed with a slope that corresponds to the ratio of the number of Ago clusters not
overlapping HuR to the number of Ago clusters overlapping HuR. (B) Top 7-mers
identified in the 22-nucleotide region 5’ and 3’ of Ago peak positions for clusters
including at least four biologic replicate samples (biologic complexity 4: BC4) and at
least ten nucleotides in the peak position of the cluster (peak height 10: ph10). Each 7mer was ranked by the p-value of the binomial test comparing the frequency of each 7mer (observed) as compared to the frequency of a shuffled sequence of that 7-mer
(shuffled). The 7-mers with the ten highest p-values and matching microRNA seed sites
are listed. (Top) All Ago clusters of BC4 ph10. (Middle) Ago clusters BC4 ph10 not
overlapping an HuR cluster. (Bottom) Ago clusters BC4 ph10 overlapping an HuR
cluster.
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number of Ago clusters with or without overlapping HuR binding sites that matched each
seed family. The solid regression line with 95% confidence intervals in red is overlaid on
top of the plotted points. Additionally, a dotted line is shown displaying the ratio
between the number of Ago clusters without HuR to the number of Ago clusters that
intersect HuR clusters. We found that a lot of seed matches seemed to hover near the
cluster number corrected line, but that there were seed families which showed preference
for binding with or without HuR. The top microRNA cloned in the Ago CLIP sample
was miR-142-3p, which represented about a third of the total number of reads in the
sequenced material. This microRNA showed a strong preference for binding in Ago
clusters that did not overlap HuR. There were roughly five-fold more Ago clusters that
contained miR-142-3p seed sequences than in sites that overlapped with HuR binding.

Next we identified the top 7-mer sequences that were most significantly represented
within 22 nucleotides up or downstream from the peak position of the Ago cluster. We
began with Ago clusters of biologic complexity 4 and peak height 10 and also split these
into two groups whether the Ago cluster was alone or overlapped with an HuR cluster.
We ranked each sequence by the p-value of the binomial test comparison of the
frequency of each 7-mer as compared to the frequency of the 7-mer within shuffled
sequences of the same nucleotide composition of the Ago footprint regions (Figure
6.10B).

We see in the top table in Figure 6.10B that permutations of the 8mer targeting sequence
of miR-142-3p is found in seven out of ten of the most significantly enriched 7-mers
surrounding the peak of robust Ago clusters. The other sequences consisted of a stretch
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of adenine, which may represent sequencing error, or the presence of AU-rich elements
in these footprints. The other sequences matched seeds of miR-103/miR-107 and miR29a. These matches were more unexpected because they did not represent microRNAs
that were highly cloned from our Ago CLIP microRNA dataset (Table 5.3). Consistent
with the plot in Figure 6.11A, almost all of the 7-mers from Ago clusters not overlapping
with HuR clusters, listed in the middle table, represented matches with miR-142-3p. This
microRNA was absent in the list of top microRNA matches for Ago clusters overlapping
HuR. Of the other top enriched 7-mers in Ago clusters overlapping HuR, the only
microRNA that was highly cloned in Ago CLIP was miR-31. We also note that miR362-3p was listed in the previous chapter as being potentially down regulated with T cell
activation, while it had a very low level of sequencing in Ago CLIP.

Another interesting result was found in examining Ago and HuR binding at primary
microRNA loci, especially in regions that represent microRNA clusters that are
independently transcribed, as opposed to processed from pre-mRNA introns. We did a
closer examination at the miR-17-92 locus because five of the six microRNA encoded on
the same primary transcript, miR-7, miR-19a, miR-19b, miR-20a, and miR-92a, were in
the top 35 sequenced Ago CLIP microRNA (Table 5.3).

Only miR-18a was not

represented as frequently and was ranked 87th overall. The Ago tags shown in Figure
6.11 map to sites that will become mature microRNA, but do not represent binding to
mature microRNA because the cloned sequences were longer than processed microRNA
sequences, with each tag being at least 27 nucleotides in length. We have observed this
affinity for Ago binding to preprocessed microRNA stem loops in previous Ago CLIP
datasets derived in the lab.
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Figure 6.11 Ago and HuR bind the Human microRNA-17-92 Locus. The position of
individual Ago and HuR unique CLIP tags in biologic complexity two clusters plotted
relative to their mapped position on the human microRNA-17-92 locus. From top to
bottom: chromosomal location, Ago CLIP tags from activated CD8 T cells (colors
represent each donor sample as shown in Table 6.1), Ago CLIP tags from resting CD8 T
cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags from resting CD8 T
cells, Gene and microRNA diagram from RefSeq.
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It was interesting to see that HuR bound robustly in the miR-17-92 locus and that the
binding appeared to map to regions either between the inferred structure of microRNA
stem loops or mostly excluding what would become the mature sequences.

We found

this same pattern of Ago binding to eventual mature microRNA sequences and HuR
binding surrounding these sequences in many other microRNA loci (data not shown).
The HuR cluster binding sites from the miR-17-92 cluster are highlighted in orange in
Figure 6.12, adapted from (Chaulk et al., 2011). The exceptions to this binding pattern of
HuR being limited to between the microRNAs in this region were binding sites coating
the entire miR-20a stem loop, and minor binding sites not highlighted in the figure on
miR-17 and miR-19b which each contained less than 10 tags between the resting and
activated state.

Discussion

We have defined reproducible genome-wide maps of Ago and HuR RNA binding sites
before and after T cell activation and have identified differences in the binding maps of
both Ago and HuR in resting and activated T cells. Both Ago and HuR rapidly assemble
on newly transcribed RNA such as EGR3 and IFNG. In the latter case these proteins
were found to bind pre-processed message as determined by the coating of binding sites
along intronic regions in addition to coding sequence and UTRs. The inclusion of RNAbinding events on intronic regions suggest that Ago and HuR may play a role in the
regulation of processing of these and other nascent transcripts. While Ago and HuR
proteins are present in the nucleus of the cell, their role there is less defined. We
speculate that shuttling of HuR out of the nucleus with T cell activation may involve the
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Adapted from Chaulk et al., 2011.

Figure 6.12 HuR binding sites mapped onto miR-17-92 Locus. Predicted secondary
structure of microRNA-17-92 locus with RNAse T1 cleavage sites indicated with arrows
from Chaulk et al. 2011. Highlighted in orange are the sequences found in robust human
HuR binding sites. The mature microRNA sequences are indicated with black lines.
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transport of RNA molecules poising them for post-transcriptional regulation. This would
allow quick association of targets with active polysomes or the combination of Ago and
HuR binding might lead to the competition of these transcripts for active translation or
storage in stress granules. As mentioned in previous chapters, while the binding maps at
one hour of activation most likely represent not only an hour of stimulation but a
combination of earlier time points, it would be interesting to see how these binding maps
resolve at earlier and later time points and if intronic binding persists with increased time
after stimulation.

Interestingly, the stoichiometry of Ago and HuR binding in the activated states differs for
these two examples. While there is more binding of HuR on the EGR3 transcript, Ago
binding predominates in the IFNG transcript. We hypothesize that these differences may
help determine the fate of these transcripts with time after stimulation. While both
transcripts are greatly induced with CD3/CD28 activation, the ultimate fate of these
transcripts is most likely determined by RNA-binding protein regulation. We speculate
that the dominant Ago binding on the IFNG transcript may help to temper the induction
of translation of the cytokine while the HuR predominance on EGR3 may be transiently
increasing the stability of this transcript. It would be interesting to study the Ago and
HuR binding events at earlier and later time points to examine whether these ratios shift
over time to help mediate the fluctuations in the availability of these transcripts and their
necessity in different sequential points of the inflammatory response. Also, studying the
translational status of these transcripts over time with paired binding maps would help
elucidate these regulatory mechanisms.
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Many Ago-binding footprints on a given transcript overlap with those of HuR, and our
results suggest that in these clusters the peak position of Ago and HuR are quite
superimposed. We also observed the overlapping of Ago and HuR binding events in both
resting and activated T cell states suggesting that the coincident binding is not solely a
function of T cell stimulation or the rapid increases in transcription therein.

One

interpretation of these observations is that Ago and HuR are directly competing for
binding interactions on the same transcript in the same cell. However, since HITS-CLIP
data represent cellular population averages, it is also possible that Ago and HuR bind to
the same sites on distinct transcript populations. In both cases, it is interesting that the
two proteins share so many sites of regulation. Because the binding patterns of both
proteins often reflect changes in transcript abundance, it appears that the binding status is
very much reflective of the abundance of targets within the cell.

Also, because these

binding changes with T cell stimulation are so similar, it appears that Ago and HuR could
be binding to these transcripts cooperatively to regulate post-transcriptional control. This
would lead to the determination of the fate of the transcripts in terms of its translational
status, stability, and cellular localization. It will be interesting to study whether this
combinatorial control results in competition between these pathways mediated by each
individual protein or whether they work in concert to determine the outcome of the target.

While overlapping Ago and HuR binding patterns are often mirrored with T cell
activation, we were able to identify examples of binding sites where the two proteins
change dynamically in opposite directions with CD3/CD28 stimulation. We highlighted
the IRF9 and SATB1 3’UTRs and the FYB transcript which show robust overlapping
binding of both proteins in both T cell states, but have opposite dynamic quantitative
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shifts for Ago and HuR with T cell stimulation. These binding interactions may represent
competition between Ago and HuR for binding sites on these transcripts. These shifts
may act to quickly change the processing of these targets during the initiation of T cell
activation. Still, the biologically reproducible binding sites in both activation states for
both of these targets indicate that the binding may not be as simple as a complete switch
between the two with T cell stimulation. These sites could in fact represent a dependence
on one protein for recruitment of the other or could represent antagonistic binding where
one protein blocks binding sites from the other in opposing stimulation states.
Furthermore, since the data represent the population average of the T cells, it is possible
that while the two proteins may compete for these binding sites that only one protein
occupies the 3’UTR in any one, or the two could be regulating the same individual
transcripts.

The microRNA seed matches and top 7-mers represented in Ago binding footprints differ
between the group of clusters that overlap with HuR or do not. We found that the most
highly cloned microRNA in Ago CLIP, miR-142-3p was overrepresented in clusters of
Ago regulation that did not overlap with HuR binding sites. Interestingly, most of the
highly represented microRNAs predicted to be in Ago clusters that overlap HuR were not
highly abundant in Ago CLIP cloning of microRNAs. In other words, there may be
enrichment of Ago to binding sites for rare microRNAs by HuR, perhaps acting as a
chaperone. At this point, it is unclear whether these microRNAs were underrepresented
in the CLIP results, or whether in clusters where Ago and HuR both bind, if the
microRNA is less critical to the specificity of Ago binding at those sites. It would be
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interesting if HuR helped recruit Ago to binding sites in a non-microRNA specific
manner to help regulate transcript ability and protein abundance.

We also considered Ago and HuR binding in primary microRNA regions. While we saw
very large and reproducible Ago clusters on transcript sites that would be processed to
become mature microRNAs, we saw reduced HuR binding there. This is consistent with
our finding that we did not see microRNAs being amplified from HuR
immunoprecipitation even when we cut at lower molecular weights from CLIP
nitrocellulose membranes (data not shown). Surprisingly, we saw very robust HuR
binding directly adjacent to and between the sequences that would become mature
microRNAs in many regions. The stem loops and tertiary structures of these transcripts
are important for the regulation of the mature sequences and the primary microRNAs can
be involved in transcript targeting in the absence of processing (Chaulk et al., 2011; Liu,
Min, Yue, & Chen, 2008; Meisner & Filipowicz, 2010; Trujillo, Yue, Tang, O'Gorman,
& Chen, 2010; S.-B. Yue, Trujillo, Tang, O'Gorman, & Chen, 2011). Thus, it will be
interesting to examine the implications of HuR binding on the regulation of microRNA
processing and targeting.

Comparing the Ago and HuR HITS-CLIP genome-wide maps suggests agonistic and
antagonistic actions of these two proteins to confer microRNA-mediated regulation of
mRNA transcripts. Our results suggest that differences in RNA interactions occur
quickly after T cell activation and provide important insight into the specificity of how
microRNA translational regulation may mediate the inflammatory response.
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CHAPTER 7. Characterization of Ribosomal Profiling
of Resting and Activated T cells

Introduction

It has been demonstrated that the levels of mRNA expression are not perfectly correlated
with protein levels in a mammalian cell. In a study by Vogel et al. combining microarray
and shotgun proteomic analysis, it was described that only roughly two thirds of protein
expression can be modeled by mRNA levels and sequence properties such as transcript
length, amino acid usage and secondary structure (Vogel et al., 2010). Another study
estimated that less than half of protein expression could be explained by mRNA levels
and that translational efficiency was the best predictor of protein abundance
(Schwanhäusser et al., 2011).

Therefore, in order to understand the biological

implications of dynamic changes in the RNA binding sites of HuR and (Argonaute) Ago,
it is important to consider factors beyond steady state RNA levels.

HuR and Ago have been shown to positively and negatively regulate gene expression at
transcriptional and translational levels. Although much work studying HuR has focused
on transcript stability, HuR has also been linked to dynamic control of translation such as
in the study of UV-C irradiation of cancer cell lines (Lal et al., 2004; Mazan-Mamczarz
et al., 2003). HuR was also shown to promote translation of cytochrome c, as evidenced
by levels and synthesis of cytochrome c being directly correlated to levels of HuR as
determined by knockdown and overexpression experiments without observable changes
in cytochrome c mRNA expression (Kawai et al., 2006). HuR overexpression studies in
macrophages, in an inducible mouse model, displayed a reduction in TNF protein levels
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with increased HuR expression. This was despite augmented levels and stability of TNF
mRNA, showing that stabilization of transcripts by HuR can be uncoupled from
translational increases (Katsanou, Dimitriou, & Kontoyiannis, 2006). This work and that
by Sureban et al., describe competition between HuR and other RNA binding proteins for
regulation of RNA targets. For example, in vitro studies showed that CUGBP2 competes
with HuR to mitigate the effect of HuR promoting increased translation of COX-2
mRNA (Sureban et al., 2007). Additionally, HuR has also been shown to relieve
microRNA localization of CAT-1 mRNA to P-bodies within the cell upon amino acid
starvation and linked to the subsequent translational de-repression of CAT-1
(Bhattacharyya, Habermacher, Martine, Closs, & Filipowicz, 2006a; 2006b).

There is evidence that microRNAs can mediate changes in protein expression without
affecting steady state levels of mRNA targets, poly-A tail length, or polysome association
of the transcript (Olsen & Ambros, 1999). Still, others have found that decreases in
mRNA levels by microRNA mediated repression can predominantly account for the
protein expression changes of their targets (Baek et al., 2008; Guo, Ingolia, Weissman, &
Bartel, 2010; Hendrickson et al., 2009). It has also been reported that the timing for
translational control may precede the corresponding changes in mRNA expression
(Bazzini, Lee, & Giraldez, 2012; Selbach et al., 2008).

Other mechanisms of

translational control by Ago have been proposed as well, such as the microRNA mediated
deadenylation of mRNA targets leading to degradation of target transcripts but uncoupled
from translational control, or microRNA interaction with targets inhibiting initiation of
translation (Pillai et al., 2005; Wu, Fan, & Belasco, 2006). While most studies have
focused on microRNA mediated repression of translation, it has also been reported that
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there are cases were Ago binding helps to mediate translational activation of its targets
(Henke et al., 2008; Jopling, Yi, Lancaster, Lemon, & Sarnow, 2005; Vasudevan & Steitz,
2007; Vasudevan, Tong, & Steitz, 2007; 2008; Ørom, Nielsen, & Lund, 2008).

In summary, microRNA mediated targeting of mRNA targets has been implicated in
enhancing or repressing translation of those targets both with and without effecting
changes in target abundance and by interfering with multiple other mechanisms of
translational control. The majority of these studies of Ago and HuR function have been
performed in cell lines with overexpression or knockdown of microRNAs or with
reporter constructs. It is therefore important to study RNA regulation and translational
control in a biologically meaningful dynamic setting of primary cells in the context of the
combinatorial control of Ago and HuR regulation.

To accomplish this, we sought to use a technique that measures the steady state
translational profile of the cell via a high-throughput sequencing approach. As proteins
are being synthesized, ribosomes translocate along transcripts to determine the ultimate
amino acid sequence to be produced. These ribosomes are able to protect around 30
nucleotides of bound RNA from nuclease digestion. After digesting surrounding and
unbound message in a cell, ribosomes and their protected RNA can be isolated and
cloned (Guo et al., 2010; Ingolia, Brar, Rouskin, McGeachy, & Weissman, 2012; Ingolia,
Ghaemmaghami, Newman, & Weissman, 2009). By sequencing fragments of ribosomal
protected material, we can gain quantitative insight into which transcripts are actively
being translated into protein at any point in time in a living cell.
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In order to determine a global view of the translational profile of the cells as it relates to
the transcriptional setting, cells were treated with cycloheximide to arrest ribosomal
complexes from translocating and thereby blocking translational elongation. The resting
and activated cluster of differentiation eight (CD8) T cells were each split into two
aliquots for analysis of the ribosomal footprints in the cells and the levels of mRNA.
From one aliquot, the cells were lysed and the RNA was digested with micrococcal
nuclease to reduce the RNA into fragments that were protected by the ribosome. The
lysate was spun over a sucrose gradient and then fractions were collected to separate the
monosomes from the remaining material. The ribosomal protected fragments (RPFs)
were purified from the monosome fraction. In parallel, total RNA was isolated from the
second aliquot of cells. The poly-A RNA was selected using Oligo (dT)25 beads to enrich
for mRNA from the lymphocytes. The poly-A RNA was alkaline hydrolyzed to reduce
the mRNA into small fragments. Both the RPFs and poly-A RNA fragments were then
cloned, amplified, and were used for high-throughput sequencing to determine the
ribosomal and transcriptional profiles of the cells (Figure 7.1).

Results

Nuclease Titration of CD8 T cells for Sucrose Gradients

To isolate fragments of RNA protected by the ribosomal complex, it was necessary to
determine an optimal nuclease digestion protocol to sufficiently degrade non-protected
RNA, but also to leave the ribosomal complexes intact so that they could be purified on
the sucrose gradient. We found that multiple cell types responded very differently to
nuclease treatment, presumably because of their endogenous nuclease activities, so a
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Figure 7.1 Ribosomal Profiling and RNA Sequencing Schematic. CD8 T cells were
treated with cycloheximide and snap frozen. (Left) Aliquots of CD8 T cells were lysed
and treated with micrococcal nuclease to digest RNA to ribosomal protected fragments
(RPFs). (Right) Total RNA was extracted from aliquots of CD8 T cells and poly-A
selected. Poly-A RNA was alakaline hydrolyzed to reduce RNA to fragments of similar
length to RPFs. RNA fragments were purified, size selected, cloned, and amplified for
high-throughput sequencing. (Adapted from Guo et al. 2010).
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titration with comparable starting material to the experimental cells was necessary. To
determine the optimal nuclease digestion protocol, we subjected equivalent aliquots of
CD8 T cells to different nucleases at varying concentrations and for different periods of
time. Next we spun the lysate through a 10%-50% linear sucrose gradient and examined
the profile of the resulting ribosomes.

When the cells were lysed, but not treated with any nuclease, a large monosomal peak
was present and then smaller peaks to the right of the monosome peak represented the
presence of polysomes within the sample (Figure 7.2.A). For ribosomal profiling, it
would be ideal to digest the RNA so that the polysomes are reduced to monosomes so
that all ribosomes would be present in the same sucrose fractions protecting RNA of
uniform size.

When we digested the lysate with RNase I, we found that although the presence of
polysomes may have decreased, we saw a drastic reduction of the monosome peak that
was further diminished with increased digestion time and or increased RNase I
concentration (Figure 7.2B,C,D). We concluded that the RNase I was not only digesting
mRNA, but also breaking apart the ribosome itself. This is not the desired outcome, as
we intended to clone all the ribosomal protected material.

We also digested T cell lysate with micrococcal nuclease. When we treated the cells with
1,000 units of the nuclease per milliliter of lysate for 25 minutes at room temperature, the
size of the monosome peak was greatly increased as compared to the non-digested
sample and the polysome peaks smoothed out slightly (Figure 7.2E). When we increased
the digestion to 20,000 units for the same time period, the monosome peak decreased
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RNAse I (0.5 U/ul), 45 min. RT
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Micrococcal Nuclease (20,000 U/ml), 25 min. RT
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Figure 7.2 Sucrose Gradients After Nuclease Titration. Cell-equivalent aliquots of
CD8 T cells were nuclease digested with the indicated protocols and applied to 10%–
50% sucrose gradients. A254 traces of total RNA distribution are shown.
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dramatically (Figure 7.2F). Therefore we determined that using 1,000 units per milliliter
lysate micrococcal nuclease would be optimal to maximize the number of monosomes
collected during sucrose fractionation.

Poly-A mRNA selection and Alkaline Hydrolysis Titration

In order to clone poly-A RNA in parallel with the RPFs, we fragmented the RNA into
smaller pieces so that the ribosomal protected and total RNA could be processed and
sequencing in the same manner. To determine the optimal amount of hydrolysis, total
RNA was Trizol extracted and ethanol precipitated from lymphocytes. The resulting
RNA was then poly-A selected using Oligo (dT)25 beads. Next, sodium hydroxide was
added to the RNA sample to increase the pH and hydrolyze the RNA into smaller
fragments. We incubated the samples at 37°C for different amounts of time ranging from
5 to 90 minutes and then quenched the base with hydrochloric acid and added buffer to
help stabilize the pH of the sample. The RNA was precipitated and analyzed on a Urea
Acrylamide gel (Figure 7.3). After only 5 minutes of digestion, the RNA remained in
large pieces and much of the sample did not enter the gel, remaining in the well at the top
of the lane. With increasing time the modal size of the RNA decreased in a stepwise
fashion.

We determined that digestion for 30 minutes would hydrolyze the RNA

sufficiently so that much of the sample would be between 30 and 50 nucleotides.

Preparation of CD8 T cells for Ribosomal Profiling and RNA Sequencing

We asked one of our normal donors (donor 1) from our CLIP experiments to return for a
repeat leukapheresis. This allowed us to acquire enough starting material to perform the
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Figure 7.3 Urea gel of Alkaline Hydrolysis Duration Titration. Poly-A RNA from
lymphocytes was alkaline hydrolyzed with sodium hydroxide. At the indicated amounts
of time, the basic solution was quenched with hydrochloric acid. 20% Urea-Acrylamide
gel with separated RNA fragments is shown. MicroRNA Marker (New England Biolabs,
N2102S), Low Range ssRNA Ladder (New England Biolabs, N0364S), and RNA 32-mer
oligonucleotides are shown with indicated sizes.
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ribosomal profiling and RNA sequencing experiment while genetically matching the
samples used to create our previous datasets. To isolate CD8 lymphocytes using the
same protocol as for CLIP, the leukapheresate was layered and spun through a Ficoll
gradient to collect PBMCs. The PBMCs were depleted of CD56+ cells and then selected
for CD8 T cells. After resting the sample overnight, the resulting sample was 97% live
cells and 94% CD8 T cells. In this preparation there were about 4% contaminating CD4
T cells and less than 1% each of B cells, monocytes, and NK cells present in the sample
(Figure 7.4A and data not shown). After the over night resting period, an aliquot was
stimulated for one hour with CD3/CD28 beads. The resting and activated T cells were
cycloheximide treated and frozen for ribosomal profiling and RNA sequencing analysis.
The cells were determined to be sufficiently activated with an almost 4,000 fold induction
of IFNG and close to 200-fold induction of TNF RNA in the activated T cells compared
to the resting ones (Figure 7.4B). This activation profile is within the range of the
activation seen in the lymphocytes prepared for HuR and Ago CLIP.

Sucrose Gradient Profile of Resting and Activated Lymphocytes

To isolate ribosomal protected fragments of RNA, an aliquot of resting and activated
CD8 lymphocytes were lysed and treated with micrococcal nuclease to digest RNA to the
size of protected pieces by ribosomes. The digested lysate was layered and spun through
a 10%-50% linear sucrose gradient. This material was run by upward displacement
through a gradient fractionator and sucrose fractions were collected. The A254 traces
showed the monosome peak was in fractions 6 through 8 and the relatively smooth trace
following the monosome peak showed a decrease in polysomes in the sample (Figure

190

!

!

104

104

103

103

10

CD8
FL4-H:FITC
CD8 APC

Scatter
Side
SSC-H: Side Scatter

A

2

97.1

101

10

0

0

200

400
600
800
FSC-H: Forward Scatter

92.7

102

10

1

10

0

10

1000

2.1

3.63
0

1.54
10

Forward Scatter

1

2

10
10
FL1-H: CD4 FITC

3

104

CD3 PE

10000

5000

3912x ↑

6000

4000

2000

0

Fold Change Relative to Resting T cells
(Normalized to SRP14)

B

Fold Change Relative to Resting T cells
(Normalized to GAPDH)

8000

NS 1

IFNgamma
TNFalpha

4000

NS 2

NS 3

NS 4

NS 5

Donor 1

Donor 2

Donor 3

Donor 4

Donor 5

3000

2000

1000

193x ↑
0
CD8

Figure 7.4 CD8+ T Cell Characteristics of Donor 1 for Ribosomal Profiling
Experiment. CD8 T cells purified from PBMC of normal human donors by CD56
depletion and CD8 positive selection. (A) Forward and side scatter determined by flow
cytometry. The percentage of live cells (97.4%) is noted in the gated population (left
panel). CD3 and CD8 staining determined by flow cytometry. Percentages of cells are
noted in each quadrant (right panel). (B) IFNG and TNF mRNA in resting and activated
CD8 T cells was analyzed by qRT-PCR. Plotted is the fold change of these transcripts in
CD3/CD28 stimulated CD8 T cells relative to resting CD8 T cells mRNA. Fold increase
for each transcript is noted above each bar.
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7.5A). To be sure that the peak in the A254 trace represented the monosomes, we spotted
a nitrocellulose membrane with 2 microliters of each sucrose fraction and probed the
membrane with RPL7 antibody. This confirmed that the bulk of ribosomal material
resided in fraction 7 for both the resting and activated cells (Figure 7.5B). We therefore
pooled the material from fractions 6 through 8 for the resting and activated T cell samples.

Ribosomal Protected Fragments and Poly-A RNA Isolation, Size Selection, and
Amplification

We isolated RPFs from the material pooled from sucrose fractions 6, 7, and 8. Smaller
aliquots of resting and activated T cells were lysed for mRNA sequencing and poly-A
RNA was prepared for cloning after a Trizol extraction, oligo (dT)25 selection, and
alkaline hydrolysis.

Both the RPFs and fragmented poly-A RNA from resting and

activated T cells were run on a Urea Acrylamide gel.

Fragments of roughly 35

nucleotides in length from the ribosomal fractions and poly-A RNA fragments of roughly
35 to 55 nucleotides were isolated from the gel (Figure 7.6).

The RNA fragments were polyadenylated to create an anchor for reverse transcription.
The polyadenylated RNA was reverse transcribed using primers specific to the poly-A
tail and containing sequences necessary for PCR amplification and high-throughput
sequencing. PCR was done in the presence of SYBR green and amplification was
monitored on a real time PCR machine to bring the products to an optimal concentration
for sequencing.

The products were purified and quantified for high-throughput

sequencing (Figure 7.7). We saw a distinct band at the size of the RPFs with the
additional poly-A and primer sequences and a smear of the expected size from the
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Figure 7.5 Sucrose Gradient Profile of Resting and CD3/CD28 Stimulated CD8+ T
Cells. (A) Cell-equivalent aliquots of resting or CD3/CD28 Stimulated normal human
donor 1 CD8 T cells were micrococcal nuclease digested (1000U/ml) for 25 minutes at
room temperature and applied to 10%–50% sucrose gradients. A254 traces of total RNA
distribution are shown. (B) 2µl aliquots of gradient fractions were dotted onto
nitrocellulose and were analyzed by western blotting for RPL7 (with Rabbit polyclonal
RPL7 specific ab72550) to determine the distribution of ribosomes.
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Figure 7.6 Urea Acrylamide Gel of RPFs and PolyA RNA. 20% Urea-Acrylamide gel
with separated RNA fragments is shown. Isolated ribosomal protected fragments (RPFs)
and poly-A mRNA (mRNA) from resting and CD3/CD28 activated CD8 T cells are
indicated. MicroRNA Marker (New England Biolabs, N2102S), Low Range ssRNA
Ladder (New England Biolabs, N0364S), and RNA 32-mer oligonucleotides are shown
with indicated sizes.
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Figure 7.7 RPFs and mRNA PCR Products for High-Throughput Sequencing. High
sensitivity DNA assay bioanalyzer results for ribosomal protected fragments (RPFs) and
poly-A mRNA (mRNA) for resting and CD3/CD28 activated T cells as indicated. PCR
cycle numbers for each sample are shown (#x).
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hydrolyzed mRNA fragments. We used different RT primer sequences for the mRNA
and RPFs so that the two samples could be pooled for sequencing for the resting and
activated samples.

Ribosomal Profiling Read Statistics and Genomic Distribution of Binding

The high-throughput sequencing produced over 200 million total reads for both the
resting and the activated samples. After filtering the raw data and collapsing it to contain
only one copy of each sequence there were between 55 and a little over 70 million unique
sequencing reads. Next we stripped the reads of the linker sequences to distinguish
whether the tags came from RPFs or mRNA. We retrieved 6 to 10 times as many raw
reads from the mRNA as from the RPF samples (Table 7.1). This may be in part due to
the differences in the amounts of starting material for each of these samples. We started
cloning from a greater amount of RNA as seen by the levels stained on the Urea
Acrylamide gel in Figure 7.6, which led to the requirement for around 10 fewer PCR
cycles to bring them to a concentration necessary for sequencing. This would lead to
many less duplicate reads being created during the amplification process, many of which
were already eliminated in the proceeding step. Furthermore, it is possible that the initial
complexity of the RNA pools was different for the RPFs and the mRNA samples. The
poly-A samples should represent the mRNA in the cell whether or not it is being
translated. It also would include all regions of the molecule, while coding regions should
predominate the translating population of RNA. Therefore, the expected complexity of
these samples would be very different.
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Table 7.1 RPFs and mRNA Sequencing Read Statistics.

Resting

Activated

Total Reads

220,007,550

215,585,970

After Quality Filtering

192,965,617

200,798,983

Exact Duplicates Collapsed

70,033,114

55,768,748

RPF

mRNA

RPF

mRNA

Linker Stripped

8,537,955

51,405,429

4,646,999

43,333,499

CLIP Adaptor Removed

8,409,472

50,369,268

4,568,050

42,476,315

Poly-A Sequences Removed

8,290,118

49,351,320

4,486,767

41,310,320

hg18 Mapping

3,903,433

33,254,982

2,582,273

29,964,273

Not Mapped to rRNA

3,822,809

31,746,326

2,504,216

28,938,339

CDS Only

3,214,813

6,995,210

2,201,969

5,976,530

PCR Duplicates Collapsed

128,780

5,251,323

218,095

5,186,994

rRNA Mapping

347,403

4,212,912

177,901

2,974,432

PCR Duplicates Collapsed

23,666

1,085,502

21,479

1,144,789
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Next, the adapter and poly-A sequences were removed from the ends of the sequences
and reads that contained only these sequences or had less than 5 nucleotides left after
their clipping were removed from the dataset. The resulting reads were mapped to the
hg18 build of the human genome. Between 2.5 million and 4 million RPF reads and
around 30 million mRNA reads mapped to the genome per sample. Next, reads that
mapped to rRNA were subtracted from the samples to remove these contaminating
sequences. We then specified that the reads must map to coding sequence or untranslated
region (UTR) exonic regions of the genome which only slightly reduced the number of
RPF reads but reduced the reads from the mRNA dataset to between 20 and 22 percent of
the mapped reads (Table 7.1). This removed the potential for contamination from nonmRNA species. As seen in Figure 7.8, the great majority of RPF reads mapping to the
human genome were either in the coding sequence or exonic regions of the 5’UTR and
3’UTR of transcripts. Still, 37 percent of the mapped RPF reads from resting T cells and
17 percent of the mapped RPF reads from activated T cells fell in intronic regions of
transcripts, deep intergenic regions of the genome or mapped to rRNA (Figure 7.8). We
removed these data from subsequent analyses from both the RPF and mRNA datasets so
that they would accurately represent material likely to be present on ribosomes.

Degenerate barcode sequences added to the RNA during the RT reaction allowed us to
collapse for PCR duplicates in the same manner as with our CLIP data. This allows us to
reduce sequences to one copy that may have mismatches but map to the identical
genomic locus and have the same barcode sequence. This again was more impactful for
the RPFs than the mRNAs because they required more PCR cycles of amplification and
therefore many more replicates of uniquely cloned events. These resulting collapsed
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reads served as the basis for subsequent analyses. We were able to identify 130,000
RPFs from resting CD8 T cells and 220,000 RPFs from activated CD8 T cells. We also
over 5 million mRNA reads for each sample (Table 7.1).

Ribosomal Profiling Changes with T cell Activation

With the RPF and mRNA reads aligned to the genome, we calculated an RPKM (reads
per kilobase per million mapped reads) value for each transcript. This allows us to
compare a normalized value for RPF and mRNA for the resting and activated states. By
comparing the RPF RPKM value for each transcript to its mRNA RPKM we can examine
the translational efficiency (TE) of the transcript (Ingolia et al., 2009). Figure 7.9A
compares the activated T cell TE with the resting T cell TE.

In this figure we

demonstrate that the general tendency for most transcripts is that the TE does not shift
dramatically between the resting and activated state because the plot seems to resemble
the trend of y=x. Still, for many transcripts the TE does change with activation. We have
highlighted in red transcripts that have the biggest increases in TE in the activated state
and are robust 3’UTR targets of either HuR and/or Ago. 3’UTR CLIP targets are
highlighted in blue that have decreased TE in the activated state. These same transcript
targets are highlighted in Figure 7.9B where the change in RPF between the activated and
resting state is plotted against the change in mRNA tags for each transcript. For most of
the highlighted transcripts, we saw a greater change in RPF than mRNA with T cell
activation, suggesting that while the steady state levels of these transcripts may be
changing, the translational status is changing even more rapidly.
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Figure 7.9 RPFs and mRNA Changes with T Cell Activation. (A) Scatter plot of the
activated T cell versus resting T cell Log2 ratio of ribosomal protected fragments (RPFs)
reads per kilobase per million mapped reads (RPKM) to the mRNA RPKM (This ratio is
called the translational efficiency: TE). Line shown is y=x. (B) Scatter plot of the Log2
ratio of RPF RPKM in the activated to the resting state versus the Log2 ratio of mRNA
RPKM in the activated to the resting state. Line shown is y=x. Highlighted in red are
transcripts with the largest increases in TE in the activated state compared to the resting
state with robust 3’UTR binding targets of Ago and/or HuR. Highlighted in blue are
transcripts with the largest decreases in TE in the activated state compared to the resting
state with robust 3’UTR binding targets of Ago and/or HuR.
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To examine this in more depth, we plotted the RPKM values of RPF versus the mRNA
for both the resting and activated states for the red and blue highlighted transcripts from
Figure 7.9 in Figure 7.10A. This is further teased apart by highlighting the transcripts
with increased TE with activation in Figure 7.10C and decreased TE with activation in
Figure 7.10B. In the background a gray point represents the mRNA and RPF data from
the resting state and a purple point the data from the activated state. A line connects the
two points from each state for each transcript. In this figure the highlighted data from the
resting state is represented in the lighter color red or blue and the activated state in the
darker color. Looking at the highlighted data of the 3’UTR CLIP target transcripts with
the most dynamic changes in TE, we found some targets that have large changes in
mRNA abundance between the two states represented by connected points being
dispersed laterally. However, most of the large changes in TE are found from targets
having dynamic changes in RPF between the resting and activated states, or are
represented graphically by shifting vertically. We hypothesize that changes in regulation
and binding by HuR and Ago help mediate these changes in translation and occupancy by
the ribosomes.

Combining CLIP, Ribosomal Profiling and RNA Sequencing

In Figure 7.11 we combined the dynamic changes seen in CLIP binding with the dynamic
changes in ribosomal profiling graphically. To do this, we plotted the Log2 ratio of
activated to resting RPKM values of RPF compared to the ratio of activated to resting
RPKM values of mRNA for transcripts containing an HuR binding site of biologic
complexity of 3 and peak height of 5, but not containing an Ago CLIP cluster of that
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Figure 7.10 T Cell RPFs and mRNA in the Resting and Activated State. (A) Scatter
plot of the Log2 ribosomal protected fragment reads per kilobase per million mapped
reads (RPF RPKM) versus the Log2 mRNA RPKM. In the background, gray points
represent data from the resting state and purple points from the activated state. A line
connects the two points from each state for each transcript. Highlighted in red are
transcripts with the largest increases in translational efficiency (TE, RPF/mRNA) in the
activated state compared to the resting state with robust 3’UTR binding targets of Ago
and/or HuR (light red points represent data from the resting state and dark red points
represent data from the activated state, a red line connects the two points from each state
for each transcript). Highlighted in blue are transcripts with the largest decreases in TE
in the activated state compared to the resting state with robust 3’UTR binding targets of
Ago and/or HuR (light blue points represent data from the resting state and dark blue
points represent data from the activated state, a blue line connects the two points from
each state for each transcript). Line shown is y=x. (B) Larger view highlighting
transcripts with the largest decreases in TE in the activated state compared to the resting
state with robust 3’UTR binding targets of Ago and/or HuR. (C) Larger view
highlighting transcripts with the largest increases in TE in the activated state compared to
the resting state with robust 3’UTR binding targets of Ago and/or HuR.
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Figure 7.11 Combining Ribosomal Profiling, mRNA Sequencing, and CLIP Data.
Scatter plots of the Log2 ratio of ribosomal protected fragment reads per kilobase per
million mapped reads (RPF RPKM) in the activated state to the resting state versus the
Log2 ratio of mRNA RPKM in the activated state to the resting state. (A) Transcripts
with HuR clusters of biologic complexity of three (BC3) and peak height five (ph5) and
no Ago clusters of those criteria. Points are colored based upon the percentage of HuR
CLIP tags in the cluster from each activation state. The color scale gradient ranges from
blue (100% of HuR tags in the resting state) to yellow (100% of HuR tags in the activated
state). (B) Transcripts with Ago clusters of BC3 and ph5 and no HuR clusters of those
criteria. Points are sized based upon the percentage of Ago CLIP tags in the cluster from
each activation state. The scale ranges from the smallest point (100% of Ago tags in the
resting state) to the largest point (100% of Ago tags in the activated state). (C)
Transcripts with both Ago and HuR clusters of BC3 and ph5. Points are colored based
upon the percentage of HuR CLIP tags in the cluster from each activation state. The
color scale gradient ranges from blue (100% of HuR tags in the resting state) to yellow
(100% of HuR tags in the activated state). Points are sized based upon the percentage of
Ago CLIP tags in the cluster from each activation state. The scale ranges from the
smallest point (100% of Ago tags in the resting state) to the largest point (100% of Ago
tags in the activated state).
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robustness. To overlay the changes in HuR binding between the resting and activated
states, the points were colored with a gradient of colors to represent the percentage of
HuR binding in the resting state (in blue) or activated state (in yellow). There are
exceptions to the general pattern, but as described in earlier chapters, the changes in CLIP
binding are most directly reflective of changes in mRNA expression levels between the
two states. Or more specifically, as transcripts are positioned from left to right on the xaxis representing more mRNA in the resting state to more mRNA in the activated state,
the colors of the points shift from dark blue to bright yellow representing a dominance in
HuR binding in proportion to the levels of RNA. The translational profile as represented
on the y-axis seems to be more scattered without a clear pattern dictating the relationship
between HuR binding with the RPF levels as they relate to mRNA expression (Figure
7.11A). This indicates that while HuR binding may impact changes in translational
control, there is not an overall rule that governs these dynamics. The role of HuR binding
is part of a complex set of interactions with other regulatory RNA-binding proteins and
may serve different functions depending on the target transcript.

These same patterns are seen for targets of Ago alone in Figure 7.11B. In this component
of the figure, the amount of Ago CLIP binding is represented in the size of the data point
on the graph for transcripts where there is a cluster of biologic complexity of at least 3
and minimum peak height of 5 tags, without an HuR cluster at that level of binding on the
transcript. If all of the Ago binding is in the resting state, the point is of the smallest size,
and would be the largest if the binding were exclusively in the activated state. As seen in
HuR binding, the amount of Ago binding in clusters in the activated state increases for
transcripts that are more highly expressed in the activated state. Graphically, this is seen
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as an increase in the size of the plotted points as transcripts are positioned with increasing
mRNA levels in the activated state from left to right. Additionally, it is difficult to
decipher a pattern of Ago regulation as it relates to the ribosomal profile of the transcripts
with an hour of activation. Similar to HuR, the consequences of Ago binding are often
dictated by the sum of interactions of the transcript not solely with Ago but also with
other RNA-binding proteins. Thus, even without being able to determine a general rule
relating Ago binding to translational status of its targets, it is important to consider the
role of Ago on individual transcripts in the context of other regulatory factors.

For transcripts that are robust targets of both HuR and Ago regulation, the correlations
between binding and transcript expression are even more apparent. The color gradient
representing HuR binding levels in Figure 7.11C clearly shift from blue (resting) to
yellow (activated) as transcript expression shifts from left to right representing more
binding in the activated state. The dot size representing Ago binding also shift from
small to large in this direction showing a strong correlation between the binding proteins
and transcript expression level. Still, there are outliers from this pattern where large blue
dots are seen or small yellow ones showing a shift in binding between the resting and
activated state of the two proteins. This is consistent with previously discussed results in
Chapter 6. While the majority of targets regulated by both proteins display binding
patterns for each that match gene expression, there are exceptions where the binding
patterns fluctuate in opposite directions with T cell stimulation.

Additionally, while Ago and HuR binding patterns seem to mirror transcript expression
as seen in their patterns with respect to the x-axis, there are many points that do not
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follow a y=x trend. In fact, it appears that there is a large density of transcripts that are
represented vertically near the origin of the plot. In this region, these vertical shifts
indicate that while gene expression has not changed dramatically, that the TE has
increased or decreased with T cell stimulation. This indicates that Ago and HuR targets
are being dynamical regulated with respect to translation without synchronous changes in
transcript abundance.

We narrowed this analysis to HuR and Ago binding in the 3’UTR region of target
transcripts and the resulting plots are shown in Figure 7.12. Generally, the same patterns
noted above are still apparent, but with this smaller subset of target transcripts it is easier
to visualize outliers. For example, for 3’UTR targets of both proteins there are notable
points in the upper right quadrant where the RPF and Ago binding is increased in the
activated state, but HuR binding is decreased in the activated state as represented by large
blue spots above the plotted y=x line (Figure 7.12C). These points represent transcripts
where the transcript abundance and Ago binding is increasing with T cell activation, but
the amount of HuR binding decreases. These points seem to go against examples in the
literature whereby increased Ago binding and decreased HuR binding would be expected
to result in a decrease in ribosomal occupancy (Bazzini et al., 2012; Bhattacharyya,
Habermacher, Martine, Closs, & Filipowicz, 2006a; 2006b; Guo et al., 2010). It is
possible that these transcripts represent breaks with this thought or they represent
dynamic changes in RNA binding that will have the expected effects on RNA regulation
at later time points.
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Figure 7.12 3’UTR CLIP Targets: Combining Ribosomal Profiling, mRNA
Sequencing, and CLIP Data. Scatter plots of the Log2 ratio of ribosomal protected
fragment reads per kilobase per million mapped reads (RPF RPKM) in the activated state
to the resting state versus the Log2 ratio of mRNA RPKM in the activated state to the
resting state. (A) Transcripts with 3’ untranslated region (3’UTR) HuR clusters of
biologic complexity of three (BC3) and peak height five (ph5) and no 3’UTR Ago
clusters of those criteria. Points are colored based upon the percentage of HuR CLIP tags
in the cluster from each activation state. The color scale gradient ranges from blue
(100% of HuR tags in the resting state) to yellow (100% of HuR tags in the activated
state). (B) Transcripts with 3’UTR Ago clusters of BC3 and ph5 and no 3’UTR HuR
clusters of those criteria. Points are sized based upon the percentage of Ago CLIP tags in
the cluster from each activation state. The scale ranges from the smallest point (100% of
Ago tags in the resting state) to the largest point (100% of Ago tags in the activated state).
(C) Transcripts with both Ago and HuR 3’UTR clusters of BC3 and ph5. Points are
colored based upon the percentage of HuR CLIP tags in the cluster from each activation
state. The color scale gradient ranges from blue (100% of HuR tags in the resting state)
to yellow (100% of HuR tags in the activated state). Points are sized based upon the
percentage of Ago CLIP tags in the cluster from each activation state. The scale ranges
from the smallest point (100% of Ago tags in the resting state) to the largest point (100%
of Ago tags in the activated state).
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Discussion

In this section we explored the dynamic changes in translation that occur with T cell
activation by comparing the deep sequencing of ribosome protected RNA fragments and
mRNA. By measuring the levels of transcripts protected by ribosomes, we were able to
directly measure the amount of protein synthesis per transcript in the resting and
activated states of a CD8 lymphocyte. Comparing this information with the parallel RNA
sequencing data generated from these same groups of cells, we intended to identify sites
of translational regulation and to extract biologically meaningful insights into changes in
HuR and Ago binding by overlaying their CLIP maps with the transcriptional and
translational cellular states.

One possible caveat to the ribosomal profiling dataset is that to date it only represents one
biologic experiment. To ensure that the dynamic changes we see in translation are
reproducible, we will repeat this experiment with other normal donors and are currently
recruiting donors to do so. If possible, we will start with a larger number of cells to
improve upon the complexity of the resulting cloned RPF dataset. In these ways, we will
define robust sites of translational changes with T cell activation. Still, we believe these
data represent biologically meaningful information and we plan to pursue interesting
targets to validate our findings by other means such as by flow cytometry and performing
quantitative western blot of resting and activated CD8 lymphocytes to investigate protein
expression changes with different time points of T cell activation.

The ribosomal profiling data combined with mRNA sequencing gives us insight into the
rapid changes that occur with T cell activation both translationally and transcriptionally.
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With only one hour stimulation with CD3/CD28 beads, it is remarkable how distinctly
the global profiles of the cells change. While many alterations in ribosomal occupancy
correlate with changes in transcript expression, we were able to identify sites that did not
match these variations in abundance and we believe these represent sites of translational
control. We were able to identify transcripts with robust HuR and Ago binding sites that
had RPF values deviating from the patterns of transcript expression.

Still, we did not uncover simple rules of translational regulation by the RNA binding
proteins. We can identify individual cases where protein binding increases or decreases
correlating with both increases and decreases in RPF abundance. This may represent the
complex dynamics of multiple layers of combinatorial control that are necessary to
dictate cellular function. Even so, for individual candidate transcripts, we can learn much
from this data about the dynamics of lymphocyte activation and the importance of tightly
regulated transcriptional and translational control.
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CHAPTER 8. Studying T cell Regulation in HuR Deficient CD8 Lymphocytes

Introduction

In Chapter 6 we introduced the necessity for understanding the combinatorial control of
Ago and HuR regulation of mRNA. In summary, previous studies have indicated that
(Argonaute) Ago and HuR may compete for regulatory function on target transcripts
(Chang et al. 2012). HuR binding may alleviate repression of microRNA-mediated
inhibition of targets by altering a transcript’s subcellular localization and targeting it for
translation upon the induction of stress (Bhattacharyya, Habermacher, Martine, Closs,
and Filipowicz 2006a; 2006b). Alternatively, HuR has been shown to work in concert
with Ago to mediate repression of other mRNA (Glorian et al. 2011; Kim et al. 2009;
Kundu et al. 2012).

We have already described the impressive overlapping binding patterns of Ago and HuR
in human cluster of differentiation eight (CD8) lymphocytes during T cell activation. In
order to further study the combinatorial control of HuR and Argonaute (Ago), we sought
to investigate the binding patterns of Ago in T cells lacking HuR. While HuR deficient
mice are embryonic lethal, mice with HuR deficient T cells are viable throughout
development. HuR null lymphocytes, due to floxed excision of HuR exon 2 from Lck
promoter driven Cre expression, have altered phenotypes in T cell maturation. These T
cells show decreased exiting of the thymus and reduced chemotaxis towards cytokines
that alter the intracellular localization of HuR. Single positive cells lacking HuR also
have a reduced proliferative response after CD3/CD28 stimulation and show defects in
intracellular signaling downstream of the T cell receptor. HuR negative T cells also
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avoided an apoptotic response when stimulated with CD3/CD28 as compared to HuR
positive T cells. The authors also found increased mRNA levels of Tnf with activation of
HuR deficient cells as compared to HuR expressing T cells (Katsanou et al. 2009;
Papadaki et al. 2009). Thus, examining Ago binding maps upon CD3/CD28 activation of
CD8 T cells with and without HuR provides a means to probe their possible synergistic
and antagonistic regulatory functions in an important biological context.

Results
Lck-Cre+ HuRfl/fl CD8 Lymphocyte Characterization

We characterized the levels of HuR in the T cells of conditional knock out (cKO) mice
for potential use in CLIP, RNAseq, and ribosomal profiling experiments. Three mice
were chosen that were Lck-Cre+ and had both alleles of the second exon of HuR floxed
and three mice that had a wild type HuR locus. The PCR products confirming these
genotypes are shown in Figure 8.1A. For this experiment, splenic CD4 T cells were
selected and their purity of nearly 99% was confirmed by flow cytometry (Figure 8.1B).
Aliquots of the T cells were run on an SDS-PAGE gel and probed for HuR using the 3A2
monoclonal antibody and also for Hsp90 as a loading control. As seen in Figure 8.1C
and quantified in Figure 8.1D, two of the three mice showed greatly reduced levels of
HuR expression in their T cells, with expression levels around 5 percent of that of a wild
type mouse.

However, in the third HuR cKO mouse, the expression of HuR was

equivalent to that of a wild type mouse.
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Fig 8.1 Lck-Cre HuRfl/fl Characterization. (A) Genotyping PCR analysis of eight
mice with determined genotypes as indicated for Lck-Cre+ HuRfl/+ (Het Cre+), Lck-CreHuRfl/+ (Het Cre-), Lck-Cre+ HuRfl/fl (KO), and Lck-Cre+ HuR+/+ (WT). (B) T cell purity
determined by CD3 and CD8 staining and flow cytometry. Percentages of cells are noted
in each quadrant. (C) Mouse CD4 T cell lysate from the indicated number of cells was
analyzed by western blotting for HuR (with monoclonal HuR specific 3A2) and HSP90
(with monoclonal HSP90 specific BA86). (D) Quantitation by phosphoimager analysis
of HuR levels in (C) normalized against levels of HSP90. Plotted are the averages of the
three lanes for each mouse with standard deviations in error bars.
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To screen the mice in the colony, we evaluated the level of HuR expression in
lymphocytes by intracellular staining for HuR and flow cytometry. This allowed us to
determine HuR expression in an ocular blood sample prior to sacrificing the animals for
an experiment. Briefly, mice were bled from the ocular vein and after red blood cell lysis,
the cells were permeablized and intracellularly stained for HuR and analyzed by flow
cytometry. We found that the amount of HuR in Lck-Cre+ HuRfl/fl mouse T cells showed
a continuous spectrum of expression levels. These expression patterns varied for each
individual mouse and ranged from levels at overlapping the isotype control, indicating
virtually no HuR expression, to levels mimicking wild type protein expression (data not
shown).

To ensure that the levels of HuR identified by flow cytometry matched the levels detected
by western blot, we sacrificed one wild type mouse and four animals that had been
screened by HuR staining of blood cells to have HuR expression levels ranging from very
low to wild type levels of protein. T cells were isolated from these five mice and
analyzed by both flow cytometry and western blot. The intracellular HuR staining
showed that the HuR expression patterns seen in peripheral blood were equivalent to
those from splenic T cells ranging from low expression of HuR in KO1 to wild type
expression in KO4 (Figure 8.2A). These protein levels were confirmed by western blot
(Figure 8.2B). We concluded that the Lck-Cre+ HuRfl/fl mouse system was unreliable for
consistently obtaining HuR deficient T cells, although it was possible to control for the
phenotype of the mice by screening them by intracellular staining of T cells for HuR
using flow cytometry.
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Figure 8.2 HuR Intracellular Stain and Western Blot. Analysis of CD4+ T cells from
four Lck-Cre+ HuRfl/fl (KO) mice and one Lck-Cre+ HuR+/+ (WT) mouse. (A)
Intracellular stain for HuR (with monoclonal HuR specific 3A2) in colored lines and
mouse IgG control antibody in gray shaded plot with secondary anti-mouse PE antibody
as analyzed by flow cytometry. Color of plotted lines match mice indicated in (B). (B)
Mouse CD4 T cell lysate was analyzed by western blotting for HuR (with monoclonal
HuR specific 3A2) and HSP90 (with monoclonal HSP90 specific BA86).
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CD4-Cre+ HuRfl/fl Mouse Characterization

In order to have a more reliable system for studying T cells lacking the HuR protein, we
began breeding the HuRfl/fl mice onto a CD4-Cre background. All T cells express both
CD4 and CD8 before they differentiate into single positive cells. Therefore, CD4-driven
Cre expression should delete HuR in all mature T cell subsets. To screen the mice in the
colony, we evaluated the level of HuR expression in the lymphocytes by flow cytometry
as described above. The HuR profiles of these cells clearly segregated by genotype. Both
CD8 and CD4 lymphocytes from CD4-Cre+ HuRfl/fl showed consistently reduced levels of
HuR as compared to wild type lymphocytes. In the HuR cKO samples, there was a small
peak of cells at expression levels comparable to the wild type mice (Figure 8.3A,B). This
signal was seen with irrelevant mouse IgG and secondary alone, so we do not believe that
it is a population of HuR expressing T cells in the HuR cKO mice, but rather background
staining in the assay. When we gated on CD3 negative cells, which should not have Cre
expression from the CD4 locus and therefore should retain full-length HuR even in
HuRfl/fl cells, we did not see a difference in HuR expression between the HuR cKO and
wild type mice (Figure 8.3C). We concluded that HuR protein levels were robustly
depleted in the HuR cKO mice and that the conditional excision of exon 2 of HuR was
specific to T cells.

Preparation of Mouse CD8 T cells for Ago CLIP

We prepared wild type and HuR cKO T cells for analysis by Ago CLIP. Originally, we
intended to prepare both resting and activated cells to match the datasets collected for the
human cells. As in human cells, we observed that freshly isolated mouse T cells had
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Figure 8.3 CD4-Cre HuRfl/fl Intracellular FACS from Blood. Analysis of
lymphocytes from CD4-Cre+ HuRfl/fl (cKO) mice or CD4-Cre+ HuR+/+ (WT) mice.
Intracellular stain for HuR (with monoclonal HuR specific 3A2) with secondary antimouse APC antibody as analyzed by flow cytometry. (A) HuR stain of CD8+ T cells.
(B) HuR stain of CD4+ T cells. (C) HuR stain of CD3- cells.
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elevated levels of Ifng mRNA, indicating that the isolation procedure caused low levels
of activation. However, unlike with human cells, resting the mouse cells overnight in
media did not permit recovery of healthy T cells the next day (data not shown).
Therefore, we decided to utilize the T cells immediately after isolation by activating them
in culture with CD3/CD28 beads.
We processed three groups of four CD4-Cre+ HuRfl/fl mice, and three groups of four
littermate wild type or CD4-Cre+ mice, to obtain six biologic samples for analysis. These
pooled T cells were determined to be more than 95% pure by flow cytometry (Figure
8.4A). The isolated T cells were stimulated for one hour in culture with CD3/CD28
beads. The activation states of the resulting lymphocytes were analyzed by isolation of
total RNA from the cells.

The RNA was reverse transcribed into cDNA and the

abundance of Ifng mRNA assayed by qPCR. The delta Ct values for Ifng normalized to
levels of GAPDH are plotted in Figure 8.4B in comparison to other mouse T cell sample
qPCR data. We saw very good stimulation of the T cells being prepared for CLIP
regardless of genotype as compared to previously isolated samples.

Furthermore, it was important to ensure that the levels of HuR in the T cell samples were
significantly reduced in the CD4-Cre+ HuRfl/fl lymphocytes compared to the wild type T
cells. We ran lysate from an aliquot of the T cell samples on an SDS-PAGE gel and
blotted for HuR and also for Hsp90 as a loading control. We saw an average of roughly
10 percent HuR expression in the HuR cKO T cells compared to matched littermate wild
type cells. In summary we were able to isolate a pure population of CD8 T cells from
wild type and HuR cKO mice. These cells had appropriate levels of HuR expression
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Figure 8.4 Mouse CD8 T Cells: Characterization for Ago CLIP. Analysis of 6 pools
of purified mouse CD8+ T cells from CD4-Cre+ HuRfl/fl (cKO) mice (Pools A, C, E) or
CD4-Cre+ HuR+/+ (WT) mice (Pools B, D, F). (A) Representative T cell purity
determined by CD8 staining and flow cytometry. Percentages of CD8+ cells are noted in
the box. (B) Ct values for Gapdh mRNA were subtracted from the Ct values for Ifng
mRNA (dCt) for resting or CD3/CD28 stimulated CD8 T cells. dCt values from each
pool of mouse cells prepared for CLIP (A to F) is compared to previous resting and
activated KO and WT mouse cells. (C) Equivalent aliquots of mouse CD8 T cell lysate
from the indicated samples were analyzed by western blotting for HuR (with monoclonal
HuR specific 3A2) and HSP90 (with monoclonal HSP90 specific BA86). (D)
Quantitation by fluorescent signal analysis of HuR levels in (C).
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corresponding to their genotype and were activated in vitro for one hour before
crosslinking. Both wild type and HuR cKO mouse CD8 T cells were applied in Ago
CLIP analysis and high-throughput sequencing. For these samples, we used the same
crosslinking immunoprecipitation protocol as for human cells, but utilized a different
cloning strategy of the CLIP tags with only one linker ligation step as described in
Chapter 2.

Tag Statistics

We performed HITS-CLIP on CD8 lymphocytes of three biologic replicates of wild type
and CD4-Cre+ HuRfl/fl mice stimulated for an hour with CD3/CD28 beads. The final
products were pooled together so that six samples were sequenced between two lanes.
Each pooled Ago associated mRNA sample produced nearly 200 million sequencing
reads.

Once we filtered and collapsed each pool so that each sequence was only

represented once, we had between 20 and 25 million reads for each sample.

As

mentioned previously, we think this dramatic decrease is due to over sequencing of the
sample and also PCR duplication of CLIP tags. We stripped the linker sequences from
each read and segregated each sample from the pooled data, the four nucleotide indices
are indicated in the table below each sample name. Each sample contributed between
close to 4 to 6 million reads, indicating that the samples were sequenced rather evenly.
Each sample had roughly 1.5 to 4 million sequences that mapped to unique locations in
the mm9 build of the mouse genome (Table 8.1).

As with the other CLIP samples processed for the human dataset, the adapters contained
a four nucleotide degenerative sequence.
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Thus, when these randomly generated
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Table 8.1 Ago CLIP Tag Statistics from HuR cKO and WT Lymphocytes.

cKO: 1,736,321
WT: 2,318,089

Pool 1

Pool 2

Total Reads

195,210,749

179,668,684

After Quality Filtering

143,705,912

141,577,140

Exact Duplicates
Collapsed

20,777,570

23,331,600

A: cKO

B: WT

C: cKO

D: WT

E: cKO

F: WT

(GCAT) 23x

(GTCA) 24x

(ACTG) 20x

(ACTG) 22x

(AGCT) 21x

(TCGA) 19x

Linker Stripped

4,578,800

4,488,975

4,190,422

4,323,854

3,792,646

5,746,463

CLIP Adapter
Removed

3,961,605

4,007,333

3,923,881

3,999,408

3,584,650

5,561,856

1,471,464

1,451,509

2,159,341

2,114,094

1,959,729

3,751,959

261,240

182,516

927,922

461,589

547,159

1,673,984

mm9 Mapping
(novoalign with trimming)

PCR Duplicates
Collapsed
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oligonucleotides were ligated to the RNA they could be used to distinguish between
independent Ago binding events at the same locus and PCR duplications of the same Ago
interaction by comparing the four-nucleotide barcodes. Thus, we collapsed sequences
that had the same start and ending footprint on the genome that also had the same fournucleotide codes in the linker sequence. In doing so, we can correct for some of the PCR
amplification that reduces the true complexity of the sample. The number of PCR cycles
used for each sample are listed under the sample names and ranged between 19 and 24
cycles. After this computation, the samples were reduced to almost 200,000 to 2 million
unique CLIP tags for each sample. As with the human samples, the colors highlighting
each sample correspond to the colors of the CLIP tags viewed on the genome browser
(Table 8.1).

Genomic Distribution of Ago Binding Sites
To determine an overview of the Ago binding distributions in wild type and CD4-Cre+
HuRfl/fl cells, we examined the regions of transcripts that were targeted in the mouse T
cells. We clustered all of the tags together from both the wild type and HuR deficient
lymphocytes, specifying that tags needed to overlap at least 5 nucleotides to be included
in a cluster. To demand that the clusters were reproducible, we only included clusters
that contained CLIP reads from all three of the biologic samples in either the wild type
and or the HuR deficient datasets. We specified the cluster as wild type only if there
were tags from all three wild type mouse samples and not more than one replicate
represented from the HuR cKO data (Figure 8.5A), and the reciprocal for HuR cKO
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Figure 8.5 Mouse Ago Clusters Genomic Distribution. Distribution of Ago clusters
comprised of at 3 biologic replicates exclusively in HuR wild-type mice (CD4-Cre+
HuR+/+, WT), HuR conditional knock out mice (CD4-Cre+ HuRfl/fl, cKO), or in both
genotypes.
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clusters (Figure 8.5B). All six replicates needed to contribute tags to a cluster for it to be
considered present in both biologic samples (Figure 8.5C).

As we saw previously for the Ago and the HuR datasets, the largest pools of robust
clusters mapped to intronic regions of target transcripts for all three groups. The next
most represented regions were the 3’ untranslated regions (UTRs) including the regions
ten kilobases downstream of the annotated transcript, and then coding sequences.
Interestingly, the proportion of intronic clusters decreased in the group of clusters present
in both genotypes, while the percentages of clusters in 3’UTRs and coding sequence
exons increased. This may reflect the increased biologic complexity for these samples
and possibly an even more robust distribution of binding. Still, the proportion of deep
intergenic clusters also increased in this set, while we might expect it to decrease with
more stringent cutoffs, signaling that the differences in binding distribution may reflect
differences in biology rather than in background signal for the samples.

Ago Binds Egr3 and Ifng in Mouse T cells with or without HuR

To begin our analysis of Ago binding in wild type and HuR cKO T cells, we examined
the binding distribution of Ago on the Egr3 and Ifng transcripts. These two transcripts
were among the top targets with increased Ago and HuR binding following T cell
activation in human lymphocytes. Figure 8.6 shows the distribution of Ago binding to
Egr3 in the mouse cells. We included the region downstream of the annotated 3’UTR in
the mouse that is homologous to the 3’UTR of the human transcript. This unannotated
mouse 3’UTR region includes the largest binding sites for Egr3 in the mouse. It is clear
from this binding map that HuR is not necessary for Ago to bind to this transcript with
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lymphocyte activation.

Interestingly, while the EGR3 binding map from human

lymphocytes mostly excluded binding in intronic regions of the transcript, there are some
clusters found in the intron in the mouse. This may reflect slight differences in the
regulatory function between species or may be an artifact of a slightly different time
course of T cell activation biology in the mouse, even though one hour of stimulation was
studied in both systems.

Similarly, HuR was not necessary for Ago to bind to Ifng (Figure 8.7). We found robust
Ago binding sites in both wild type and HuR cKO activated T cells. While we found
robust intronic binding sites in the Egr3 transcript in mouse but not human, we saw no
biologic complexity of three sites in intronic regions for Ifng in the mouse while we did
in the human. On the mouse transcript, we saw robust and reproducible binding in the
coding sequence and UTRs, but not as much in introns. Furthermore, it appears that the
5’UTR binding in the mouse was limited to the HuR cKO T cells and increased in the
coding region and 3’UTR in cells without HuR as well. Therefore, we hypothesize that
HuR may help recruit Ago to bind certain sites in Ifng, although this does not explain the
differences in intronic binding between the biologic systems.

Revisiting Dynamic Binding Changes from the Human Dataset: IRF9 and SATB1

During the analysis of the human Ago and HuR CLIP data, we identified the IRF9 and
SATB1 transcripts as being regulated in overlapping regions by the two RNA binding
proteins. We examined the binding patterns on these transcripts in particular, because the
binding intensities changed dramatically in the opposite direction for Ago and HuR with
T cell activation. For the IRF9 transcript, although Ago binding increased with T cell
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stimulation, HuR binding decreased (Figure 8.8A). While there was robust binding in
both activation states for both Ago and HuR, this binding pattern shift suggested that the
proteins might be interacting antagonistically to exclude each other from this site.
Interestingly, in examining the homologous region in the mouse, we found a robust
binding site in the wild type activated T cells, matching the human activated state, but
only scattered tags in the HuR cKO samples (Figure 8.8B). This suggests that this
binding site is conserved across species and that HuR may be necessary for robust Ago
binding. There is similarly scattered binding for both genotypes throughout the rest of
the transcript, suggesting that there are comparable levels of this transcript available for
potential regulation in both groups of mice (data not shown). While Ago and HuR may
compete for binding to this site, the mouse data suggests that HuR is necessary for Ago
regulation.

The human SATB1 binding map showed the opposite pattern for Ago and HuR in the
human T cells. With lymphocyte activation, Ago binding at this 3’UTR site was almost
completely depleted, although HuR binding quantitatively increased (Figure 8.9A).
Because of the low binding levels of Ago at this site in activated human T cells, it was
interesting to find that the corresponding region in the mouse Satb1 3’UTR contains the
largest region of Ago binding in both wild type and HuR cKO mice. In fact, it appeared
that the levels of Ago binding at this site were higher in the wild type mice (Figure 8.9B).
Still, this is consistent with the IRF9 transcript, where we found that a possibly
antagonistic site in the human transcript required HuR for binding in the mouse.
Although the mouse Satb1 site clearly does not require HuR for Ago binding, as it is
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Figure 8.9 Ago and HuR Binding in Human and Mouse: SATB1 3’UTR. (A) The
position of individual Ago and HuR unique CLIP tags in biologic complexity two
clusters plotted relative to their mapped position on the human SATB1 3’UTR. The
CLIP cluster showing dynamic reciprocal Ago and HuR binding changes is outlined in
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robustly present in the HuR cKO cells, HuR does appear to enhance binding in the wild
type cells despite the suggested competition in the human data.

Exploring Ago Binding Changes between HuR Wild type and KO T cells

Although it appeared that generally much of Ago binding was maintained in the HuR
cKO cells, we identified sites of Ago regulation that were present only in wild type or
HuR cKO cells. We sorted the clusters by biologic complexity and then by tag numbers
in each state.

The top coding region and 3’UTR binding sites changing between

genotypes are listed in Figure 8.10. Figure 8.10A represents binding sites where all three
wild type replicate samples are represented in the cluster, but there is no robust binding
site in the cells lacking HuR. We suggest that these sites represent potential agonism in
the binding of HuR and Ago because HuR would be necessary for Ago to be present at
that regulatory site.

Interestingly, the top target in this category was the Fyb transcript. This 3’UTR cluster is
in the homologous region as the binding changes discussed in the 3’UTR of the human
FYB transcript in Chapter 6. In the human 3’UTR, we saw overlapping binding of Ago
and HuR. While the binding for Ago was biologically complex in both states, actually
increasing in biologic complexity with T cell activation, the number of tags represented
in the Ago cluster decreased with T cell stimulation. This contrasted with HuR, which
had maximal biologic complexity in both states, but increased binding quantitatively with
activation (Figure 8.11A). In the mouse system, we see a robust binding site at this
3’UTR location in the wild type animals, but no binding in the HuR cKO mice (Figure
8.11B). This suggests that Ago requires HuR at that site to bind. There is binding of
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positions of at least 5 nucleotides. We sorted the clusters by biologic complexity and
then by tag numbers in each state. The top coding region and 3’UTR binding sites
changing between genotypes are listed. Each table lists the name of the transcript, the
location of the cluster within the transcript, and the number of tags and biologic
complexity (BC) of the cluster for each genotype. (A) Binding sites where all three wildtype replicate samples are represented in the cluster, but there is no robust binding site in
HuR cKO mouse T cells. (B) Binding sites where all three HuR cKO replicate samples
are represented in the cluster, but there is no robust binding site in wild-type mouse T
cells.
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Figure 8.11 Ago and HuR Binding in Human and Mouse: FYB 3’UTR. (A) The
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position of individual Ago and HuR unique HuR
CLIP
tags in biologic complexity two
clusters plotted relative to their mapped position on the human FYB 3’UTR. The CLIP
cluster showing dynamic reciprocal Ago and HuR binding changes is outlined in the
3’UTR. From top to bottom: chromosomal location, Ago CLIP tags from activated CD8
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unique CLIP tags are plotted relative to their mapped position on the mouse Fyb 3’UTR.
The homologous 3’UTR region showing dynamic reciprocal Ago and HuR binding
changes on the human transcript is outlined. From top to bottom: chromosomal location,
Ago CLIP tags from activated HuR wild-type CD8 T cells (colors represent each donor
sample as shown in Table 8.1), Ago CLIP tags from activated HuR cKO CD8 T cells,
Gene diagram from RefSeq.

!

RefSeq Genes

!
233

FYB
FYB

Ago in other sites along the Fyb transcript in the HuR cKO mouse cells indicating that it
is not a lack of the Fyb transcript in these animals that can explain the absence of binding
at that site in the HuR cKO mice. The mapped patterns in the human T cells are
consistent with a model in which Ago and HuR compete quantitatively to bind in that site.
Still, Ago and HuR both display robust binding patterns in both states. Based on the
mouse data, HuR binding appears to be necessary for Ago targeting to this 3’UTR region.

We also examined sites of Ago regulation that were present in the HuR cKO mouse cells
but not in the wild type lymphocytes. We think these may represent sites of antagonism
between HuR and Ago because Ago is only able to bind these RNA regions when HuR is
not present in the cells. The top ranked site in this category was in the Ppp1r15b
transcript (Figure 8.10B). The cluster was located in the first coding exon and although
there were robust Ago binding sites in both genotypes upstream of this binding site, there
were no tags seen in the wild type mice in that location (Figure 8.12B). The human data
supported this pattern, with a robust HuR binding site matching the same locus without a
corresponding Ago site. Upstream of the highlighted region in the exon there were a few
small Ago clusters that matched the robust site in the HuR wild type mice. Therefore, it
appears that HuR may block Ago from binding to the highlighted site in the coding
region of the Ppp1r15b transcript in both mice and human T cells.

Another example of potential Ago and HuR antagonism was in a coding exon in the
middle of the Pdcd4 transcript. In this region, there was binding observed in the HuR
cKO lymphocytes but not in the wild type cells (Figure 8.13B). In concordance with this
observation, there was HuR binding observed at this position in the human T cells
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without binding of Ago, although there was an intronic cluster just downstream of this
position in the resting state (Figure 8.13A). Thus, these binding patterns suggest that
HuR binding at this position in the Pdcd4 transcript precludes binding of Ago.

Discussion

In this chapter we examined the role of Ago in T cells lacking the normally ubiquitous
HuR protein. We first began by studying HuRfl/fl mice where the Lck promoter drove
expression of Cre. These mice had been previously described as having aberrant T cell
maturation, migration, proliferative responses, and gene expression patterns (Papadaki et
al. 2009). We found that although the genotypes of Lck-Cre+ HuRfl/fl mice appeared to
be identical, the down regulation of HuR in their lymphocytes was not. Instead we
observed that certain mice of this genotype maintained wild type levels of HuR while
others showed highly reduced levels of HuR protein. We were able to determine the
levels of HuR in lymphocytes by screening the T cells by intracellular staining of HuR
and flow cytometry and observed phenotypes in the mouse colony of HuR protein
expression of around 5% to 100% of wild type HuR levels by western blot.

In order to have a more phenotypically uniform population of mice with HuR deficient T
cells, we bred the HuRfl/fl mice to those expressing Cre under control of the CD4
promoter. In contrast to the Lck-Cre mice, CD4-Cre+ HuRfl/fl mice showed reliable down
regulation of HuR protein in their CD4 and CD8 T cells, which was not seen in CD3
negative cells. We therefore prepared CD8 T cells from pooled groups of CD4-Cre+
HuRfl/fl mice and littermate control wild type mice for Ago CLIP. After isolating CD8
lymphocytes, we activated the cells for one hour with CD3/CD28 beads and crosslinked
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them. We monitored the purity of the cells by flow cytometry, the activation state of the
cells by qPCR for Ifng and did western blotting to confirm that the cells had the correct
expression levels of HuR. It is important to note that the isolated CD4-Cre HuR cKO
mouse CD8 lymphocytes still maintained a low level of detectable HuR protein. This
may be due to contaminating cell populations or small numbers of T cells that escaped
deletion of the second exon of HuR.

Still, the dramatic reduction in HuR protein

expression in these samples provides a useful system for studying the reliance on HuR for
Ago regulation in CD8 T cells.

We performed Ago CLIP in the three biologic pools of wild type and HuR cKO CD8
lymphocytes and were able to clone between 180,000 to almost 2 million unique Ago
binding sites for each sample. Similar to our human dataset, we found that clusters were
most represented in intronic regions of target transcripts, followed by 3’UTRs and then
coding sequences. However, in the mouse data, 3’UTR regions were a larger percentage
of the total than in the human dataset and there were almost twice the percentage of
coding sequences represented here. While these still do not resemble the previously
published binding distributions for Ago in the brain or in regulatory CD4 T cells, they are
more similar (Chi et al. 2009; Loeb et al. 2012). Thus, in addition to the possibility of the
patterns being specific to this cell subset, the differences may also reflect those between
Ago regulation in humans and mice.

For the majority of Ago binding sites, the patterns were not greatly altered without the
presence of HuR in the T cells. For example, the binding patterns looked very similar in
wild type and HuR cKO lymphocytes for the Egr3 and Ifng transcripts. For these two
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targets we found that, contrasting in the human cells, Ago binding was apparent in the
intronic region of Egr3 and not reproducibly in the introns of Ifng. These may reflect
differences in the biology of human and mouse lymphocytes in terms of the targets of
Ago regulation or may be due to differences in the time course of the CD3/CD28 induced
stimulatory cascades between the two species.

Although we first identified the IRF9 and FYB transcripts in the human dataset as
showing potential competitive regulation between Ago and HuR, the results from the
mouse data suggest that these suggested quantitative changes in binding might not be as
critical as the qualitative ones. It therefore may be more important to examine the
binding in the 3’UTR of this transcript as being robustly present for both Ago and HuR
rather than trying to dissect quantitative changes in the binding patterns for the two
proteins. The cloning of bound RNA may not be reliably enumerative to that degree.
Further examination of changes between wild type and HuR cKO Ago maps will provide
a guide to interpret HuR dependent changes in Ago binding and will help define its
regulatory role as it pertains to transcriptional and translational changes.

This finding also emphasizes the previously discussed results in the human datasets, that
the majority of Ago and HuR binding changes seen with activation are congruous. While
the two proteins may not always be dependent on each other, such as in the cases of the
Egr3 and Ifng transcripts, the small percentage of overlapping clusters that represented
possible antagonism between the proteins may only represent a small subset of the
interactions between Ago and HuR. Still, it appears that there are cases of Ago and HuR
antagonism that are identifiable by studying Ago binding in the HuR cKO CD8

239

lymphocytes. By overlaying RNAseq and Ribosomal Profiling data in these cells, we
will learn more about the cooperative and antagonistic regulatory roles of Ago and HuR
in the dynamics of T cell activation.
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CHAPTER 9. Exploring Tumor Immunity and Neurologic Autoimmunity in
Paraneoplastic Neurologic Degeneration

Introduction

Paraneoplastic disorders are defined as symptoms resulting from damage caused by a
malignant neoplasm at a site in the body remote from the tumor and can affect most
organs and tissues.

This set of disorders can be caused by hormone and cytokine

secretion by tumor cells or by an immune response against the tumor. In some patients,
tumor cells express proteins that are normally restricted to the brain, termed onconeural
antigens. The ectopic expression of onconeural antigens in tumors can elicit a strong
immune response against the tumor. It is thought that because the antigens are not
normally presented in the body’s periphery, the immune system recognizes the antigens
as foreign. This can create a strong anti-tumor immune response yielding occult tumors
in these patients and good outcomes with cancer treatment. Unfortunately, this immune
reaction can also lead to severe autoimmune disease in the brain leading to paraneoplastic
neurologic degeneration (PND) (Figure 9.1). This set of disorders represent some of the
best-known cases of tumor immunity and are fairly unique in that the antigenic targets of
the immune system have been characterized (R. B. Darnell, 1996; R. B. Darnell & Posner,
2003a; 2003b; 2006).

One such paraneoplastic disorder involves the onconeural antigen cerebellar
degeneration-related protein 2 (cdr2). While cdr2 is thought to normally be restricted to
Purkinje neurons in the brain, this tumor rejection antigen is expressed in many breast
and ovarian tumors, 25% and 60%, respectively. In rare cases, an anti-tumor immune
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Figure 9.1 Model of Paraneoplastic Neurologic Degeneration. The presence of tumor
cells in the periphery that expresses onconeural antigen (represented by green stars)
results in an immune response to the onconeural protein that is able to respond to the
tumor, resulting in tumor immunity. Trafficking of this immune response to the nervous
system targets onconeural antigen-expressing neurons, resulting in neuronal degeneration.
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response to this onconeural antigen breaks immune tolerance in the brain leading to
severe neurodegeneration called paraneoplastic cerebellar degeneration (PCD).
Frequently, PCD patients have limited oncologic disease when they are diagnosed with
the disorder due to an impressive immunologic rejection of their gynecologic tumor
(Albert & Darnell, 2004; Corradi, Yang, Darnell, Dalmau, & Darnell, 1997; J. C. Darnell,
Albert, & Darnell, 2000; R. B. Darnell & Posner, 2003a; Peterson, Rosenblum, Kotanides,
& Posner, 1992).

A second paraneoplastic neurologic disorder, the Hu Syndrome arises from ectopic
expression of the neuronal protein HuD in Small Cell Lung Cancer (SCLC) tumors. It is
thought that because HuD is typically restricted to the nervous system, an antiinflammatory and somewhat immune-privileged site, ectopic expression of HuD in a
SCLC tumor stimulates tumor immunity as well as an autoimmune response in the
nervous system. Roughly one fifth of SCLC patients have a tumor immune response that
breaks tolerance to this onconeural antigen, which is indicated by antibodies to Hu in
patient sera. In rare cases, the immune response results in severe autoimmunity in the
form of PND called subacute sensory neuropathy and encephalomyelopathy (Figure 9.2).
Patients with any HuD immunity display better outcomes with cancer treatment,
suggesting that the HuD tumor immune response can be constructive and uncoupled from
neuronal autoimmunity (Albert & Darnell, 2004; Dalmau, Furneaux, Gralla, Kris, &
Posner, 1990; R. B. Darnell & Posner, 2003b; Rauer & Andreou, 2002).

Although the presence of onconeural antibodies is useful in diagnosing patients with
paraneoplastic neurologic degeneration, it is unclear what role they might play in disease
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Figure 9.2 Hu Patient Schematic.
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progression. Typically, circulating antibodies mediate immune responses to extracellular
antigens, while HuD and cdr2 are expressed intracellularly (Okano & Darnell, 1997).
Furthermore, disease models utilizing autoantibodies recognizing onconeural antigens
have failed to initiate disease (Sakai, Gofuku, Kitagawa, Ogasawara, & Hirose, 1995).
Generally, intracellular proteins are presented as peptides extracellularly to the immune
system in major histocompatibility complex (MHC) Class I molecule complexes. Each T
cell expresses a unique T cell receptor (TCR) that can bind a particular peptide-MHC
complex. In this way, T cells can initiate an immune response in an epitope and MHC
restricted manner.

Non-self proteins that indicate that a cell has been compromised, such as viral proteins,
will be detected on the cell surface by cluster of differentiation eight (CD8) T cells and
targeted for killing. Because tumor cells often express unusual protein repertoires, CD8
T cells are prime mediators of tumor immunity (Trombetta & Mellman, 2005). In fact,
activated T cells are often found in the cerebral spinal fluid of PND patients and members
of the lab have identified cdr2 and HuD-specific CD8 T cells in PND patients (Albert,
Austin, & Darnell, 2000; Albert et al., 1998; Roberts et al., 2009). While CD8 T cells
can mediate tumor immunity, their priming may rely on help from CD4 lymphocytes.
CD4 T cells interact with antigen presenting cells and license the activation of CD8 T
cells (Lanzavecchia, 1998; Ridge, Di Rosa, & Matzinger, 1998). Additionally, CD4
lymphocytes interact with B cells to induce the production of antibodies. Thus it is
important to consider the role of both CD4 and CD8 T cells to model PND syndromes.
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To explore the possibility of using cdr2 as a potential target for immunotherapy of breast
and ovarian cancer, the lab identified a peptide derived from human cdr2 (cdr2-290) that
stably binds to MHC I molecule HLA-A2.1. Additionally, cdr2-290 specific T cells were
identified in HLA-A2.1+ PCD patients’ peripheral blood, but not normal HLA-A2.1+
donors, indicating that this epitope is part of the repertoire of the naturally occurring antitumor response. Using HLA-A2.1 expressing transgenic mice, high avidity cdr2-290
cytotoxic T lymphocyte clones were isolated which are able to recognize and kill a
number of human cancer cell lines that endogenously present cdr2. One murine T cell
clone shown to have a strong anti-tumor response against human tumor cell lines was
chosen for subsequent analysis. The alpha- and beta-T cell receptor (TCR) genes from
the murine T cells were shown to recognize human cdr2-290 presented on HLA-A2.1 and
were subsequently cloned. Transfection of RNA derived from this alpha and beta-TCR
into normal human donor CD8 T cells afforded the human T cells with the capability to
lyse human tumor cell lines endogenously expressing cdr2 (Santomasso et al., 2007).

In order to better understand the varying T cell responses in Hu patients, a murine system
was used to study the immune response to HuD. To study the CD8 T cell response to
HuD in C57BL/6 mice, the dominant HuD epitope was defined as being peptide 321.
The nature of the immune response to HuD in mice was explored by interrogating the
difference between immune responses to the neuronal HuD, and the foreign antigen Betagalactosidase (β-gal). To assay the CD8 T cell responses to these intracellular antigens,
groups of mice were immunized with adenovirus expressing either HuD (AdV-HuD) or
β-gal (AdV-β-gal). After immunization with the virus and pertussis toxin, an agent
which functions as an adjuvant and may help to disrupt the blood brain barrier, and again
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with pertussis toxin two days later, CD8 T cells were harvested from the mouse spleens
after thirteen days and were stimulated in culture with target cells presenting cognate
antigen (Figure 9.3A) (DeLuca, Blachère, Santomasso, & Darnell, 2009).

After wild type C57Bl/6 mice were immunized with AdV-HuD, there was no CD8 T cell
IFNG response seen directly ex vivo to HuD, but there was an antigen-specific response
after in vitro T cell stimulation. This suggests that there is peripheral tolerance to the
neuronal HuD protein because the HuD-specific T cells are present in the immune
repertoire, but they are not active directly ex vivo after antigen challenge. In contrast,
mice lacking HuD (HuD KO) and immunized with AdV-HuD did not display HuD
tolerance. HuD-specific T cells from HuD KO mice were active directly ex vivo and after
in vitro stimulation, because HuD is a foreign antigen in the HuD KO. Similarly, after
immunizing wild type mice with AdV-β-gal, there was no immune tolerance observed to
the foreign β-gal antigen; there was a detectable response directly ex vivo and after in
vitro stimulation. (Figure 9.3B) (DeLuca et al., 2009). This suggests that the expression
of the neuronal HuD protein in a wild type host tolerizes the immune response to HuD
epitopes. However, the mechanism is unknown and the critical method by which this
tolerance is broken in SCLC patients leading to tumor immunity and the Hu syndrome is
not understood. In the future, by mimicking the T cell phenotypes found in PND patients,
we intend to model the neurologic degeneration central to these diseases in mice.
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Figure 9.3 Mouse Adenovirus-HuD Immunizations. (A) Cartoon of adenovirus
immunization protocol. Mice were immunized on day 0 (d0) with both adenovirus and
pertussis toxin. Two days later, they were given another dose of pertussis toxin. The
mice were sacrificed on day thirteen and half of the splenocytes were used directly in an
ex vivo IFNG ELISPOT and the other half were incubated in flasks with peptide for in
vitro stimulation (IVS). On day 20, the in vitro stimulated splenocytes were harvested
and used in an IFNG ELISPOT assay. (B) Cartoon representing mouse immunization
and ELISPOT results. (Top) Wild-type (WT) mice were immunized with adenovirusHuD (AdV-HuD). There was no IFNG response directly ex vivo, but there was a visible
response after IVS. (Middle) HuD knock out (HuD-/-) mice were immunized with AdVHuD. There was a detectable IFNG response directly ex vivo and after IVS. (Bottom)
WT mice were immunized with adenovirus-βgal (AdV-βgal). There was a detectable
IFNG response directly ex vivo and after IVS.
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Results

Cdr2 T cell Receptor Optimization

We sought to further characterize the cytotoxic capacity of mouse-derived, human cdr2reactive CD8 T cell clones in a human system. For this purpose, we engineered the TCR
genes from the high avidity cdr2-290 cytotoxic T lymphocyte clone described above
(termed Clone 11/12) and from a second clone shown to have good tumor cell line
reactivity (Clone 1) to improve the stability of the TCR RNA and increase the abundance
of the receptor pair on the cell surface (Santomasso et al., 2007). The TCR genes were
originated and cloned from mouse cells but need to be expressed in human cells. To
maximize the translational efficiency of the TCRs, human codon-optimized versions of
each of the alpha and beta chain genes were generated by de novo gene synthesis.
Furthermore, it has been demonstrated that an additional cysteine residue in the constant
region of each receptor chain helps proper TCR pairing by allowing for an added
disulfide bond to form between the correctly paired alpha and beta-receptor chains
(Cohen et al., 2007). To enhance the ability of the electroporated cdr2-290 TCRs to pair
correctly while competing with the endogenous TCRs in the human CD8 cells, a cysteine
codon was incorporated into the constant region of each receptor chain during gene
synthesis. We cloned the synthetic TCR constructs into an expression vector for efficient
RNA transcription of a polyadenylated mRNA, which was used for T cell
electroporations (Figure 9.4) (vector kindly provided by Dr. Eli Gilboa).

We electroporated human CD8 T cells with alpha and beta-chain TCR RNA from Clone
1, Clone 11/12, or with no RNA in a mock electroporation. After allowing the cells to
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rest in culture, we screened the lymphocytes for TCR expression by tetramer staining
with a cdr2-290 tetramer or a Flu-M1 tetramer as a negative control. When we stained
the electroporated cells with the Flu-M1 tetramer, we saw less than half a percentage of
tetramer-positive CD8 cells. This negative result was also seen for the cdr2-290 tetramer
staining of mock electroporated cells and cdr2 TCR Clone 1 electroporated cells. This
negative result for Clone 1 was expected. The inability of Clone 1 to bind tetramer was
one of the main factors for it not being pursued previously, although we are uncertain
why it fails to do so. We did see a population of tetramer positive cells comprising ~7%
of CD8 lymphocytes electroporated with cdr2 TCR Clone 11/12 (Figure 9.5).

Characterization of Ovarian Cancer Patient Ascites Samples

To study the potency of the electroporated T cells’ response to primary cancer tissue, we
processed ovarian tumor cells from neurologically healthy oncologic patients’ ascites
fluid for use in vitro. The cancer cells would need to be both cdr2 positive and HLA-A2
positive for the TCR clones to recognize cdr2-290 peptide presented on the cells. To
screen the haplotype of the cancer patients, we stained PBMC and analyzed the cells by
flow cytometry. We found that three patients were HLA-A2 negative and that five of the
eight patients were HLA-A2 positive (Figure 9.6).

In order to determine which tumor samples expressed cdr2, we immunoprecipitated cdr2
from four ovarian ascites samples using sera from PCD patients. Of the four patients
tested, three expressed detectable cdr2 protein (data not shown).

Importantly, we

identified the ascites from patients 4 and 6 as being cdr2 positive and HLA-A2 positive.
Therefore, we would expect the cdr2 specific T cells to respond to these tumor cells. The
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Figure 9.5 cdr2 TCR Tetramer Stain of Electroporated Lymphocytes. Flu-M1 (5866 peptide) or cdr2 (290-298 peptide) specific HLA-A2.1 tetramer staining of CD8 T
cells electroporated with no RNA (Mock) or with the indicated cdr2 TCR Clone RNA
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gated populations.
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Figure 9.6 HLA-A2 Stain of Ovarian Cancer Patient PBMC. Peripheral blood
mononuclear cells (PBMC) from eight ovarian cancer patients were stained with FITCconjugated HLA-A2 antibody or Isotype Control (BD Biosciences). Cells were washed
and analyzed immediately by flow cytometry.
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tumor from patient 3 was also cdr2 positive, but because this patient is HLA-A2 negative,
the T cell clone should not be able to react to it. Although patient 8 is HLA-A2 positive,
the cdr2-290 specific T cells should not be able to engage these cells, as they are cdr2
negative. Thus, we identified tumor samples that should be targeted by the cdr2 specific
T cells and also samples that will serve as important negative controls for future work.

Flow Cytometry Based Killing Assay Development

To determine the reactivity of the cdr2 specific lymphocytes against the primary tumor
cells, we developed a flow cytometry based killing assay, schematized in Figure 9.7. T
cells electroporated with cdr2-290 TCRs or electroporated without RNA (mock) were cocultured overnight with target cells comprising cancer cell lines and primary ascites
samples. After the incubation, all of the cells were harvested from the well, stained with
viability dye TO-PRO to designate dead cells and analyzed by flow cytometry. A
defined number of non-fluorescent beads were added to each sample as a means to
normalize counts, and events were collected by flow cytometry until a set number of
beads were captured. In this manner, the number of target cells that had been killed and
missing from the well could be distinguished between paired groups of cognate and
irrelevant stimulators. The total number of cells killed in the well by cognate T cells
could then be calculated by taking the sum of TO-PRO positive dead cells and an
estimate of the number of cells missing from the well. Furthermore the percentage of
killed target cells could be determined by comparing the killed cells to the number of
collected target cells from paired co-cultures of T cells with irrelevant targets.
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Figure 9.7 Tumor Killing Assay Schematic. T cells electroporated with TCR RNA
were co-cultured with target cells. After an overnight incubation, the cells were
harvested and stained with TO-PRO. An equivalent aliquot of beads were added to each
tube and events were collected on the flow cytometer until a set number of beads was
collected. The forward and side scatter distribution of the cells was used to gate on target
cells as shown in the cartoon. The number of TO-PRO positive cells indicates the dead
target cells within the sample. The number of killed target cells was estimated by adding
the number of cells missing from the well as determined by the number of paired target
cells collected from an incubation with irrelevant T cells and the number of TO-PRO
positive cells. From this number, the percentage of killed cells was calculated by
comparing the number of killed cells to the total number of paired target cells co-cultured
with irrelevant T cells.
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Figure 9.8 shows representative data from one replicate of a killing assay set up with
cdr2-290 Clone 11/12 TCR and mock electroporated T cells with different tumor cell
lines and ascites samples. T cells were co-cultured with T2 cells pulsed with irrelevant
Flu-M1 peptide or cognate cdr2-290 peptide. T2 cells are a human lymphoblast cell line
deficient in TAP function containing abundant HLA-A2 molecules on the cell surface
that can be loaded with exogenous peptide (Salter, Howell, & Cresswell, 1985). The
FACS plots in Figure 9.8A show the TO-PRO staining of these target cells. We observed
that mock electroporated T cells stimulated with T2 cells pulsed with either peptide gave
a background of about 14% TO-PRO positive dead cells and nearly 20,000 total T2 cells
were collected. We saw the same results from Clone 11/12 TCR electroporated cells
incubated with T2 cells pulsed with Flu-M1 peptide. When cdr2-specific T cells were
cultured with cognate T2 cells pulsed with cdr2-290 peptide, we were only able to collect
about 5,000 target events and of those events 60% of the cells were dead. Therefore we
calculated that approximately 15,000 cells had been eliminated from the well and roughly
3,000 additional cells were dead, but present in the well, leading us to determine that the
cdr2-290 Clone 11/12 T cells had killed nearly 90% of the cognate T2 cells.

We calculated the percentage of killed targets for each cell type and have displayed the
results in Figure 9.8B. Compared to mock electroporated T cells, cdr2-290 lymphocytes
were able to kill ovarian cancer cell line COV413 cells that are both cdr2 and HLA-A2
positive. This killing was not enhanced by adding an irrelevant Flu-M1 peptide, but was
greatly increased when the cells were pulsed with cdr2-290. Treating the COV413 cells
with IFNG to increase MHC Class I expression and processing of peptides did not
increase the killing of these cells.
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Figure 9.8 cdr2-Specific CD8 T Cell Tumor Killing Assay. (A) Representative
histograms of TO-PRO staining of target cells collected for the groups indicated. The
total number of targets and percentage of TO-PRO positive cells are indicated for each
plot. Targets included T2 cells pulsed with either Flu-M1 peptide or cdr2-290 peptide
and the T cells included T cells electroporated without RNA (mock) or T cells
electroporated with cdr2-290 specific T cell receptor RNA. (B) Quantification of results
from flow cytometry data as in (A). Plotted is the percentage of killed Target cells for
each sample (calculations described in Figure 9.7). Targets included T2 cells: HLA-A2
positive and cdr2 negative (T2), COV413: HLA-A2 positive and cdr2 positive (COV),
and Ascites Sample 8: HLA-A2 positive and cdr2 negative (Asc8). Some of the target
!
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When we co-cultured lymphocytes with ascites cancer cells from patient 8, we did not
see specific killing of tumor cells by the cdr2-290 TCR electroporated cells as compared
to the background death of cells co-cultured with T cells that were mock electroporated.
This was not surprising given that this tumor sample did not express detectable levels of
cdr2 by IP-western blot.

Still, this patient was HLA-A2, and the cdr2-TCR

electroporated cells were able to target ascites cells pulsed with cdr2-290 peptide. This
showed that primary cancer cells could present pre-processed peptide to CD8
lymphocytes for killing. IFNG treatment of the ascites cells increased the background
level of dead target cells in the culture. Nevertheless, increased MHC I expression on the
cell surface enhanced the killing potential of the cdr2-290 specific T cells in response to
the ascites. With IFNG treatment and pulsed with cdr2 peptide, the ascites served as
comparable targets to the HLA-A2 cell lines (Figure 9.8B).

This suggests that

endogenously, the primary tumor cells may display decreased presentation of peptides to
help shield them from the surveying immune system. This could serve as a potential
problem for T cell therapy although it could potentially be overcome with cytokine
treatment. Nevertheless, we were able to see specific targeting of a peptide-pulsed
primary ascites tumor sample by cdr2-TCR electroporated lymphocytes. This assay
provides the potential to quantify the ability of cytotoxic T cells to kill target cells in vitro.

Cdr2-specific CD8 T cell Responses to Primary Human Cancer Cells

In addition to the flow cytometry based killing assay, we examined the responsiveness of
the electroporated T cells to target cells in an IFNG ELISPOT assay. Human CD8 T
cells were electroporated with either cdr2-290 Clone 1 TCRs, Clone 11/12 TCRs, or GFP
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RNA as a negative control. The T cells were co-cultured with target cells in ELISPOT
plate wells coated with anti-IFNG antibody to capture the released cytokines from
activated T cells. After twenty hours, the cells were washed from the wells and bound
IFNG was used to develop spots on the membranes in each well. In this way the number
of spot-forming lymphocytes could be counted per million plated T cells.

We found that Clone 1 and Clone 11/12 cdr2-290 TCR electroporated cells were able to
respond to both high and low concentrations of cdr2-290 peptide pulsed T2 cells but not
to T2 cells pulsed with the irrelevant Flu-M1 peptide. Both were also able to kill
humanized mouse kidney epithelial cells infected with adenovirus expressing human cdr2
(AdV-hcdr2). Neither of the T cell clones responded to adenovirus driven expression of
mouse cdr2 (AdV-mcdr2) in these cells, showing specificity to the human cdr2-290
peptide (Figure 9.9A). Clone 11/12 had a higher number of spot forming cells than
Clone 1 at both concentrations of peptide pulsed T2 cells and with the adenovirus
infected cells signaling that it may be a higher avidity T cell clone. The reactivity to the
AdV-hcdr2 infected cells is important because it shows that the T cell clones were able to
respond to endogenously processed and presented cdr2 peptides, not just cells pulsed
with peptide on their cell surfaces.

We also used tumor cell lines and patient ascites cells as targets in the ELISPOT. We
found that both cdr2-290 clones were able to respond to COV413 ovarian cancer cells
that are HLA-A2 positive and express cdr2. The clones could not respond to the cdr2
expressing HeLa cells that are not HLA-A2 positive, demonstrating that the immune
response is HLA restricted. Unfortunately, we did not see any significant response to
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Figure 9.9 cdr2-Specific CD8 T Cell IFNG ELISPOT. To test for recognition of
endogenous cdr2 tumors by the electroporated cdr2 specific T cells, cdr2 T cell receptor
RNA electroporated T cells (Clone 1 or Clone 11/12) or control GFP RNA electroporated
T cells were co-cultured with target cells in a twenty-hour IFNG ELISPOT assay. Values,
representing spot forming cells per million CD8 T cells, are the average of triplicate
wells; error bars indicate standard deviation. (A) T cells co-cultured with: T2 cells
(HLA-A2 positive and cdr2 negative) pulsed with Flu-M1 peptide (+M1) or cdr2-290
peptide (cdr2) at low [lo] or high [hi] concentrations, humanized kidney epithelial cells
(KECS) (HLA-A2 positive and endogenously cdr2 negative) infected with adenoviruses
driving expression of either human cdr2 or mouse cdr2. (B) T cells co-cultured with:
COV413 tumor cells (HLA-A2 positive and cdr2 positive), HeLa tumor cells (HLA-A2
negative and cdr2 positive), ascites sample 3: HLA-A2 negative and cdr2 positive (Asc3),
ascites sample 4: HLA-A2 positive and cdr2 positive (Asc4), ascites sample 6: HLA-A2
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cdr2 expressing primary ascites samples whether they were HLA-A2 negative (Ascites 3)
or HLA-A2 positive (Ascites 4 and 6) with or without IFNG treatment (Figure 9.9B). It
is possible that the cdr2 expression in these cells is below the detection of the T cell
clones or that the presentation of cdr2-290 on the surfaces of the cells is not efficient.

In order to screen for the effector potential of T cells that were in contact with cognate
targets, we stained cdr2-290 TCR electroporated cells for CD107a and TNF following
co-culture with target cells as in the ELISPOT assay. Following TCR engagement, the
secretion of lytic granules from activated CD8 T cells should lead to the presence of
CD107a on the cell surface of the lymphocytes. CD107a that is normally present on the
lytic granule membrane will fuse with the cell membrane to release its contents and
interrogate the target cell (Betts et al., 2003). After co-culture with T2 cells pulsed with
cognate peptide, we saw a dramatic increase in the CD107a expression on the surface of
CD8 T cells electroporated with Clone 1 or Clone 11/12 TCRs, but not mock
electroporated cells. The expression of TNF also increased in these cells as seen by a
shift upward in the scatter plot (Figure 9.10). Interestingly, the percentage of activated
cells in this assay greatly exceeds the percentage of tetramer positive cells indicating that
tetramer staining may be an underestimate of functional cdr2 specific TCR expressing T
cells (Figure 9.5).

In parallel with the results from the IFNG ELISPOT assay, we saw a strong shift in both
TNF and CD107a in cdr2-specific T cells in response to humanized KECs infected with
AdV-hcdr2 but not AdV-mcdr2 and no response from the mock electroporated T cells.
While we did not observe a significant response to the HLA-A2 positive cdr2 positive
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Figure 9.10 cdr2-specific CD8 T Cell CD107a and TNF Assay. FACS analysis for the
degranulation marker protein CD107a and TNF was performed after co-culture T cells
electroporated without RNA (mock) or T cells electroporated with cdr2-290 specific T
cell receptor RNA (Clone 1 or Clone 11/12) with target cells: T2 cells (HLA-A2 positive
and cdr2 negative) pulsed with Flu-M1 peptide (+M1) or cdr2-290 peptide (cdr2),
humanized kidney epithelial cells (KECs) (HLA-A2 positive and endogenously cdr2
negative) infected with adenoviruses driving expression of either human cdr2 or mouse
cdr2, ascites sample 3: HLA-A2 negative and cdr2 positive (Asc3), ascites sample 4:
HLA-A2 positive and cdr2 positive (Asc4), ascites sample 6: HLA-A2 positive and cdr2
positive (Asc6). Gating was performed on live lymphocytes based on forward and side
scatter characteristics. The percentages of cells staining for CD107a were as indicated.
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ascites tumor cells in the ELISPOT assay (Ascites 4 and 6), we did see a slight but
detectable increase in CD107a expression on the surface of cdr2-specific T cells in
response to the tumors that was not present in response to the HLA-A2 negative cdr2
positive cells (Ascites 3) (Figure 9.10). Although small, this was the first example of a
cdr2-specific TCR electroporated lymphocyte response directed against primary human
cancer cells.

HuD Specific CD8 T cell Clone Characterization

To isolate a CD8 T cell clone specific for HuD peptide 321, a wild type mouse was
immunized with AdV-HuD and pertussis toxin as described previously. Isolated T cells
were in vitro stimulated with peptide 321 and a bulk line of HuD peptide 321 CD8 T cells
was established. The line was plated in limiting dilutions and the clonal T cells were then
continually re-stimulated with peptide 321 while being characterized.

We chose a

peptide 321 HuD clone that proliferated well in culture, was able to specifically recognize
targets pulsed with minimal peptide 321 (Figure 9.11A,B), could respond to cells
endogenously presenting HuD (Figure 9.11C), was able to specifically kill targets pulsed
with peptide 321 (Figure 9.11D), and stained completely with MHC HuD-p321 tetramer
as analyzed by flow cytometry (Figure 9.11E).

We isolated RNA from the HuD peptide 321 CD8 T cell clone of interest and amplified
cDNA for the alpha- and beta-TCRs using the 5’ RACE PCR technique and known TCR
constant region sequences. Using gene specific primers, we cloned the entire TCR genes.
Isolated HuD peptide 321 TCR genes could now be sub-cloned into a cassette vector and
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Figure 9.11 HuD peptide 321 CD8 T Cell Clone Characterization. (A) Cloned HuD
peptide 321 (p321) T cells specifically recognize peptide 321 pulsed targets. T cells were
co-cultured with EL4 cells (HuD negative) alone or with HuD p321 in a low
concentration [low] or high concentration [high] in a twenty-hour IFNG ELISPOT assay.
Values, representing spot forming cells per million CD8 T cells, are the average of
triplicate wells; error bars indicate standard deviation. (B) Cloned HuD p321 T cells
respond to targets pulsed with less peptide 321 than the bulk line of T cells. Cloned T
cells or bulk HuD T cell line were co-cultured with EL4 cells (HuD negative) with
irrelevant peptide (EL4+irr) or with HuD p321 at the µM concentrations indicated in a
twenty-hour IFNG ELISPOT assay. Values, representing spot forming cells per 5,000
CD8 T cells, are the average of triplicate wells; error bars indicate standard deviation.
(C) Cloned HuD p321 specific T cells respond to cells presenting endogenously
processed HuD. T cells were co-cultured with kidney epithelial cells (KECs) alone or
infected with irrelevant (AdV-Irrel.) or HuD expressing adenovirus (AdV-HuD) in a
twenty-hour IFNG ELISPOT assay. Values, representing spot forming cells per 5,000
CD8 T cells, are the average of triplicate wells; error bars indicate standard deviation.
(D) Cloned HuD p321 specific T cells specifically kill targets pulsed with p321. T cells
were plated with chromium labeled peptide-pulsed EL4 cells at the indicated T cell to
EL4 cell ratios. Values represent the percentage of chromium released from the target
cells. (E) Cloned HuD p321 specific T cells were all MHC HuD-p321 tetramer positive.
T cells were stained with CD8 antibody and MHC-tetramer specific for cognate HuD
peptide or irrelevant peptide. The percentages of tetramer-positive cells are noted in the
gated populations.
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injected into embryonic cells to create a transgenic mouse where the majority of T cells
will have the same HuD-specific TCR (Kouskoff, Signorelli, Benoist, & Mathis, 1995).

Attempts at HuD Specific CD4 T cell Epitope Discovery

To determine the dominant epitope for the CD4 T cell response to HuD, we used an
algorithm to predict potential MHC Class II epitopes. To ascertain whether there were
HuD T cells specific for any of the predicted peptides in the C57Bl/6 repertoire, we
immunized mice with each potential peptide emulsified in the Titermax adjuvant. After
seven days, the draining lymph nodes were harvested and CD4 T cells were isolated. The
T cells were then plated in a forty-hour IFNG ELISPOT assay with targets pulsed with
the cognate peptide or an irrelevant Class II peptide as a negative control. Three out of
the six predicted peptides were present in the mouse T cell repertoire (Figure 9.12).
Although possible epitopes have now been identified, it is important to characterize the T
cell responses to all of these HuD peptides to determine if any of them are naturally
processed and presented, and which is optimal. This has proven difficult due to the
strong response of CD4 T cells to sera used to grow AdV-HuD for injection into the mice
and the dependence on sera to grow the resulting mouse cells in culture.

Exploring Tolerance to HuD Using Wild Type and HuD KO Mouse Bone Marrow
Chimeras

To determine whether the expression of HuD in bone marrow derived cells plays a role in
the tolerance to HuD, we transferred bone marrow from wild type and HuD KO mice into
sub-lethally irradiated wild type and HuD KO hosts. After bone marrow transplantation,
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with targets pulsed with cognate or irrelevant peptide. Values, representing spot forming
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standard deviation.
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the mice were rested for two months to allow for the new bone marrow to fully
reconstitute the host immune system. The mice were then immunized with AdV-HuD
and pertussis toxin as previously described (Figure 9.13). We expected that the T cell
responses in each mouse would behave like their host. For example, we hypothesized
that even with wild type bone marrow the T cells would not be peripherally tolerized in
the HuD KO host due to a lack of neuronal HuD expression. Therefore, we expected that
the isolated T cells from HuD KO hosts would respond to antigen-specific targets directly
ex vivo and expanded by in vitro stimulation with or without HuD being present in the
bone marrow. The T cells from wild type bone marrow or HuD KO bone marrow
transferred into wild type hosts were expected to only respond to antigen-specific targets
after in vitro stimulation because we hypothesized that HuD expression in the host
neuronal system would be sufficient to tolerize HuD specific T cell responses regardless
of the genotype of the bone marrow derived cells.

The collated results from IFNG ELISPOT assays from two different immunization
experiments are summarized in Figure 9.13.

In HuD KO hosts reconstituted with

transferred HuD KO bone marrow, we were able to recapitulate the HuD KO phenotype
in seeing a response to HuD peptide 321 directly ex vivo and after in vitro stimulation. In
contrast, peripheral tolerance to HuD was maintained in wild type hosts reconstituted
with either the wild type or HuD KO bone marrow, as these mice maintain expression of
HuD in the neuronal system. The peripheral tolerance to HuD was maintained as in a
fully wild type mouse and antigen specific responses to HuD peptide 321 were not seen
directly ex vivo. The T cells from both groups continued to mimic wild type mouse
responses and showed antigen-specific activation to HuD peptide 321 after in vitro
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Figure 9.13 HuD Tolerance Bone Marrow Chimera Experiment Summary. Cartoon
representing bone marrow chimera genotypes, mouse immunizations, and ELISPOT
results. Bone marrow from HuD knock out (green colored animals: HuD-/-) or wild-type
mice (purple colored animals: WT) were transferred into sub-lethally irradiated hosts that
were either HuD-/- or WT. Control WT mice that were not chimeric are indicated in the
bottom two rows. After allowing for bone marrow reconstitution, mice were immunized
with adenovirus-HuD (AdV-HuD) and pertussis toxin on day 0 (d0) and again with
pertussis toxin on d2, except for control mice represented in the bottom row of the figure
as indicated. The mice were sacrificed on d13 and half of the splenocytes were evaluated
directly in an ex vivo IFNG ELISPOT and the other half were incubated in flasks with
peptide for in vitro stimulation (IVS). On day 20, the in vitro stimulated splenocytes
were harvested and analyzed in an IFNG ELISPOT assay. The results of individual mice
from two different experiments are enumerated as a ratio of the number of responsive
mice to HuD peptide 321 out of the total number of mice assayed between the two
experiments. A blue check mark indicates a positive response of the group and a red “X”
indicates no HuD p321 response.
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stimulation indicating that even the HuD KO derived T cells were able to be tolerized in
the wild type host and were not centrally deleted in either case. More specifically, in
bone marrow chimeras in wild type hosts, we did not see a response to HuD-specific
targets directly ex vivo, but did observe T cell expansion and a an HuD-specific response
after an in vitro stimulation with the HuD 321 peptide. Importantly, we did not see HuDspecific responses after in vitro stimulation with HuD peptide of T cells from wild type
mice that were not immunized with AdV-HuD indicating that the in vitro stimulated
response was specific to viral immunization (Figure 9.13).

In addition, to explore the role of neuronal antigen absence or expression on the induction
of tolerance in bone marrow derived cells from wild type mice, we transferred bone
marrow from wild type mice into sub-lethally irradiated HuD KO hosts. Remarkably, the
mice also displayed a wild type phenotype. The CD8 T cells did not respond to HuD
peptide 321 directly ex vivo, but did display an antigen-specific response after in vitro
stimulation (Figure 9.13). This suggests that even in an HuD KO mouse that does not
express the neuronal HuD, the presence of bone marrow derived cells containing a
functional HuD gene is enough to tolerize emerging HuD-specific T cells. This implies
that the presence of HuD in neurons is not necessary to induce tolerance in T cells to
HuD, and that bone marrow derived cells may be sufficient to tolerize CD8 T cells to a
neuronal antigen.

Development of Tools to Study Tolerance to HuD

Experiments transferring T cells or bone marrow from wild type or HuD KO mice into
different hosts have begun to address whether HuD reactive T cells are being tolerized

269

and/or deleted in the periphery. One difficulty with these experiments was that we
needed to challenge mice with AdV-β-gal in parallel to the mice challenged with AdVHuD as a positive control for an antigen specific response upon virus challenge. While
this helped to control for adenovirus immunization, it was not a control within the same
animal and also doubled the number of mice needed for each experiment. A new strategy
was tested and adopted to intradermally immunize with both AdV-HuD and AdV-β-gal
on opposite sides of the same mouse. In these experiments, we observed a response to βgal directly ex vivo while we were still unable to detect an HuD-specific response at this
time. We were able to recover a response to HuD after in vitro stimulation (Figure 9.14).
The magnitudes of the response to both antigens after the double adenovirus
immunization were comparable to the responses to that antigen in a singly immunized
mouse. With this new approach, we can recapitulate the phenotypes we observe with
single immunizations in a mouse immunized with both viruses. This strategy internally
controls for natural variability or abnormalities in the immune response in a mouse
specific manner.

In parallel, an approach for double immunization with Titermax emulsified peptides was
also explored. We observed that a mouse immunized with different Titermax emulsified
peptides in each of the back footpads mounts a detectable antigen-specific response in the
corresponding draining popliteal and inguinal lymph nodes. Interestingly, we only see
the response in the draining lymph nodes from each footpad and not on the opposite side
of the same doubly immunized mouse. Furthermore, the response to each peptide in the
double immunized mouse is of the same magnitude of a singly immunized mouse (Figure
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Figure 9.14 Tools to Study Tolerance to HuD: Double Adenovirus Immunization.
Two mice were immunized with adenovirus-β-Gal (AdV-β-Gal), adenovirus-HuD (AdVHuD) or both adenoviruses with pertussis toxin on day 0 (d0) and again with pertussis
toxin on d2. The mice were sacrificed on d13 and half of the splenocytes were evaluated
directly in an ex vivo ELISPOT and the other half were split into two flasks and incubated
with HuD peptide 321 (p321), β-Gal peptide 96 (p96), or β-Gal peptide 297 (p297) for in
vitro stimulation (IVS). On day 20, the in vitro stimulated splenocytes were harvested
analyzed in an ELISPOT assay. In the twenty-hour IFNG ELISPOT assays, T cells were
co-cultured with EL4 cells (HuD and β-Gal negative) with HuD p321, β-Gal p96, β-Gal
p497, irrelevant Ova peptide 257, or alone. Values, representing spot forming cells per
million CD8 T cells, are the average of triplicate wells; error bars indicate standard
deviation. (A) Ex vivo IFNG ELISPOT Results from each immunized mouse are shown.
(B) IVS IFNG ELISPOT results from each immunized mouse stimulated in two flasks
each with either β-Gal peptide (AdV-β-Gal immunized mice), replicate stimulations of
HuD p321 (AdV-HuD immunized mice), or β-Gal p96 and HuD p321 (AdV-β-Gal and
AdV-HuD immunized mice) as indicated.
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CD8 T cells, are the average of triplicate wells; error bars indicate standard deviation.
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9.15). With this internal control, we have a better way to monitor the effectiveness of our
bone marrow or T cell transfers and for abnormal responses in an animal specific control.

Discussion

In this chapter we examined the immune responses to onconeural antigens. We were able
to deliver cdr2-specific T cell receptors to human CD8 T cells by electroporation of TCR
alpha- and beta-chain RNA. Using optimized TCR genes for two different mousederived human cdr2-specific clones, we were able to confer cdr2-290 peptide immunity
to normal human donor cells. Although the majority of cells showed cdr2 reactivity in
functional assays, it is unclear why such small percentages of cells were stained by cdr2290 tetramer. If we increased the TCR expression further, it is possible that the T cells
could confer an even more promising functional outcome.

We demonstrated specific targeting of HLA-A2 cdr2-expressing tumor cell lines by both
TCR clones. Furthermore, working with primary tumor cells collected from ovarian
cancer patient ascites samples, we were able to show reactivity to primary samples that
were HLA-A2 positive and expressed cdr2. Still, the magnitude of this immune reaction
would need to be improved to consider the possibility of cancer treatment. We also need
to repeat the flow cytometry based killing assays with both cdr2-specific TCR Clone 1
and Clone 11/12 with HLA-A2 and cdr2 positive primary ascites samples. By exploring
the ability of the electroporated lymphocytes to recognize and attack primary tumor cells
endogenously expressing cdr2, these future experiments would explore the potential of
using adoptively transferred cdr2-290 TCR T cells in clinical therapy for breast and
ovarian cancer.
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We have previously described the dominant CD8 T cell epitope of HuD in C57BL/6 mice,
peptide 321 (p321) (DeLuca et al., 2009). Here we described establishing clonal HuDspecific CD8 T cells and characterizing their responses to targets expressing HuD.
Although potential CD4 T cell epitopes have been established, future work is needed to
identify the CD4 T cell dominant HuD epitope.

We have cloned the TCR genes from

optimal CD8 T cell clones and this could be repeated for the CD4 T cell epitope. The
identified TCR genes could be used to make transgenic mice expressing HuD-specific
CD4 or CD8 TCRs.

There is currently no animal model for the Hu syndrome. The laboratory’s discovery of
two different kinds of CD8 T cells in Hu patients suggests that generating HuD-specific
transgenic T cells may allow us to learn how to skew HuD-specific CD8 T cells to
different phenotypes and monitor the functional consequences (Roberts et al., 2009).
Also, nothing is known about CD4 T cell responses in the Hu syndrome. We believe that
a critical component in determining whether patients are tolerant of their tumor or react to
it may be related to the presence or absence of effective CD4 T cell responses. Therefore,
both proposed HuD TCR transgenic mice would be critical tools for understanding the
immune response to HuD.

In future work, we propose to characterize the persistence of TCR transgenic CD4 and
CD8 T cells in WT and HuD KO hosts. It is possible that the transgenic lymphocytes
would be deleted due to their recognition of native antigen, but as in a WT mouse, we
expect the HuD-specific T cells would persist, even if in small quantities. Therefore, it
will be important to study the transgenic T cells’ migration patterns in the thymus and
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throughout the mice and to study their proliferation patterns. We would also study the
presence of the lymphocytes in the nervous system and whether they cause damage to
neurons expressing HuD. We would expect the transgenic cells to be tolerized to HuD
and therefore not cause damage to neurons in a resting state. We hypothesize that by
challenging mice with a peripheral tumor expressing HuD and providing disruptions to
the blood brain barrier, using agents such as pertussis toxin, we may be able to uncover a
link to promote an escape from tolerance and possibly lead to neuronal degeneration.

By making bone marrow chimeras of wild type and HuD KO mice, we were able to
further study the peripheral tolerance to HuD. As expected, we recapitulated the HuD
KO mouse phenotype when transferring HuD KO bone marrow into a KO host. In these
animals, we were able to detect an active immune response to HuD peptide 321 directly
ex vivo following immunization with AdV-HuD and pertussis toxin. This immunity was
also seen after in vitro stimulation of splenocytes with the HuD peptide.

Also as

anticipated, having either HuD KO or wild type bone marrow in a wild type host
produced tolerance to HuD in the peripheral T cells.

For these mice, no immune

response to HuD was seen directly ex vivo after immunization, but was recovered after in
vitro stimulation. We consider this response to be a case of tolerance because although
the HuD specific T cells were present in the mice, we were not able to detect their
activity until they were propagated in culture. Interestingly, we saw this same wild type
phenotype in HuD KO mice with transferred wild type bone marrow. We did not expect
to see the presence of a functional HuD gene in bone marrow derived cells be able to
confer tolerance in an otherwise HuD deficient animal, when HuD is thought to be
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restricted to the nervous system. Further work is needed to explore the source of HuD
expression in bone marrow derived cells and its role in tolerance in a normal mouse.

With transgenic T cells, we could challenge the mice to mimic possible Hu syndrome
initiating events and follow the migration of the HuD-specific cells in the mouse,
including the CNS. By conducting transfer experiments using the transgenic TCR mice
in combination with wild type and HuD KO littermates, we aim to elucidate the
mechanism mediating the anergy of HuD-specific T cells and understand how this
tolerance is broken in Hu syndrome patients. Understanding the tumor immune response
and the autoimmune neurologic disease for both PCD and the Hu Syndrome are of major
clinical importance and could lead to new interventions for disease.

276

CHAPTER 10. General Discussion

Summary

The careful control of the adaptive immune response allows for the host to respond to
rapid changes in its homeostasis and protect against the invasion of pathogens and other
systemic injury. While the processes mediating these important retaliations have been
studied in extensive detail, the acute molecular processes of regulatory control in T cell
activation have still not been completely elucidated. Lymphocytes have the ability to
react quickly to confront the presence of cognate antigen within their host. They initiate
and terminate cytotoxic and inflammatory pathways abruptly to contain the damage of
the invading offense and simultaneously protect the surrounding environment from their
own dangerous defense mechanisms. The induction of new transcription is important to
shaping these responses.

Nonetheless, the rapid control of translation post-

transcriptionally is also critical to the immediate function of these cells.

RNA-binding proteins, such as Ago and HuR, have previously been shown to mediate
both the proper development of lymphocytes and the regulation of their translational
responses. Though there is a vast literature analyzing the targets of Ago and HuR control,
the majority of work has been done in non-physiologic in vitro systems and little is
known about the dynamics of their regulation in vivo.

The results presented here

represent the determination of Argonaute (Ago) and HuR RNA-binding maps in ex vivo
normal healthy donor cluster of differentiation eight (CD8) lymphocytes before and after
T cell stimulation. By overlaying the transcriptional and translational status of these
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dynamically changing lymphocytes, we provide a system to functionally decipher the
roles of these regulatory proteins and their impacts on the inflammatory response.

Overlapping RNA-Binding of Ago and HuR

We observed that 40% of Ago clusters and 14% of HuR clusters overlap each other,
within 64-nucleotides up or downstream of their peak binding positions. Interestingly,
not only do many Ago and HuR clusters overlap within a small distance, but also their
peak positions are highly superimposable. This implies that in a large proportion of their
binding sites, the two proteins are found in the same position.

While CLIP data

represents the binding specificities of a population of cells and not necessarily a map of a
single RNA molecule, this propensity of two such distinct proteins to preferentially bind
the same loci is remarkable. These binding similarities were not limited to one T cell
stimulation state and quantitative differences in binding for both proteins were often
similarly reflective of the transcriptional levels of the targets. This suggests that Ago and
HuR may bind these sites cooperatively or in a step-wise fashion to instigate regulatory
control. In this way the two proteins could work together or antagonistically to regulate
function.

Because the majority of Ago binding was preserved in the HuR cKO mice, it is unlikely
that Ago is dependent on HuR as a rule. Still we were able to observe clusters that were
present in either one of the mouse genotypes and not in the other, so HuR may be
necessary for the binding of Ago to some regulatory sites and may preclude Ago binding
in others. We propose that while the binding of these proteins to the same message may
in some cases be independent, that their regulatory capacities are still intertwined.
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Rapid Changes in RNA-Binding with CD8 T cell Activation

Ago and HuR display rapid changes in binding patterns with CD3/CD28 stimulation of
CD8 lymphocytes. While viewing the distributions of binding at one hour represents an
early point in the T cell activation regulatory cascade, it is clear that we could learn much
from the regulatory states of these cells at both even earlier and later time points. For
example, assessing Ago and HuR de novo binding to a transcript at early time points after
stimulation may allow a determination of whether there is an ordered hierarchy of
binding between these two proteins. Repeating a time course in HuR cKO T cells would
complement such studies.

One model to address the binding of Ago and HuR to the same RNA sequence domains is
that Ago and HuR do not bind simultaneously to their joint targets. In this model, if
binding of one protein proceeds the other in binding pre-processed RNA, then the ratios
of binding events in the intronic regions of transcripts to the exonic regions, that will
remain in the final mature mRNA, may be indicative of a time line of regulation. For
example, in the activated lymphocyte Ago CLIP map of IFNG (Figure 6.2), the larger
binding sites in the 3’UTR as compared to intronic regions may indicate that Ago is
binding later in the life cycle of the mRNA than HuR. HuR is bound more evenly in its
introns and exons, even though it too shows some preference for 3’UTR binding. It is
possible that HuR is important in the immediate processing of the IFNG transcript in the
nucleus and that the large induction of transcription needs to be tempered by Ago after
processing to mediate translational control as time progresses in the stimulatory cascade.
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Assaying the timing and efficiency of mRNA processing in the wild type and HuR cKO
T cells could help define this regulation.

Studying the transcriptional and translational statuses of T cells at later time points may
also help resolve the functional outcome of Ago and HuR binding events. Because both
proteins often displayed correlative changes in binding with transcript levels, it is
possible that the large changes in transcript abundance with T cell activation may be
occluding our ability to identify the regulatory consequences of these binding events.
While we have largely focused in our examples on messages that had increased binding
and message levels with activation, it is important to note that we also see the reverse as
well. Understanding the rapid changes in RNA-protein interactions may give us clues to
the eventual stability and translational control of the message, and the interactions
between both Ago and HuR may dictate these fates.

For example, within one hour of activation, the levels of IFNG transcript can increase by
a factor of 102-103. Since Ago and HuR robustly bind this message, it is not surprising
that their interactions with IFNG would increase in this time period. Still, the eventual
effect of Ago binding, for example, is most likely to help degrade this message in a
pattern common to the decreases seen in many early activation genes quickly increased
after transcription. While HuR may be functioning synergistically with Ago, it is more
likely from previous work that it is helping to stabilize or steer copies of the message to
translational machinery to balance this repressive Ago response. This kind of balanced
regulation could be critical for IFNG so that too much cytokine is not produced after T
cell stimulation, which could be detrimental to healthy cells in the immediate
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environment of the lymphocyte.

While Ago may be necessary to dampen IFNG

expression for host safety, rapid translational increases in IFNG protein mediated by HuR
stabilization may be just as critical to the inflammatory response. With considerable
increased message being made at one hour, even if Ago were mediating degradation of
IFNG, we would still observe this as an overall rise in transcript levels. Therefore, it may
be informative to look at later times for transcription level responses of targets, when the
immediate escalation of the activation has quelled, to determine the functional outcomes
of these early binding events. Looking at IFNG levels over time in the HuR KO mice
could also help assess this.

Analysis of CLIP Data in the Context of Translational Status

With both proteins changing binding patterns congruently with the dynamic variations in
transcript expression, it appears that the large changes in message levels may be
obscuring Ago and HuR mediated dynamic changes in transcript stability, or that these
proteins often work together to modify transcript abundance. This differs from the results
of the ribosomal profiling work. While it is hard to define a single general rule for shifts
in ribosomal occupancy of Ago and HuR targets with T cell activation, it is clear that
these messages do not automatically enter the translational machinery in proportion to
their levels.

In the analysis of Ago and HuR 3’UTR targets, we see that the binding patterns of the
proteins correlate well with the patterns in gene expression changes of the messages. For
example, in Figure 7.12A, as the ratio of message levels between the resting and
activated state shifts from left to right on the axis, signifying transcripts with more RNA
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in the resting state on the left or more RNA in the activated state on the right, HuR
binding patterns also shift from having more binding in the resting state to more in the
activated state shown by points changing in color from blue to yellow. If this pattern
were reflected in the translational state of each message, the plotted points would
resemble the y=x line. Instead, we see a scattering of points mainly around the origin of
the graph. This pattern suggests that for many HuR targets, the translational changes
(vertical shifts, up or down) are greater than transcriptional changes (horizontal shifts, left
or right). These rapid changes suggest that HuR is part of a critical and complex network
of translational regulation shortly after lymphocyte stimulation.

Differences in the

translational responses of individual transcripts with activation may reflect the
interactions of HuR, or analogously Ago, with other factors such as other RNA-binding
proteins or subcellular localization changes to mediate translational control.

We have reported multiple examples of dynamic reciprocal changes in Ago and HuR
binding patterns in overlapping sites throughout this work. For messages such as FYB
and SATB1, we described shifts where the binding levels for HuR increased with
activation and Ago decreased with activation, although both represented biologically
reproducible binding in both states. This corresponded to CLIP binding maps in the
mouse data, where dynamically changing but robust binding of Ago and HuR in the
human reflected a preference for binding in wild type cells as compared to HuR cKO.
We propose that these may be examples where robust binding in both states in the human
is more salient than quantitative differences observed in CLIP tag numbers with
activation for predicting the necessity of coincident binding for Ago and HuR in the
mouse. As shown in Table 10.1, while we saw subtle shifts in the transcript levels of
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Table 10.1 Dynamic Changes in Ago and HuR binding and Translational Efficiency.

Human
Ago

Human
HuR

Resting
RPF
(RPKM)

Resting
mRNA
(RPKM)

EGR3

Act

Act

---

IFNG

Act

Act

IRF9

Act

Rest

Activated
mRNA
(RPKM)

Activated
TE

RPF/mRNA

Activated
RPF
(RPKM)

---

---

1533

1418

1.08

---

---

---

22,375

6871

3.26

51

72

0.70

67

60

1.11

SATB1

Rest

Act

187

273

0.69

134

199

0.67

FYB

Rest

Act

500

496

1.01

364

384

0.95

*8 cloned tags
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Resting
TE

*18 cloned tags

RPF/mRNA

these genes in human T cells, which both decreased with activation, we did not see
dynamic shifts in the translational efficiency. The binding patterns of Ago and HuR are
similar in these sites and may suggest that the decrease with Ago binding of these
transcripts with activation is linked to the reduction in message, while HuR maintains the
correlative translational status of these targets.

In the case of the IRF9 transcript, we saw the opposite binding pattern changes for Ago
and HuR in the human T cells with activation. Ago binding increased with T cell
activation, while HuR binding decreased.

Again, both binding sites were still

reproducible in both states even though their levels shifted in opposite directions.
Analyzing the homologous site in the mouse suggests that HuR is supportive of Ago
binding because there was more binding seen in the wild type mice than in the HuR cKO.
Interestingly, we did see a shift in translational efficiency for the IRF9 mRNA in human
T cells with activation. In the resting state, there was less ribosomal occupancy than
message, but the opposite was true after T cell activation (Table 10.1). Although these
changes represent differences in relatively small numbers of cloned tags and therefore
need to be independently validated, including with additional human samples and in the
mouse, these results suggest that HuR may help recruit Ago binding to IRF9 and that
with T cell activation this translates into increased ribosomal occupancy.

Generally, we have observed large dynamic shifts in translational status acutely with T
cell activation that are often not mediated by similar transcriptional changes. Still, there
does not appear to be a single universal rule governing all of the effects of Ago and HuR
binding on target transcripts. This is likely due to the complexity of the regulatory
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systems in which these proteins interact, and suggest that individual transcripts have
evolved to be differentially regulated by the same Ago and HuR proteins. There are
many possibilities for how this might happen, such as via the action of additional factors,
by the timing of their binding events, or due to the effects of Ago and HuR binding
different regions within the transcript such as the coding sequence versus the 3’UTR or
even more subtle differences in the precise binding positions of Ago compared to HuR.
With more replicates and analysis of translational profiles in the HuR cKO mouse system,
it will be interesting to try to define patterns in these changes and to determine pathways
of regulation by these proteins that can be separated out from the massive changes in
cellular states.

Genomic Distribution of Ago and HuR Regulation in CD8 Lymphocytes

Previous work on Ago and HuR regulatory control of target mRNA has largely focused
on their binding interactions with 3’ untranslated regions (3’UTRs).

However, the

analysis described here indicates the first role for Ago and HuR interaction in intronic
regions of transcripts. While the rapid increase in transcription with T cell stimulation
might indicate a large pool of newly synthesized RNA available for RNA-binding, these
patterns are maintained in both the resting and the activated states. Additionally, the
predominance of intronic mapping of Ago CLIP tag clusters in the HuR cKO T cells
indicates that Ago binding in these regions is not dependent on the presence of HuR. The
data suggest that these proteins are deposited on transcripts either co-transcriptionally or
soon after transcription.
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In the mouse brain, Hu proteins most frequently bind to 3’UTRs, but also bind to intronic
sequences and can mediate alternative splicing of neuronal transcripts (Ince-Dunn et al.
2012). HuR has also been shown to bind intronic sequences in human cell lines and its
potential role in splicing and the possible link between pre-mRNA processing and
transcript stability inferred. The stability of RNA targets was more greatly impacted in
HuR knockdown experiments if the RNA contained HuR binding sites in both the 3’UTR
and the intron than either of the two alone (Lebedeva et al. 2011; Mukherjee et al. 2011).
Still, the interaction of HuR and Ago in these intronic regions has not been previously
explored.

We propose that the formerly described effects of HuR on pre-mRNA

processing and mRNA stability involve interactions with Ago. HuR and Ago may
interact with target transcripts in the nucleus to direct splicing events, although it is
currently unclear whether they function cooperatively or antagonistically in this process
to control the mature message. It is possible that the binding of HuR or Ago could not
only direct the sites of splicing, but could also regulate the timing of splicing events by
interfering with splicing machinery and other RNA-binding proteins. Their binding
could help mediate processing or sequester the RNA, similar to their roles in the
cytoplasm. Analysis of Ago target transcripts in the HuR cKO mice might help elucidate
a clearer model of control.

Furthermore, the role of immediate binding of HuR and Ago to nascent RNA may serve
an even more important role in the regulation of immune function than in previously
studied systems. As previously described, the abundant initiation of transcription with
the induction of an immune reaction needs to be carefully titrated to secure that cytotoxic
and inflammatory signals are directed properly. Binding of RNA by both HuR and Ago
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in the nucleus may ensure that when being shuttled into the cytoplasm, that the messages
are already being directed for the appropriate fate. They could be directed by HuR
directly to active polysomes, or filtered by Ago into cytoplasmic foci such as P-bodies
and stress granules for quick interactions with other RNA-binding proteins, or simply
degraded.

It would be interesting to consider the binding positions of HuR and Ago on transcripts at
further time points after T cell activation. We propose that if HuR and Ago are deposited
co-transcriptionally on pre-processed RNA, that after the message has been spliced and
shuttled to the cytoplasm, that we may observe the resolution of these intronic sites in an
increase in binding in the 3’UTRs more similar to what is seen in the steady state of the
brain. Still, the binding events in the intronic regions appear to be sequence specific and
present in the resting state as well. Thus, the regulation of the timing and sites of splicing
by HuR and Ago may represent another level of post-transcriptional control, whereby
target mRNAs could have different availabilities for maturation and processing in the
nucleus due to their interrogation by Ago and HuR. The quick shuttling of HuR out of
the nucleus with T cell activation could therefore represent the transportation of targets to
the cytoplasm or also the release of nuclear targets for the availability of processing.

Ago and HuR and microRNA Regulation

The regulation of RNA processing by Ago and HuR is not only restricted to mRNA. We
observed robust binding sites for both proteins in primary microRNA transcript loci. In
the example of the microRNA-17-92 locus, we see binding of Ago to microRNA stem
loop regions that are greater in length than mature microRNA sequences. This binding is
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robust in both the resting and the activated states, indicating that microRNA processing is
active in both groups of cells. Ago has been shown to aid Dicer in microRNA processing,
or in the case of miR-451, microRNA can be processed by Ago without Dicer
involvement (Cheloufi et al. 2010; Cifuentes et al. 2010; Diederichs and Haber 2007).
Our data reveals that in vivo, Ago associates with microRNA before they are mature
species. Interestingly, there is an increase in binding of Ago to regions between stem
loops with stimulation induced transcript level induction, indicating that Ago may bind to
microRNA transcripts in the nucleus with T cell activation. This may indicate a new role
for Ago in the processing of microRNA and may have been previously missed due to the
predominant analyses of steady state biology.

We also see an impressive increase in binding in the miR-17-92 region by HuR,
mirroring the increase in transcript levels with lymphocyte activation. Thus, HuR may
play a role in regulating the dynamics of processing immediately following transcription
of microRNA message. Furthermore, the HuR binding pattern is distinct from Ago.
Most notably, unlike Ago, the predominant binding sites appear to match sequences
between the microRNA stem loops and not as frequently in sites that will eventually
make up the mature microRNA 22-mers. We therefore propose that HuR is involved in
the processing of microRNAs in the nucleus and would expect to see differences in the
levels of mature microRNA bound to Ago in the HuR cKO T cells.

Interestingly, the levels of Ago binding in the mouse miR-17-92 cluster vary in some
regions between the wild type and HuR cKO T cells. Although some of these CLIP tags
are 22-nucleotides in length and represent mature microRNA, we did not specifically
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clone the microRNA population and so our analysis is limited mostly to mRNA binding
sites. While there are robust Ago binding events in both animals, even though there are
less total unique reads in the HuR cKO dataset, there are quantitatively more binding
sites specifically on what will be the mature miR-92a and miR-20a transcripts. The rest
of the microRNAs have similar binding patterns in both mice (Figure 10.1).

There is little Ago or HuR binding to or around miR-92a in the human dataset, so it is
hard to infer a conclusion about this change in the mouse system. However, miR-20a had
a unique pattern of HuR binding in human T cells among this cluster of microRNA. HuR
displayed binding sites covering the stem loop region instead of being restricted to only
up or downstream of the mature microRNA site. Thus, it is very interesting that Ago
binding would be increased preferentially for this microRNA in the HuR cKO cells. This
suggests that HuR binding to miR-20a impedes efficient binding of Ago and may explain
why their binding patterns are almost exclusive of each other in other parts of this region
in the human dataset. We hypothesize that because HuR binding mostly excludes mature
microRNA message, HuR plays a role in loading microRNAs into Ago and that binding
of HuR to eventual mature sequences would inhibit Ago association in those sites.

Intriguingly, most of the top 7-mers represented in Ago clusters that overlap HuR were
microRNAs that were cloned in low frequencies in Ago CLIP. And conversely, the seed
matches from the most highly represented microRNA from Ago CLIP, miR-142-3p, was
preferentially not found in these sites, but rather in sites where Ago binding did not
overlap HuR. This suggests that HuR binding together with Ago may enrich for target
sites utilizing more rare microRNAs in T cells. Furthermore, it supports our model that
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A

B

Human HuR CLIP:
Scale
chr13:

100 bases
90801300

90801350
90801400
HuR CLIP BC2: Activated

Mouse Ago CLIP:

Scale
chr14:

90801450

500 bases
115443000

115443500
Ago CLIP: HuR WT

Ago CLIP: HuR cKO

HuR CLIP BC2: Resting

RefSeq Genes
MIR17HG
MIR17HG
MIR20A

MIR19B1

Mir17
Mir18

RefSeq Genes
Mir19a
Mir19b-1
Mir20a
Mir92-1
Mir17hg

Figure 10.1 Ago and HuR Binding in Human and Mouse: microRNA-17-92 Locus.
(A) The position of individual Ago and HuR unique CLIP tags in biologic complexity
two clusters plotted relative to their mapped position on the human microRNA-17-92
locus. From top to bottom: chromosomal location, Ago CLIP tags from activated CD8 T
cells (colors represent each donor sample as shown in Table 6.1), Ago CLIP tags from
resting CD8 T cells, HuR CLIP tags from activated CD8 T cells, HuR CLIP tags from
resting CD8 T cells, Gene diagram from RefSeq. (B) The position of individual Ago
unique CLIP tags are plotted relative to their mapped position on the mouse microRNA17-92 locus, with microRNA-20a highlighted. From top to bottom: chromosomal
location, Ago CLIP tags from activated HuR wild-type CD8 T cells (colors represent
each donor sample as shown in Table 8.1), Ago CLIP tags from activated HuR cKO CD8
T cells, Gene diagram from RefSeq.
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HuR could be a chaperone for loading Ago with microRNAs or for Ago message
targeting and it is possible that without this interaction, Ago would not show a binding
preference for these rare microRNA seed sites. This might not be necessary for highly
abundant microRNAs such as miR-142-3p.

Additional analysis of Ago-microRNA

association in the HuR cKO animals is needed to further explore this model.

Conclusion

The results presented in this thesis represent the identification and careful
characterization of Ago and HuR RNA-binding in the activation of CD8 lymphocytes.
Studying normal healthy donor CD8 T cells, we have characterized a system to
investigate lymphocyte stimulation ex vivo to probe the regulation of this important
immune function.

These studies also serve as a useful surrogate system for

understanding larger issues of dynamic control of RNA regulation in other cellular stress
conditions. We demonstrated the reproducibility of our methods to robustly identify Ago
and HuR RNA-binding events in human biologic samples representing two cellular states.
Furthermore, we identified the transcriptional and translational status of each lymphocyte
activation state using ribosomal profiling and RNA sequencing, providing a means to
functionally interpret the Ago and HuR binding maps.

Moreover, by studying the

binding maps for Ago in mouse CD8 T cells with or without HuR, we establish a system
for investigating the dependence of Ago on HuR for its target specificities in the mouse,
and for focusing on regions in which Ago and HuR binding is likely to be interdependent
following the stimulation of human T cells.
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